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ABSTRACT 
Major Histocompatibility Complex Class-II (MHC-II) molecules are critical regulators of 
adaptive immunity that present extracellular antigens required to activate CD4
+ 
T cells.  MHC-II 
are regulated at the level of transcription by master regulator, the Class II Transactivator      
(CIITA), whose association with the MHC-II promoter is necessary to initiate transcription. Re-
cently, much research focused on novel mechanisms of transcriptional regulation of critical 
genes like MHC-II and CIITA; findings that the macromolecular complex of the 26S-proteasome 
is involved in transcription have been perhaps the most exciting as they impart novel functions to 
a well studied system.  Proteasome is a multi-subunit complex composed of a 20S-core particle 
  
capped by a 19S-regulatory particle. The 19S contains six ATPases which are required for tran-
scription initiation and elongation.  We demonstrate that 19S ATPase-S6a inducibly associates 
with CIITA promoters. Decreased expression of S6a negatively impacts recruitment of the tran-
scription factors STAT-1 and IRF-1 to the CIITA due to significant loss in histone H3 and H4 
acetylation.  S6a is robustly recruited to CIITA coding regions, where S6a binding coordinates 
with that of RNA polymerase II. RNAi mediated S6a knockdown significantly diminishes re-
cruitment of Pol II and P-TEF-b components to CIITA coding regions, indicating S6a plays im-
portant roles in transcriptional elongation.  
Our research is focused on the ways in which accessibility to and transcription of DNA is 
regulated. While cancers are frequently linked to dysregulated gene expression, contribution of 
epigenetics to cancers remains unknown. To achieve metastatic ability, tumors alter gene expres-
sion to escape host immunosurveilance. MHC-II and CIITA expression are significantly down-
regulated in highly metastatic MDA-MB-435 breast cancer cells.  This suppression correlates 
with elevated levels of the silencing modification H3K27me3 at CIITA and a significant reduc-
tion in Pol II recruitment. We observe elevated binding of the histone methyltransferase to CII-
TApIV and demonstrate this enzyme is a master regulator of CIITA gene expression. EZH2 
knockdown results in significant increases in CIITA and MHC-II transcript levels in metastatic 
cells. In sum, transcriptional regulation by the 19S-proteasome and histone modifying enzymes 
represents novel mechanisms of control of mammalian gene expression and present novel thera-
peutic targets for manipulating MHC expression in disease. 
 
INDEX WORDS: Major histocompatibility class II, Class II transactivator, Transcription regula-
tion, 26S proteasome, 19S ATPase, S6a, epigenetic, histone modifications, histone methyltrans-
ferase EZH2
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1 CHAPTER I: INTRODUCTION 
 
 
1.1 MHC MOLECULES AND THE ADAPTIVE IMMUNE SYSTEM:  
 
Human beings are constantly exposed to pathogens; thus the immune system is essential 
for survival as it functions to protect against invading pathogens. The immune system of higher 
vertebrates is composed of two responses, termed innate and adaptive, which collaborate to pro-
vide efficient and effective protection. Innate immunity is non-specific and provides the first line 
of defense against pathogens (Janeway and Medzhitov 2002). Adaptive immunity has evolved 
only in higher vertebrates and provides specific, although delayed, responses against pathogens. 
Cells of the adaptive immune response, unlike those of the innate response, have the capacity to 
develop memory against invading pathogens they have previously contacted and can provide 
long term protection against pathogens. Specificity and long term memory are therefore critical 
characteristics of the adaptive immune response (Janeway 2001) .  
 
1.2 Innate immunity: 
 
Innate immunity broadly includes molecular and cellular mechanisms present prior to in-
fection capable of quickly developing a localized non-specific response against invading patho-
gens. Invading microorganisms initially encounter the host‟s physical barriers of defense includ-
ing the skin and the epithelial linings of internal organs as well as secondary barriers including 
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the acidic stomach and perspiration. Beyond these initial barriers, the innate response includes 
groups of effector cells and antimicrobial compounds capable of neutralizing the invading patho-
gen based on common molecular markers present on pathogen surfaces. If the pathogen over-
comes initial barriers, reactions of the innate system are activated based on recognition of the 
presence of the pathogen and recruitment of effector cells capable of killing and eliminating the 
pathogen (Janeway and Medzhitov 2002). Effector cells of the innate response include dendritic 
cells, natural killer cells, mast cells, basophils, and eosinophils which function together to recog-
nize the invading pathogen and to prevent the infection from spreading.  
 
1.3 Adaptive immunity: 
 
A second form of immunity, the adaptive immune response develops in response to infec-
tion. Adaptive immunity differs from innate in that the adaptive response is highly specific and 
has the ability to develop immunological memory. Adaptive immunity is slower to develop in a 
primary response, but is able to recognize a much wider repertoire of foreign substances.  
 
An effective adaptive immune response involves lymphocytes and antigen presenting 
cells. Lymphocytes are produced in primary lymphoid organs and, following development, circu-
late through the blood to various secondary lymphoid organs. Two major populations of lympho-
cytes are B cells and T cells. Both B and T lymphocytes have membrane bound receptors, the B 
cell receptor (BCR) and T cell receptor (TCR), respectively, which recognize specific antigens 
(Farber, Acuto et al. 1997; Gerloni and Zanetti 2005). Upon activation, B cells give rise to plas-
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ma cells which produce antibody to aid in clearance of extracellular pathogens. T cells also par-
ticipate in pathogen clearance, but unlike B cells, are able to clear infections of both intracellular 
and extracellular origin. There are three major types of T cells: cytotoxic CD8
+ 
T cells (Tc), 
CD4
+
 T helper T cells (Th), and regulatory T cells (Treg). T lymphocytes are defined as CD4 or 
CD8 based on the presence of a CD4 or CD8 glycoprotein which is bound on the cell surface 
(Farber, Acuto et al. 1997). CD4 T cells are further subdivided into T helper 1 (Th1) and T hel-
per 2 (Th2) cells, based upon cytokine secretion profiles (Gerloni and Zanetti 2005). Broadly 
speaking, cytotoxic T cells defend against intracellular infections and helper T cells fight extra-
cellular infections. Both CD4
+ 
 and CD8
+
 T cells can, following activation, transition to a subset 
of memory cells which persist after an infection has been resolved and allow for quick expansion 
following re-exposure to the same pathogen (Jelley-Gibbs, Lepak et al. 2000; Seder and Ahmed 
2003). CD4+ T cells also play roles in establishing immunological memory by promoting the 
generation of CD8+ memory T cells (Harbertson, Biederman et al. 2002). 
 
In contrast to antibodies or B cell receptors which recognize free antigens, a majority of T 
cell receptors recognize antigen only when bound to cell surface Major Histocompatibility com-
plex (MHC) molecules (Gerloni and Zanetti 2005). Recognition of antigens by a BCR or TCR 
complex together with MHC presentation and additional co-stimulatory signals is required to ac-
tivate both B and T lymphocytes (Janeway 2001). Activated T and B cells induce multiple sig-
naling cascades which activate transcription of genes and result in efficient proliferation of acti-
vated, antigen specific B and T cells, and initiation of the adaptive immune response (Janeway 
2001; Parham 2009). 
4 
 
1.4 Major Histocompatibility Complex: 
 
The Major Histocompatibility complex (MHC) was initially studied as a genetic compo-
nent that determines the ability to accept or reject transplanted tissue from individuals of the 
same species (Kuo, Maruyama et al. 2005).  All mammals have a tightly packed cluster of genes 
located on a chromosome 6 which determines the structure of the MHC. MHC molecules play 
important roles in the ability of the immune system to differentiate between „self‟ and „non-self,‟ 
and are thus crucial in the activation of immune responses against both pathogens and tumors. 
There are two major types of MHC molecules: MHC class I which present peptides derived from 
intracellular pathogens and MHC class II which present peptides derived from extracellular pa-
thogens (Drozina, Kohoutek et al. 2005). MHC I are expressed on all nucleated cells with the 
level of expression differing between cell type, while MHC II are constitutively expressed on 
antigen presenting cells (APCs) and are inducible by inflammatory cytokine on all nucleated 
cells. MHC I present intracellular antigens to cytotoxic T cells via the CD8 receptor while MHC 
II molecules present extracellular peptides to CD4
+
 T helper cells (Figure 1.1) (Rojo, Saizawa et 
al. 1989; Gerloni and Zanetti 2005).  
 
MHC II molecules play important roles in activating adaptive immune responses and 
MHC II deficiencies lead to the development of bare lymphocyte syndrome, (BLS), which re-
sults in death in infancy (Reith and Mach 2001). Severe combined immunodeficiency (SCID) is 
also developed due to lack of MHC II expression. Patients with SCID are extremely vulnerable 
to infection because their lack of CD4
+
 T cells also results in an inability to activate B cells, nor 
are they able to provide CD4
+
 T help during CD8
+
T cell responses (Reith and Mach 2001). Over 
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expression of MHC II molecules is also associated with disease development as all autoimmune 
diseases correlate with over expression of MHC II in the targeted tissues (Swanberg, Lidman et 
al. 2005). MHC II molecules play important roles in anti-tumor immunity. The presentation of 
tumor cell antigens by MHC class II molecules is particularly critical in the  detection of a newly 
formed tumor as MHC class II proteins are capable of activating multiple arms of the anti-tumor 
immune response (Guy, Krajewski et al. 1986; Garrido and Ruiz-Cabello 1991). As MHC II mo-
lecules play critical roles in the activation of adaptive immune responses, and as deregulation of 
MHC II expression has such dire consequences, MHC II expression is tightly regulated, primari-
ly at the level of transcription (Benoist and Mathis 1990).  
.  
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Figure 1.1 MHC II molecules are an indispensable arm of the adaptive immune response as 
they present processed extracellular antigens to CD4+T cells which in turn initiate adaptive 
immune responses.   
Antigen presenting cells (APC) play an essential role in recognizing, processing, and presenting 
proteins. Processed antigens are presented by APCs and, by all interferon gamma (IFN-) stimu-
lated cells, on MHC II molecules. MHC II are cell surface glycoproteins that present antigens to 
CD4+ T cells resulting in T cell activation.  Activated CD4
 
T cells can activate B cells to pro-
duce specific antibodies and elicit adaptive immune responses. Activated CD4+ T cells can also 
activate cytotoxic CD8+
 
T cells to mediate direct killing (Kindt Thomas J 2007; Parham 2009). 
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1.5 Regulation of MHC II Transcription: 
 
MHC II molecules are glycoproteins which are constitutively expressed on the surface of 
antigen presenting cells such as activated macrophages, B cells, dendritic cells, and activated T 
cells (Cresswell and Howard 1997; Morris, Beresford et al. 2002).  Expression of MHC II can be 
induced in all nucleated cells by inflammatory cytokines, primarily the cytokine interferon gam-
ma (IFN-γ) (Benoist and Mathis 1990; Kaufman, Salomonsen et al. 1994).  IFN-γ is a type II in-
terferon which, through binding to the type II IFN receptor, activates transcription of target genes 
including MHC II. In contrast to IFN-α and IFN-β, which can be expressed by all cells, IFN-γ 
secretion is restricted to T lymphocytes, dendritic cells, and NK cells (Mach, Steimle et al. 1996; 
Boss and Jensen 2003; Platanias 2005).  Inducible expression of MHC II allows for enhanced 
antigen presentation and induction of localized immune responses.  The expression of MHC II 
genes is tightly regulated by multiple transcription factors and by chromatin remodeling enzymes 
that bind to a conserved regulatory region in the MHC II gene (Ting and Trowsdale 2002; Boss 
and Jensen 2003; Drozina, Kohoutek et al. 2005).  This regulatory region consists of conserved 
sequences designated as the X1 box, X2 box, and Y box (Benoist and Mathis 1990; Ting and 
Trowsdale 2002).  These sequences are respectively recognized by ubiquitously expressed DNA 
binding factors.  The X1 box is bound by the regulatory factor X (RFX) which is a trimer con-
sisting of RFX5, RFXANK, and RFXAP (Masternak, Barras et al. 1998; Nagarajan, Louis-
Plence et al. 1999).  The c-AMP responsive element-binding protein (CREB) binds to the X2 
box (Moreno, Beresford et al. 1999).  The Y box is bound by the nuclear factor Y (NF-Y) trimer-
ic complex which consists of NF-YA, NF-AB, and NF-YC (Mantovani 1999; Drozina, Kohoutek 
et al. 2005).  Together, these factors form an enhanceosome, formation of which is necessary but 
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not sufficient for the initiation of MHC II transcription. Instead, the enhanceosome serves as 
platform for binding the master regulator of MHC II transcription, the class II transactivator, 
CIITA (Masternak, Muhlethaler-Mottet et al. 2000) (Figure 1.2).   
 
CIITA is a co-activator as it is not a DNA binding protein, but instead binds to the enhan-
ceosome complex through interactions with RFX, NFY, and CREB (Masternak, Muhlethaler-
Mottet et al. 2000; Ting and Trowsdale 2002). As seen in Figure 1.2, CIITA initiates transcrip-
tion of MHC II genes by recruiting the basal transcriptional machinery including the TATA 
binding protein (TBP), TATA associated factors (TAFs) (Mahanta, Scholl et al. 1997), histone 
acetyltransferases (HATs) (Spilianakis, Papamatheakis et al. 2000; Wright and Ting 2006; 
Koues, Dudley et al. 2008), and histone methyltransferases (HMTs) (Koues, Mehta et al. ; Zika, 
Fauquier et al. 2005), which act together to change MHC II promoter accessibility.  CIITA re-
cruitment leads to enhanced levels of acetylation at the proximal promoter of MHC II genes that 
in turn promotes efficient assembly of transcription machinery and rapid activation of MHC II 
transcription (Koues, Mehta et al. ; Sisk, Gourley et al. 2000; Wang, Huang et al. 2001).  There-
fore, interactions of CIITA with the MHC II proximal promoter are crucial for the activation of 
MHC II transcription.   
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Figure 1.2  MHC II promoter region.  
(Top) MHC II proximal promoter contains X1, X2 and Y boxes. The X1 box is bound by RFX 
which is a trimer consisting of RFX-5, RFX-ANK and RFX-AB. CREB binds X2 box.  The Y 
box is bound by the NF-Y trimeric protein consisting of NF-YA, NF-YB and NF-YC.  The bind-
ing of each of these constitutively expressed transcription factors forms the MHC II enhanceo-
some complex, which is necessary but insufficient to mediate cytokine inducible MHC II tran-
scription (Kretsovali, Agalioti et al. 1998; Fontes, Kanazawa et al. 1999; Zika, Greer et al. 2003; 
Zika, Fauquier et al. 2005).   
(Bottom) The complex creates a surface necessary to recruit CIITA that is absolutely necessary 
for MHC II expression.  After prolonged cytokine stimulation CIITA then recruits RNA pol II 
with the transcription machinery and histone modifying enzymes including histone acetyltransfe-
rases (HATs), histone methyltransferases (HMTs) (Kretsovali, Agalioti et al. 1998; Fontes, 
Kanazawa et al. 1999; Zika, Greer et al. 2003; Zika, Fauquier et al. 2005).  
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1.6 CIITA, the Master Regulator of MHC II:  
 
CIITA is the master regulator for MHC II gene expression (Mach, Steimle et al. 1996).  
Its activity is absolutely required for the expression of the MHC class II genes, however the 
regulation of CIITA itself is less understood (Chang, Fontes et al. 1994).  In order to maintain 
tight regulation of MHC II, CIITA expression is also tightly regulated at the level of transcription 
(Ting and Trowsdale 2002).  Transcription of CIITA is regulated in a cell specific manner by 
four different promoters: pI, pII, pIII and pIV (Muhlethaler-Mottet, Otten et al. 1997) (Figure 
1.3).  By virtue of different transcriptional start sites illustrated in the top part of Figure 1.3, each 
promoter yields a different CIITA isoform that will have a unique first exon.  The promoter I (pI) 
isotype is expressed primarily in dendritic cells and macrophages.  Promoter II (pII) is not well 
conserved amongst different species and often considered to be inactive (Baton, Deruyffelaere et 
al. 2004).  Promoter III generates the CIITA isotype (pIII) in constitutively expressed in B cells, 
and can also be enhanced by the IFN-γ stimulation (Piskurich, Gilbert et al. 2006).   
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Figure 1.3 CIITApIV proximal region.  
(TOP) CIITA is transcribed from 4 different promoter regions depending on a cell type. Promo-
ter I drives expression of CIITA in dendritic cells. The function of promoter II is not conserved 
between species and the promoter is believed to be inactive. Promoter III primarily functions in 
B cells and promoter IV is responsible for the IFN-γ induced expression of CIITA.  
(Bottom) The promoter region of CIITApIV isoform has 3 conserved sequences: GAS, ISRE and 
E-BOX.  STAT-1 binds the GAS box within 30 minutes post IFN-γ stimulation, IRF-1 and IRF-
2 gets recruited to ISRE within 4 hours of cytokine stimulation and USF-1 is the constitutively 
expressed transcription factor (Muhlethaler-Mottet, Di Berardino et al. 1998; Morris, Beresford 
et al. 2002). 
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Figure 1.4  Activation of a JAK –STAT signal transduction pathway.   
IFN-γ binds to its receptor and initiates the kinase function of JAK, which autophosphorylates 
itself. The STAT protein then binds to phosphorylated receptor. Once phosphorylated STAT-1 
translocates to nucleus, where it binds to DNA and promotes transcription of genes that are res-
ponsive to STAT-1. STAT-1 binds to CIITA isoform IV and IRF-1 promoter regions. IRF- ones 
transcribed and translated binds to CIITApIV together with ubiquitously expressed USF-1 and 
inducibly recruited STAT-1and initiate expression of CIITA. CIITA protein, the master regulator 
of MHC II genes then binds ubiquitously expressed components of the enhanceosome complex 
and initiate expression of MHC class II genes (Piskurich, France et al. 1993; Morris, Beresford et 
al. 2002; Piskurich, Gilbert et al. 2006).   
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Promoter IV CIITA isotype (pIV) is the IFN-γ responsive form of CIITA which is pre-
dominantly expressed in IFN-γ stimulated cells (Piskurich, Gilbert et al. 2006)  resulting in paral-
lel INF-γ induction of MHC II expression (Muhlethaler-Mottet, Otten et al. 1997; Muhlethaler-
Mottet, Di Berardino et al. 1998; Morris, Beresford et al. 2002).  It is critical that CIITA 
expression is tightly regulated because abbearant expression is associated with multiple diseases 
including autoimmune conditions and cancer (van den Elsen, Gobin et al. 2001; Satoh, Toyota et 
al. 2004).  
 
Cytokine dependent MHC II transcription allows for enhanced antigen presentation by all 
nucleated cells and is achieved by binding of the transcription factors signal transducer and acti-
vator of transcription (STAT-1) and interferon regulatory factor 1 (IRF-1) to CIITApIV 
(Piskurich, France et al. 1993; Piskurich, Blanchard et al. 1995; Piskurich, Youngman et al. 
1997; Piskurich, Wang et al. 1998; Piskurich, Linhoff et al. 1999). Cytokine activated CIITApIV 
is also occupied by the constitutively expressed transcription factor upstream stimulating factor 1 
(USF-1) (Figure 1.3) (Muhlethaler-Mottet, Di Berardino et al. 1998; Piskurich, Linhoff et al. 
1999; Pattenden, Klose et al. 2002).  Activation of inducible CIITApIV is initiated when IFN-γ 
binds to its surface receptor and occurs via the Janus kinase signal transducer and activator of 
transcription (JAK-STAT) signal transduction pathway (Figure 1.4) (Morris, Beresford et al. 
2002; Pattenden, Klose et al. 2002; Piskurich, Gilbert et al. 2006).  Activated JAK1 and JAK2 
phosphorylate STAT-1, causing STAT-1 to translocate to the nucleus. In addition to binding to 
the gamma activating sequence (GAS) box of CIITApIV, STAT-1 binds the IRF-1 gene STAT-1 
binding site (Muhlethaler-Mottet, Di Berardino et al. 1998).  CIITApIV also has conserved GAS 
and interferon stimulated response elements (ISRE) (Morris, Beresford et al. 2002) which bind 
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interferon regulatory factors (IRFs) that are globally involved in IFN responses (Piskurich, 
Linhoff et al. 1999; Piskurich, Gilbert et al. 2006; Wright and Ting 2006). In addition to promot-
ing binding of transcription factors to pIV, IFN-γ induces acetylation of histones which loosens 
the chromatin structure and increases the accessibility of CIITApIV (Sterner and Berger 2000; 
Wright and Ting 2006). Because MHC II plays important roles in initiating, maintaining, and 
eventually terminating adaptive immune responses, the unique ability of CIITA to regulate the 
expression of MHC II genes makes CIITA a major player in the regulation of antigen presenta-
tion and adaptive immune responses. 
 
1.7 The 26S Proteasome 
 
The ubiquitin proteasome system (UPS) is well known for its role in the degradation of 
polyubiquitinated proteins, including transcription factors and chromatin remodeling proteins 
(Ciechanover 1994). However, recent investigations indicate subunits of the 26S proteasome are 
essential for transcriptional regulation of various genes independent of their roles in protein de-
gradation (Conaway, Brower et al. 2002; Ferdous, Kodadek et al. 2002; Greer, Zika et al. 2003). 
Research in the Greer lab has shown that subunits of the UPS are necessary for transcriptional 
regulation of MHC II and CIITA genes (Koues, Mehta et al. ; Truax, Koues et al. ; Bhat, Turner 
et al. 2008; Koues, Dudley et al. 2008; Koues, Dudley et al. 2009).  The role of the proteasomal 
subunit S6a in transcription will be described in detail in chapters 2 and 5 of this dissertation.  
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Figure 1.5 Enzymatic cascade of ubiquitination.  
Molecule of Ubiquitin (Ub) is activated in ATP dependent manner and covalently linked to E1 
ubiquitin activating enzyme. Activated ubiquitin is transferred from E1to E2 ubiquitin conjugat-
ing enzyme and then directly or with a help of E3 ubiquitin ligase to a lysine residue on a tar-
geted protein. If the targeted protein is marked for degradation multiple Ub molecules will be 
added via K-48. Once when at least 4 Ub molecules are attached, the protein is recognized by the 
26S proteasome and degraded. The 19S proteasome e recruits the polyubiquitinated proteins, 
cleaves of the Ub, unfolds and directs the proteins into the 20S core that cleaves proteins into 
peptides (Ciechanover 1994; Coux, Tanaka et al. 1996; Strickland, Hakala et al. 2000).  
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Figure 1.6  Ubiquitination regulates numerous cellular processes.  
Ubiquitin (Ub) can be attached to lysine residues of cellular proteins either as a single unit 
(monoubiquitin) or in the form of branched, polyubiquitin chains. Several distinct structural 
forms of polyubiquitin can be assembled. Each modification confers different effect on the 
targeted protein they are attached to. In general, proteians that are monoubiquitinated are not 
degraded by the proteasome and play an important role in vesicle trafficking, gene activation and 
DNA repair. Polyubiquitination via K-48 tragets proteins for degradation via 26S proteasome 
and polyubiquitination via K-63 is important in various signaling pathways (Chau, Tobias et al. 
1989; Finley, Sadis et al. 1994; Thrower, Hoffman et al. 2000; Kim, Kim et al. 2007).  
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It is well established that polyubiquitination targets proteins for degradation by the 26S 
proteasome (Pickart 2004; Haglund and Dikic 2005).  The 8.5 Kd, 76 amino acid protein ubiqui-
tin was initially described as a protein modification which is covalently attached to lysine resi-
dues of target molecules (Ciechanover 1994; Adams 2003; Shmueli and Oren 2005). Chains of 
four ubiquitin molecules are necessary for recognition and degradation by the 26S proteasome 
(Figure 1.5) (Ciechanover 1998; Conaway, Brower et al. 2002). Ubiquitin is attached to proteins 
via an isopeptide bond between the C terminus of the ubiquitin molecule and a lysine (K) side 
chain on the target protein. A protein targeted for degradation is tagged with ubiquitin molecules 
via a three step enzymatic cascade. Polyubiquitination occurs when  these steps are repeated, re-
sulting in the formation of a chain of four ubiquitin molecules on the target protein (Figure 1.5) 
(Thrower, Hoffman et al. 2000).  
 
Ubiquitin has seven lysine residues (K-6, K-11, K-27, K-29, K-33, K-48 and K-63) and, 
while a majority of proteins are marked for proteasomal degradation by polyubiquitination via 
K-48, recent studies have shown that K-63 linked polyubiquitination also marks proteins for de-
gradation (Chau, Tobias et al. 1989; Finley, Sadis et al. 1994) (Kim, Kim et al. 2007). Proteins 
polyubiquitinated via K-63 play roles in the activation of several cellular pathways and are even-
tually degraded in lysosomes (Tan, Wong et al. 2007). Alternatively, monoubiquitination regu-
lates many cellular processes including nuclear export, DNA repair, protein interactions, and his-
tone modifications (Figure 1.6) (Terrell, Shih et al. 1998; Lucero, Penalver et al. 2000; Lotocki, 
Alonso et al. 2003; Gupta-Rossi, Six et al. 2004; Sigismund, Polo et al. 2004; Haglund and Dikic 
2005).  Despite the multiplicity of possible ubiquitin combinations, relatively little is known of 
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the outcomes of alternative, ie, non-lysine 48 or 63 linked, ubiquitination; these alternative ubi-
quitination reactions will likely be a primary focus of ubiquitin research for years to come. 
Once a protein is tagged via lysine 48 polyubiquitination with 4 or more molecules of ubiquitin, 
the protein is targeted to the 26S proteasome for degradation (Ciechanover 1998; Thrower, 
Hoffman et al. 2000; Finley, Ciechanover et al. 2004).  
 
The 26S proteasome in mammalian cells is a 2.5 MDa multi-protein complex made of a 
19S regulatory particle (RP) and a 20S proteolytic core (Baumeister, Walz et al. 1998) which can 
exist independently in both the nucleus and cytoplasm (Peters, Franke et al. 1994). The 19S can 
be further divided into two parts: a lid and a base. The lid is composed of eight non-ATPase sub-
units which are required for protein degradation (Coux, Tanaka et al. 1996; Baumeister, Walz et 
al. 1998; Gorbea, Taillandier et al. 1999). The base of the 19S contains six ATPases belonging to 
the ATPases associated with a variety of cellular activities (AAA) family: S4, S6a, S6b, S7, 
Sug1 (S8) and Sug2 (S10b) which correspond, respectively, to the yeast homologous proteins 
Rpt 1-6, and four non-ATPase subunits, Rpn1, Rpn2, Rpn10, and Rpn13 (Figure 1.7) (Gorbea, 
Taillandier et al. 1999; Adams 2003; Bhat, Turner et al. 2008). The 20S catalytic core is a 700 
kDa cylinder which consists of four stacked rings, with each ring containing seven α and β sub-
units in order of α β β α (Coux, Tanaka et al. 1996; Gorbea, Taillandier et al. 1999). 
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Figure 1.7  The 26S Proteasome.   
The 26S proteasome is composed of a 20S proteolytic core and a 19S regulatory particle (RP). 
The 20S core particle is a hollow cylindrical structure composed of two heptameric rings of α 
subunits and two heptameric rings of β subunits (αββα). The 20S core particle is capped on one 
or both sides by a 19S regulatory particle to form the active 26S proteasome.  Four non-ATPase 
(Rpn1, Rpn2, Rpn10 and Rpn13) and six ATPase subunits (Rpt1-6) are found in the 19S base.  
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The base ATPases contain a C terminal  hydrophobic tyrosine X motif that docks into the 
pockets of the α rings of the 20S (Smith, Chang et al. 2007). In the presence of ATP, the 20S 
catalytic core associates with the 19S regulatory particle on both sides to form the 26S protea-
some, allowing for the recognition of the ubiquitinated substrates which are marked for degrada-
tion (Coux, Tanaka et al. 1996; Gonzalez, Delahodde et al. 2002). The 19S regulatory particle 
recognizes the ubiquitin chains on targeted proteins, cleaves the chains, unfolds the protein, and 
directs the unfolded protein to the 20S core for degradation (Figure 1.5) (Coux, Tanaka et al. 
1996; Strickland, Hakala et al. 2000). The result of proteasomal degradation is cleaved peptides 
with an average length of 8-12 amino acids and free ubiquitin, which is reactivated and recycled 
(Jung, Catalgol et al. 2009). Through these mechanisms the 26S proteasome eliminates a variety 
of unwanted and/or misfolded proteins, (Hilt and Wolf 1996; He, Qi et al. 1998) and thus 
regulates many important cellular processes.  
 
1.8 Non-proteolytic roles of the proteasome:  
 
Growing studies indicate the 26S proteasome plays critical regulatory, but degradation 
independent, roles in gene expression. While it is well accepted that 19S ATPases recognize and 
unfold ubiquitinated proteins for degradation, these ATPases have RNA/DNA helicase activity, 
indicating their potential involvement in cellular processes independent of proteolysis (Coux, 
Tanaka et al. 1996; Baumeister, Walz et al. 1998; Adams 2003).  Studies in yeast demonstrate 
the 19S ATPases associate with transcription factors, with RNA polymerase II, with activated 
promoters, and with transcriptional elongation complexes (Ferdous, Kodadek et al. 2002; 
Gonzalez, Delahodde et al. 2002; Gillette, Gonzalez et al. 2004).  Knockout studies in yeast and 
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in mammalian cells have shown that the 19S base is essential for initiation and elongation by 
RNA pol II, but that proteolytic activity of the 26S is not required (Ferdous, Kodadek et al. 
2002).  Work in the Greer has demonstrated the 19S ATPases associate with the MHC II prox-
imal promoter, with CIITA, and with the enhanceosome complex where they play important role 
in regulating CIITA activity and MHC II expression (Truax, Koues et al. ; Bhat, Turner et al. 
2008; Koues, Dudley et al. 2008; Koues, Dudley et al. 2009).  Evidence also indicates inhibition 
of the 19S decreases elongation, while inhibiting the catalytic activity of the 20S increases elon-
gation, thus the balance between the 19S/20S subunits is crucial for transcriptional regulation 
(Gillette, Gonzalez et al. 2004).  These observations indicate the ubiquitin/proteasome pathway 
plays multiple roles in transcription and imply the non-degradative roles of the proteasome may 
more far reaching than its known roles in protein degradation.  
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1.9 ROLES FOR THE 26S PROTEASOME COMPONENTS IN TRANSCRIPTION:  
 
Transcription is a first step in gene expression and is divided into 5 stages: pre-initiation, 
initiation, promoter clearance, elongation, and termination. During pre-initiation, general tran-
scription factors guide RNA pol II to proximal promoter regions.  In eukaryotes transcription re-
quires special sequences, known as TATA boxes, located around 30 base pairs upstream of start 
sites. The TATA box is a binding site for the TATA binding protein (TBP) which is itself a part 
of Transcription Factor II B (TFIIB), here illustrated on the MHC II proximal promoter (Figure 
1.2). The core domain of TFIIB associates with TBP at the TATA box and interacts with the 
DNA both upstream and downstream of the TATA box, thus recruiting RNA pol II to the correct 
site (Calvo and Manley 2003; Deng and Roberts 2007). Eukaryotic RNA pol II is not directly 
recruited to the DNA region of interest. Instead, groups of transcription factors create an initia-
tion complex that recruits RNA pol II and initiates transcription. Although extensively investi-
gated, the full mechanisms that control transcriptional initiation, elongation, and termination re-
main unknown.  
 
In 1992, Swaffield and colleagues first indentified roles for proteasome subunits in tran-
scriptional regulation. These researchers demonstrated 19S ATPase subunits Rpt6 (Sug1) and 
Rpt4 (Sug2) rescued a mutant transactivator Gal4 in Saccharomyces cerevisae (Swaffield, 
Bromberg et al. 1992; Rubin, Coux et al. 1996). Soon thereafter, the intact 26S proteasome, as 
well as the 19S regulatory particle and the 20S core, were demonstrated to localize in both the 
nucleus  and the cytoplasm (Peters, Franke et al. 1994). These early experiments were the first to 
link the 26S proteasome to transcription, and in the years that followed, researchers have ob-
23 
 
served that the 19S component of the proteasome also plays important roles in regulating tran-
scription at a variety of different genes (Koues, Mehta et al. ; Kinyamu, Chen et al. 2005; Lassot, 
Latreille et al. 2007; Zhu, Wani et al. 2007; Bhat, Turner et al. 2008; Koues, Dudley et al. 2008; 
Koues, Dudley et al. 2009). Subunits of the proteasome are required in the formation of initiation 
complexes, in maintaining elongation, and in executing termination. Roles for the 19S ATPases 
in transcriptional initiation at CIITApIV will be described in this dissertation in Chapter 2 and in 
Chapter 5, we demonstrate how 19S subunits maintain transcriptional elongation of CIITA 
genes.  
 
1.10 Roles in transcription initiation:  
 
Recent publications have demonstrated the 19S ATPases play important roles in initiating 
transcription of various yeast and mammalian genes. In yeast, the 19S proteasome has been 
shown to be responsible for the recruitment of the histone acetyltransferase (Spt-Ada-Gcn5-
acetyl-transferase) SAGA to promoter regions. Lack of the 19S ATPase Rpt6, the yeast homolog 
of mammalian Sug1, results in reduced recruitment of the HAT SAGA and in lower levels of 
histone H3 acetylation, indicating that 19S ATPases are important for recruiting HATs to promo-
ter regions (Lee, Ezhkova et al. 2005). Furthermore, as mentioned above, alleles of Rpt6 rescue 
mutations in the Gal4 activation domain (Rubin, Coux et al. 1996). Rpt6 also mediates the re-
cruitment of transcription factors to TBP (Swaffield, Melcher et al. 1995) and binds to various 
actively transcribing genes (Gonzalez, Delahodde et al. 2002). Overall, these observations dem-
onstrate the 19S proteasome plays important roles in transcriptional initiation of yeast promoters. 
The ubiquitin proteasome system is also linked to transcription initiation in mammalian cells. In 
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2006, Rasti and colleagues demonstrated the 19S ATPase Sug1 plays positive roles in adenovirus 
E1A dependent transcription (Rasti, Grand et al. 2006). In 2007, Zhu determined the 26S protea-
some enhances recruitment of p53 to p21 wafl responsive promoters (Zhu, Wani et al. 2007). 
Concurrent observations from Lassot and colleagues demonstrated 19S ATPases play important 
roles in regulating Tat dependent transcription of HIV-1 genes (Lassot, Latreille et al. 2007). The 
19S ATPase Sug-1 also plays an important proteolytic and non proteolytic role in regulating 
transcription mediated by retinoic acid (Ferry, Gianni et al. 2009).  
 
The 19S ATPases play critical roles in regulating transcription initiation of MHC II and 
CIITA genes. The ATPase Sug1 is recruited to the MHC II proximal promoter following IFN-γ 
stimulation.  Decreased expression of Sug1 results in decreased recruitment of CIITA to the 
MHC II promoter and in reduced expression of MHC II genes (Bhat, Turner et al. 2008). Sug1 
exerts control over CIITA promoter binding by regulating histone H3 acetylation at the MHC II 
proximal promoter through interactions with acetylated histone H3.  In cells treated with Sug1 
specific siRNA, MHC II histone acetylation is decreased with a preferential impact on acetyla-
tion at histone H3 lysine 18. Sug1 also recruits the histone acetyltransferase CREB binding pro-
tein (CBP) to MHC II promoters, further implicating Sug1 as an important regulator of histone 
modifications at the MHC II proximal promoter (Koues, Dudley et al. 2008). 
 
Sug1 is also important for regulating H3 lysine 4 trimethylation and H3 arginine 17 dime-
thylation at both MHC II and CIITA genes.  However, Sug1 does not impact H3 lysine 36 trime-
thylation or histone H2B lysine 120 ubiquitination.  As both arginine 17 dimethylation and lysine 
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4 trimethylation are important activating modifications, these observations further implicate 
Sug1 as being involved in activating transcription initiation (Koues, Dudley et al. 2009). Sup-
porting a role for Sug1 in initiation are observations that the absence of Sug1 enhances levels of 
H3 lysine 27 trimethylation, resulting in repression of transcription initiation (Koues, Mehta et 
al.). Chapter 2 of this dissertation details observations that an additional 19S ATPase, S6a, plays 
critical roles in initiating transcription of CIITApIV. Decreased expression of S6a significantly 
impacts the recruitment of transcription factors STAT-1 and IRF-1 to the CIITApIV proximal 
promoter and diminishes levels of activating acetylation on histone H3 and histone H4 with a 
preferential loss of histone H3 lysine 18 acetylation and H4 lysine 8 acetylation (Truax, Koues et 
al.) Together, these observations provide evidence that the19S proteasome plays regulatory roles 
in transcriptional initiation of the cytokine inducible genes MHC II and CIITA.  
 
1.11 Regulation of transcriptional elongation:  
 
Following transcription initiation, the multi-component transcriptional machinery falls 
under the control of positive and negative transcription factors which regulate gene expression. 
During the early steps of elongation, RNA polymerase II is paused by negative transcription 
elongation factors (N-TEFs) (Sims, Belotserkovskaya et al. 2004).  As illustrated in Figure 1.8, 
positive transcription elongation factor (P-TEF-b) is recruited to the N-TEF complex where it 
phosphorylates the carboxy terminal domain (CTD) of RNA pol II and N-TEF, thus permitting 
elongation (Sims, Belotserkovskaya et al. 2004). P-TEF-b exists in two distinct molecular forms 
as an active and inactive complex (Nguyen, Kiss et al. 2001; Yang, Zhu et al. 2001). P-TEF-b 
activity is inhibited by association with hexamethylene bisacetamide (HMBA) inducible protein 
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1 (Hexim-1) or 2 (Hexim-2) that is bound to 7SK small nuclear RNA (snRNA) (Figure 1.8) 
(Barboric, Kohoutek et al. 2005; Blazek, Barboric et al. 2005; Dulac, Michels et al. 2005; 
Schulte, Czudnochowski et al. 2005).  The CTD domain of RNA pol II is composed of 52 re-
peats of the heptapeptide sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser. During transcriptional initia-
tion, the CTD domain remains hypophosphorylated and becomes hyperphosphorylated during 
elongation (Corden, Cadena et al. 1985). The switch from transcriptional initiation to elongation 
is dynamic and is controlled by interactions between positive and negative transcription factors. 
Additional regulation through pausing of RNA pol II allows the replacement of initiation factors 
with molecules required for transcriptional elongation and RNA processivity.  
 
In addition to the above described roles in transcription initiation, the 26S proteasome al-
so regulates transcription elongation.  Initial observations that inhibition of proteasome activity 
reduces recruitment of RNA pol II to various yeast promoters first implicated the proteasome as 
involved in of transcriptional elongation (Lipford, Smith et al. 2005). Evidence has since accu-
mulated that 19S ATPases play important roles in pol II dependent elongation that are indepen-
dent of the presence of the 20S core (Ferdous, Gonzalez et al. 2001). Rpt 6, the yeast homolog of 
mammalian Sug1, has been demonstrated to link histone ubiquitination and methylation, which 
are both important steps in elongation (Sun and Allis 2002; Ezhkova and Tansey 2004; 
Pokholok, Harbison et al. 2005). 19S components also interact with the yeast elongation factor 
CDc8 (Ferdous, Gonzalez et al. 2001). Studies in mammalian systems are less extensive, but also 
support roles for proteasomal subunits in transcriptional elongation. 19S ATPases are recruited 
to coding regions of HIV-1 genes with a preferential abundance of the 19S ATPase S6a (Lassot, 
Latreille et al. 2007). Proteasome subunits also associate also with coding regions of estrogen 
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receptor responsive pS2 genes a complex with elongin and RNA pol II (Zhang, Sun et al. 2006), 
suggesting proteasomal subunit cooperation with transcriptional factors to mediate elongation. 
Observations in the Greer lab indicate robust occupancy of 19S ATPases in coding regions of 
CIITA and MHC II genes (Truax, Koues et al.), mechanistic details of these associations are de-
scribed in detail in Chapter 5 of this dissertation.  
 
More than a decade has passed since scientists first explored non-degradative roles for 
the proteasome. The discovery of nuclear proteasome, followed by preliminary research in yeast 
first indicated the proteasome is „not just degrading‟ anymore. Recent studies in both mammalian 
and yeast systems indicates 19S ATPase components of the ubiquitin proteasome system play 
important roles in regulating transcription of various genes via both proteolytic and non proteo-
lytic roles. Data described in detail in Chapters 2 and 5 of this dissertation adds to this growing 
body of evidence by demonstrating that the 19S ATPase S6a is a crucial regulator of both tran-
scriptional initiation and elongation of CIITA genes.  As MHC II and its master regulator CIITA 
are major players in adaptive immunity, tight transcriptional regulation of these genes is essential 
to a properly functioning immune system. The contributions of my data increase our understand-
ing of the transcriptional regulation of not only these genes, but of all inducible genes where a 
rapid response to stimulation is essential. 
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Figure 1.8  Dynamics at the transcriptional initiation and elongation of CIITA.  
Transcriptional initiation and elongation at CIITA is regulated by interacting with specific tran-
scription factors. P-TEF-b is in a large inactive complex with 7SK and Hexim dimmers. Once 
stimulated Hexim and 7S dissociates from the complex allowing the P-TEF-b to transform into 
active form that is recruited to proximal promoter. The CDK9 subunit of P-TEF-b then phospho-
rylates RNA pol II at Ser5 and also phosphorylates N-TEF to release the inhibition on RNA pol 
II and thus help in the transition from initiation to elongation(Corden, Cadena et al. 1985; Peng, 
Marshall et al. 1998; Michels, Fraldi et al. 2004; Sims, Belotserkovskaya et al. 2004; Barboric, 
Kohoutek et al. 2005) .  
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1.12 THE ACCESSIBILITY OF CHROMATIN:  
 
DNA exists in a highly organized, tightly packed form termed chromatin (Berger 2007). 
Differential packaging of DNA with histone and non-histone proteins into chromatin determines 
DNA accessibility during transcription. Chromatin is dynamic and can be found in multiple 
forms, from condensed, tightly packed heterochromatin that is inactive to loosely organized, and 
transcriptionally accessible, euchromatin (Berger, Kouzarides et al. 2009). The fundamental unit 
of chromatin is the nucleosome (Mandel and Fasman 1976; Berger 2007). Histones (H) are 
integral components of nucleosome structures as they provide a scaffold for double stranded 
DNA to wrap around.  There are four histone proteins: H2A, H2B, H3, and H4, two copies of 
which form the octameric nucleosome structure along with a fifth linker histone, H1 (Figure 1.9) 
(Kornberg and Thomas 1974; Luger, Mader et al. 1997). Histones are positively charged, while 
DNA is negatively charged due to phosphate groups in its sugar backbone.  Because of this 
charge differential, DNA is wrapped tightly around the histone octamers (Ward, Bowman et al. 
2009). As such, the base unit of chromatin are nucleosomes, consisting of histone proteins 
around which DNA is wrapped 1.67 times (Luger, Mader et al. 1997). Nucleosome cores consist 
of two H2A-H2B dimers and H3-H4 tetramers. Histone H1 stabilizes nucleosomes by interacting 
with double stranded DNA as it enters and exits the nucleosome (Kouzarides 2007) and aids 
formation of dinucleosomes (Widom 1998).  Dinucleosomes fold over to form 30nm fibers that 
coil and wrap around to form chromatin.  
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Figure 1.9 Structure of nucleosomes.  
Histones are small proteins that provide a scaffold for the DNA to wrap around. There are four 
histone proteins which form an octomer structure. The nuclesome histone core consists of central 
H3/H4 tetramer that is surrounded on either side by a H2A/H2B dimer. DNA wraps tightly 
around the histone proteins to form the intact nucleosome structure. Chromatin is very dynamic 
and can be found in multiple forms depending on how tightly DNA wraps around those histone 
proteins (Kornberg and Thomas 1974; Luger, Mader et al. 1997; Clapier and Cairns 2009).  
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Figure 1.10 Histone code.  
Posttranslational modifications of the histone molecules are located on the tail regions that are 
extended out of the nucleosome structure. Potential modifications occurring on histone tails in-
clude acetylation, methylation, ubiquitination and phosphporylation (Kornberg and Thomas 
1974; Jenuwein and Allis 2001; Zhang and Reinberg 2001; Shilatifard 2006).  
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In inactive heterochromatin, histone proteins bind tightly to DNA and regulate access to 
DNA of transcription factors and the general transcription machinery.  Structural changes to his-
tones are facilitated by posttranslational modifications that render chromatin more or less availa-
ble for transcription.  The N- and C-terminal tails of histones are regions available for posttran-
slational modifications (Felsenfeld and Groudine 2003).  Modifications to histone tails include 
acetylation (Morris, Rao et al. 2007), phosphorylation (Ivaldi, Karam et al. 2007), methylation 
(Li, Lin et al. 2002), sumoylation (Nathan, Sterner et al. 2003), ADP ribosylation (Boulikas 
1990) and ubiquitination (Davies and Lindsey 1994; Ng, Xu et al. 2002; Ting and Trowsdale 
2002; Shukla, Stanojevic et al. 2006; Shukla and Bhaumik 2007).  These  modifications have 
been linked to gene expression through a histone code hypothesis which proposes that the com-
binatory effects of these modifications determines the “open” and “closed” state of chromatin 
and thereby aids in determining the expressivity of genes (Wray, Hahn et al. 2003). Histone 
modifications create a variety of modifications that alter N terminal tails of histones and create 
the epigenetic code that, in part, determines the accessibility of chromatin.  
 
Contributions from histone modifications are just one element of regulation that deter-
mines the overall structure of chromatin. The state of chromatin packaging is determined by a 
combination of factors in addition to histone modifications including DNA methylation and nuc-
leosome remodeling, which together define gene expression patterns and regulate transcription. 
In eukaryotes, DNA methylation occurs by covalent modification of cytosines to CpG dinucleo-
tides (Illingworth and Bird 2009). Promoter regions in the human genome are embedded with 
CpG islands, where methylation occurs and provides an additional mechanism of transcription 
regulation through silencing (Sandelin, Carninci et al. 2007; Illingworth and Bird 2009). While 
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multiple mechanisms contribute to gene expression, histone modifications are the most studied 
of these mechanisms.  Due to the complex relationship between DNA and the histones around 
which it is wound, modifications to histones are a key component of transcriptional regulation.  
Of histone modifications, acetylation and methylation are the most critical as they impart signifi-
cant structural alterations in histones and dramatically change interactions with DNA.   
 
1.13 Histone acetylation: 
 
One of the most studied histone modifications is acetylation of lysine residues on his-
tones which loosens interactions between histone proteins and DNA, and contributes to an 
“open” state of chromatin (Cosgrove 2007).  Acetylation primarily occurs on lysine residues lo-
cated on histones H3 and H4 (Figure 1.10). A deacetylated tail of histones H3 and H4 are posi-
tively charged and, as DNA is negatively charged; deacetylated histones tightly bind DNA and 
render it inaccessible to transcriptional activation. The addition of acetyl groups to targeted ly-
sine residues neutralizes the positive charge on histone tails and loosens interactions with DNA 
(Struhl 1998). Alterations in histone acetylation result from changes in the balance between the 
enzymes which catalyze histone acetylation: histone acetyltransferases (HATs) and histone dea-
cetyltransferases (HDACs), which remove acetyl groups (Utley, Ikeda et al. 1998; Yang 2004). 
HATs and HDACs are recruited to chromatin as transcriptional coactivators by transcription fac-
tors and are generally found in large remodeling complexes. There are a variety of known HATs, 
including several which are discussed in this dissertation: general control of amino acid synthesis 
5 (GCN5), CREB binding protein (CBP), p300 and p300/CBP associated factor (PCAF), 
(Bannister and Kouzarides 1996; Ogryzko, Schiltz et al. 1996; Chan and La Thangue 2001; 
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Legube and Trouche 2003). Acetylation is reversed by histone deacetylases (HDACs) which re-
move acetyl groups from lysine residues (de Ruijter, van Gennip et al. 2003). Both HATs and 
HDACs influence a myriad of cellular processes including signal transduction, apoptosis, cell 
cycle regulation, cell growth and transcription (Utley, Ikeda et al. 1998; Yang 2004).  
 
1.14  Histone methylation: 
 
Methylation plays dual roles in regulating histone accessibility as it has been linked to 
both activation and silencing of transcription (Daujat, Bauer et al. 2002; Naeem, Cheng et al. 
2007). Methylation confers additional levels of complexity as methylation can be mono, di- or 
tri- methylation and occurs at lysine (K) and arginine residues (R) (Figure 1.10). Methylation of 
arginine residues has been linked to gene activation (Bauer, Daujat et al. 2002) while lysine me-
thylation has been linked with gene silencing and activation (Jenuwein and Allis 2001; 
Nakayama, Rice et al. 2001; Berger 2002; Lehnertz, Ueda et al. 2003; Shilatifard 2006). Argi-
nine is a positively charged amino acid and the nitrogen of arginine can be modified by the addi-
tion of one or two methyl groups (Gary and Clarke 1998). Currently eight mammalian protein 
arginine methyltransferases (PRMTs) have been identified (Bedford and Richard 2005).  While 
the mechanism through which arginine methylation enhances transcripition remains unknown, 
evidence exists that methylated arginines collaborate with other transcriptional activators and 
enhance their activity to promote transcriptional activation (Stallcup 2001). Methylation on ly-
sine residues generally correlates with gene suppression but can also contribute to gene activa-
tion. One, two or three methyl groups can be added by histone methyltransferases (HMTases) 
(Lachner and Jenuwein 2002). Trimethylation of histone 3 lysines 9 and 27 or histone 4 lysine 20 
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is associated with gene silencing, while H3K4 di- and trimethylation, H3K36 trimethylation, and 
H3K79 di- and trimethylation methylation contributes to gene activation (Varier and Timmers 
2011).  
 
The histone methyltransferase Enhancer of Zeste Homolog 2 (EZH2) belongs to Poly-
comb Group (PcG) and is involved in gene repression (Laible, Wolf et al. 1997; Satijn and Otte 
1999). EZH2 catalyzes trimethylation of H3K9 and K27 with a strong preference for K27 (Cao, 
Wang et al. 2002; Czermin, Melfi et al. 2002; Muller, Hart et al. 2002). EZH2 has a cysteine rich 
SET domain which is involved in binding to the Polycomb repressive complex (Cao, Wang et al. 
2002). Data in Chapter 3 of this dissertation demonstrates EZH2 binds to the CIITA proximal 
promoter and is a “master regulator” of the silencing histone modifications at CIITApIV, thus 
implicating roles for EZH2 in regulating other silenced, but inducible genes (Mehta, Truax et al. 
2011). Of note are recent studies indicating expression of EZH2 is elevated in multiple human 
cancers, including breast cancer, which will be described in detail in this dissertation in Chapter 
4.  
 
While the mechanisms by which histone methylation contributes to gene silencing are not 
known, cross talk between various modifications has been observed (Muller and Verrijzer 2009).  
H3K4 methylation blocks methylation of H3K9 and induces the dimethylation of H3K27, result-
ing in an opening of chromatin structure (Wang, Huang et al. 2001; Agger, Cloos et al. 2007; 
Lee, Villa et al. 2007). H3K36 methylation recruits histone deacetylases and reestablishes closed 
structure resulting in decreased gene expression (Carrozza, Li et al. 2005; Lee and Shilatifard 
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2007). Similar to reversible acetylation, histone methylation can also be reversed by histone de-
methylases (HDMTs).  One of first identified HDMT is LSD1 which demethylates mono- and 
di- H3K4in a flavin adenine dinucleotide (FAD) dependent oxidative reaction (Wysocka, Milne 
et al. 2005). This observation led to discovery of highly conserved Jumonji C containing proteins 
which remove methyl groups from lysine residues (Fodor, Kubicek et al. 2006; Klose, Yamane 
et al. 2006; Tsukada, Fang et al. 2006; Whetstine, Nottke et al. 2006; Yamane, Toumazou et al. 
2006). This recent observation that methylation is reversible by histone demethylases provides 
new levels of regulation for gene expression. There are also additional interactions between me-
thylated histones and the DNA methylation machinery which further determines the availability 
of DNA for gene expression. While histone methylation and the impact on DNA structures is 
reversible, DNA methylation is permanent and leads to stable repression of gene expression. The 
interactions between methylated histones and methylated DNA are complex as histone methyla-
tion mediates DNA methylation and DNA methylation also serves as a template for modifica-
tions to histones (Ooi, Qiu et al. 2007; Mohn, Weber et al. 2008). Greater understanding of the 
crosstalk between modifications to histones and modifications to DNA provide new, and largely 
unexplored, levels of regulation of gene expression (Cedar and Bergman 2009). 
 
1.15 Additional Histone Modifications: 
 
Although histone acetylation and methylation are the most studied, there are a variety of 
additional histone modifications including phosphorylation, ubiquitination, sumoylation, and 
poly ADP ribosylation which contribute to the status of chromatin. While phosphorylation of his-
tone tails is indicative of active transcription, the mechanism by which this modification effects 
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gene expression is unknown (Nowak and Corces 2000). Phosphorylation of histone H3 at serine 
10 (Figure 1.10) plays an important role in the very early events of transcriptional elongation 
that occur prior to P-TEF-b recruitment (Ivaldi, Karam et al. 2007). Furthermore, several histone 
acetyltransferases have enhanced activity towards phosphorylated histone substrates (Cheung, 
Tanner et al. 2000; Lo, Trievel et al. 2000). Histone sumoylation is generally associated with 
transcriptionally silenced genes (Nathan, Sterner et al. 2003) (Shiio and Eisenman 2003) and his-
tone ubiquitination, similarly to histone methylation, plays dual roles in transcription activation 
and silencing, depending on the residue targeted. For example, histone H2A ubiquitination 
(ubH2A) plays roles in both gene activation and in H3K27me3 mediated silencing (Cao, 
Tsukada et al. 2005; Wei, Zhai et al. 2006; Lee, Norman et al. 2007). Finally, poly (ADP ribosy-
lated) histones are important in the assembly of histone complexes during DNA replication 
(Boulikas 1990). Thus, the structure of chromatin and the availability of DNA for transcription is 
determined by various posttranslational modifications.  
 
1.16 Histone modifications and DNA accessibility:  
 
 
 Posttranslational modifications to N terminal tails of histones affect chromatin structure 
and availability for gene expression (Figure 1.10). The state of chromatin is determined by a 
combination of modifications on single histones which orchestrates a histone code that regulates 
transcriptional activation. While this field remains in its infancy, a histone code has begun to 
emerge.  Methylation at histone H3K9 and H3K27 are considered to be silencing modifications, 
while active chromatin is characterized by acetylation at H3K9, H3K14, and H3K18, as well as 
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trimethylation at H3K4.  Poised chromatin is identified by the activating modification H3K4me2 
and the silencing modification H3K27me3 (Jenuwein and Allis 2001; Lachner, O'Carroll et al. 
2001; Zhang and Reinberg 2001; Bernstein, Humphrey et al. 2002; Santos-Rosa, Schneider et al. 
2002; Shilatifard 2006). The full mechanisms which determine interactions between various his-
tone modifications and regulate their effects on chromatin remain unknown and are areas of in-
tense investigation. Thus, the interplay between those various modifications creates a so-called 
“epigenetic landscape” which determines the expressivity of genes.  
 
1.17 Chromatin structure of MHC II and CIITA promoters:  
 
 Extensive work has established the epigenetic map of MHC II and CIITA genes as know-
ledge of the epigenetic modifications to histones of these genes is critical to understanding their 
transcriptional regulation.  Among the most well documented modifications associated with ac-
tive transcription of  MHC II genes is acetylation of lysine residues on histone H3 (primarily K9 
and K18) and histone H4 (primarily K5 and K8) (Beresford and Boss 2001; Masternak, Peyraud 
et al. 2003; Spilianakis, Kretsovali et al. 2003; Zika, Fauquier et al. 2005; Rybtsova, Leimgruber 
et al. 2007). Basal levels of acetylation are constitutively observed on MHC II histones H3 and 
H4 which dramatically increases upon recruitment of CIITA (Beresford and Boss 2001; Zika, 
Fauquier et al. 2005). Multiple histone modifying enzymes are recruited to MHC II with CIITA 
including histone acetyltransferases CBP/p300, pCAF, and Src-1, to establish an open state of 
chromatin. In the absence of CIITA, basal levels of acetylation are observed, but the lack of re-
cruitment of HATs diminishes the availability of MHC II promoter DNA, indicating HATs are 
required to fully open MHC II chromatin (Zika, Greer et al. 2003; Zika, Fauquier et al. 2005; 
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Koues, Dudley et al. 2008).  Histone H3 acetylation at K9, K14, K18, and K27, and histone H4 
acetylation at K8, are the active marks of MHC II genes (Gomez, Majumder et al. 2005). 
Changes in methylation are also associated with active transcription of MHC II genes including 
CARM1 mediated dimethylation of histone H3R17 and trimethylation of histone H3K4 and K36, 
K9, and K27 (Zika, Greer et al. 2003; Zika, Fauquier et al. 2005; Chou and Tomasi 2008; Koues, 
Dudley et al. 2008).  
 
 CIITA is the master regulator of MHC II genes, thus CIITA expression correlates with 
that of MHC II. Relatively few studies have analyzed the epigenetic status of CIITApIV. How-
ever we and others have documented significant increases in acetylation of histone H3 and acety-
lation of histone H4 at CIITApIV within moments of IFN-γ stimulation (Morris, Beresford et al. 
2002).  Specific increases in acetylation have been observed at H3K9, H3K18, and H4K8 (Ni, 
Karaskov et al. 2005). Trimethylation of CIITApIV H3K4, indicative of active transcription, is 
also observed after prolonged stimulation with IFN-γ (Ni, Karaskov et al. 2005).  Histone mod-
ifying enzymes that have been mapped to the CIITA promoter region include the HATs 
CBP/p300, the HMT CARM1, and the chromatin remodeler BRG-1 (Koues, Mehta et al. ; 
Pattenden, Klose et al. 2002; Ni, Karaskov et al. 2005; Mehta, Truax et al. 2011).  Detailed cha-
racterization of histone modifying enzymes which mediate additional MHC II and CIITA histone 
modifications remains to be completed. Increased knowledge of epigenetic regulation of MHC II 
and CIITA genes will allow us to better understand dysregulated expression of MHC II genes in 
various disorders and diseases.  
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1.18 DYSREGULATION OF MHC II MOLECULES IN CANCER: 
 
During an immune response, foreign antigens are detected by CD4
+ 
T cells via the T cell 
receptor and MHC II molecules. As MHC II plays a central role in a properly functioning im-
mune system, its faulty expression is related to many diseases.  Expression of MHC II genes and 
its master regulator CIITA is thus tightly regulated at multiple levels (Handunnetthi, 
Ramagopalan et al. 2010) with a majority of regulation focused at the level of transcription. Un-
derstanding the regulatory mechanisms that dictate MHC II and CIITA gene expression is an im-
portant step towards developing better and more specific therapies to regulate MHC II expres-
sion in disease states. While it is well understood that over expression of MHC II leads to many 
autoimmune disorders, it has recently become obvious that lack of MHC II expression is equally 
destructive, resulting in a severe combined immunodeficiency disorder when expression is 
blocked (de Preval, Hadam et al. 1988) and in tumor formation and metastasis when MHC II ex-
pression is suppressed (Chamuleau, Ossenkoppele et al. 2006). 
 
Cancer develops from a deadly combination of activation of oncogenic pathways and in-
activation of tumor suppressor pathways. Initially cancer was believed to result exclusively from 
genetic events including mutations, gene rearrangements, and gene deletions.  However, we now 
know that dysregulated epigenetics and DNA methylation profiles are equal contributors to the 
development of cancer growth. These malfunctions include global hypomethylation (Eden, 
Gaudet et al. 2003) and deacetylation, hypermethylation at specific promoters, and altered ex-
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pression of a multiplicity of enzymes involved in epigenetics. Despite these observations, global 
histone profiling in cancer is still quite limited. Great effort has been devoted to understanding 
the role of DNA methylation in cancer cells, but these efforts provide insight into only one level 
of regulation amongst many, including those provided by various posttranslational modifications 
to histone tails. Although histones modifications play important roles in regulating gene expres-
sion, knowledge of histone modifications in cancers, and correlation to various stages of cancer, 
remains poor.  
 
 Of cancers, the most lethal are those that have gained metastatic ability.  In general, the 
ability of cancer cells to metastasize is determined by their ability to travel to distal sites through 
the bloodstream.  Once established in a new location, cancer cells proliferate and give a rise to 
secondary tumors that are a major cause of death in cancer patients. Metastasized cancers often 
down regulate expression of various genes to avoid recognition and response by the immune sys-
tem. It has rapidly become appreciated that epigenetic alterations play critical roles in aberrant 
expression of genes which contribute to tumor cell metastasis.  Tumor associated antigens 
(TAA), which are selectively expressed by tumors, can be taken up by antigen presenting cells 
and presented via MHC II to CD4
+ 
T cells which in turn activate CD8
+  
cytotoxic T cells to elim-
inate the tumor cell (Chamuleau, Ossenkoppele et al. 2006; Meissner, Whiteside et al. 2008). 
Tumor cells expressing MHC II molecules can also initiate an efficient antitumor immune re-
sponse. Activated CD4
+ 
T cells multiply and activate B cells to initiate a killing response via an-
tibodies. CD4
+ 
T cells also secrete cytokines to activate CD8
+
 T cells to mediate direct killing of 
tumor cells.  
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Recent evidence indicates one mechanism utilized by tumor cells to escape recognition 
and elimination by the immune system is suppression of cell surface expression of MHC II. The 
absence of MHC II expression results in tumor escape and tolerance (Chamuleau, Ossenkoppele 
et al. 2006). Studies performed in mouse tumor models indicate CD4
+ 
T cells are essential for 
initiating effective anti-tumor immune responses (Greenberg, Cheever et al. 1981; Fujiwara, 
Fukuzawa et al. 1984; Hock, Dorsch et al. 1991; Lauritzsen, Weiss et al. 1994). Loss of tumor 
cell MHC II expression is associated with decreases in tumor infiltrating T cells and increased 
aggressiveness of multiple carcinomas (Garrido and Ruiz-Cabello 1991; Warabi, Kitagawa et al. 
2000). These studies suggest MHC II presentation of tumor derived antigens generates critical 
targets for activation of the anti-tumor immune response and emphasizes the importance of un-
derstanding transcriptional regulation of MHC II. Observations that metastatic tumor cells spe-
cifically suppress CIITA genes expression resulting in decreased expression of MHC II mole-
cules and tumor immune evasion are described in Chapter 4 of this dissertation.  
 
1.19 SUMMARY:  
 
The regulation of gene expression is one of the most intensely studied processes in 
science. Dysregulated gene expression has profound effects on cellular function and is the cause 
of a majority of human disease. Although there are many processes that modulate gene expres-
sion, transcription is the most direct.  While it has long been understood that the molecular and 
functional characterization of chromatin modulating enzymes and transcription factors is impor-
43 
 
tant, recent observations of dysregulated chromatin dynamics and transcription factor activity in 
disease have made clear that transcription offers unlimited potential in medicine and in cancer 
treatment in particular.  
 
Induction of an antigen specific immune response is critical for eliminating infections and 
for recognizing cancer cells. MHC II molecules present peptides derived from extracellular pro-
teins to activate the adaptive immune response.  As a direct result, dysregulated expression of 
MHC II results in serious illness. Over expression of MHC II leads to autoimmune disease while 
the loss of MHC II results in a severe combined immune deficiency. MHC II is also very impor-
tant in regulating anti-tumor response. Because MHC II plays such an important role in initiating 
the adaptive immune response to infections and tumors, it is critical to fully understand transcrip-
tional regulation of MHC II and CIITA. 
 
 It is known that the “master of degradation,” the 26S proteasome, plays important roles 
in transcriptional regulation of MHC II and CIITA genes. Therefore, multiple roles likely exist 
for the ubiquitin/proteasome pathway in initiating transcription, in stabilizing transcriptional 
complexes, and in regulating removal of transcription factors from promoters leading to tran-
scriptional termination.  We have learned much regarding the transcription of protein coding 
genes in eukaryotes, but much remains to be learned if we are to harness the power of transcrip-
tion and, as in the case of CIITA and MHC II, regulate the regulators.  
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In order to better understand the transcriptional regulation of CIITA, the master regulator 
of MHC II genes, we have investigated novel regulatory mechanisms of CIITA. As described 
above, expression of mammalian genes is regulated at multiple levels, including transcriptional 
control. Chapters two and three of this dissertation focus on the novel roles played by the 19S 
ATPase S6a in regulating transcription initiation and elongation of CIITApIV. S6a is an impor-
tant ATPase known for binding polyubiquitinated proteins that are marked for degradation. Our 
studies have shown that following cytokine stimulation, S6a rapidly binds to MHC II and CII-
TApIV proximal promoters where S6a mediates chromatin accessibility and recruitment of tran-
scription factors STAT-1 and IRF-1 to CIITApIV. S6a also binds robustly to CIITA coding re-
gions where it mediates the recruitment of the proteins RNA pol II and cyclin T1, both of which 
are required for transcriptional elongation.  In these chapters we therefore demonstrate novel 
ways of regulating transcription of CIITApIV, where the 19S ATPase S6a plays important roles 
in transcription initiation and elongation.  
 
Chapters four and five of this dissertation focus on transcriptional regulation of CIITA-
pIV via histone modifying enzymes and the histone methyltransferase EZH2. As CIITA is the 
master regulator of the critical inflammatory gene MHC II, transcription at CIITApIV must be 
rapidly activated.  Therefore, I in Chapter four, I determined the order and timing of epigenetic 
events that occur at the CIITA proximal promoter. Silencing modifications of trimethylation on 
histone H3 lysine 9 and lysine 27 are significantly reduced within the first 20 minutes post cyto-
kine stimulation and reach basal levels within two hours. The opposite trend was observed with 
the activating methylation at CIITApIV histone H3 lysine 4. Together, these results suggest that 
changes observed in chromatin structure occur very rapidly post stimulation with IFN-γ to allow 
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transcription factors like STAT-1 to bind CIITApIV. Binding of the histone methyltransferase 
EZH2 to CIITApIV also declines rapidly following IFN-g stimulation.  Work in Chapter five 
delves further into the role played by EZH2 and demonstrates EZH2 is a master regulator of 
CIITA. We determined that eliminating EZH2 expression through knockdown restores expres-
sion of CIITA and MHC II in MDA MB 435 breast cancer cells. These results hold exciting 
promise for the use of EZH2 knockdown in tumor therapies to reconstitute expression of CIITA 
and MHC II. 
The overall focus of this dissertation is the transcriptional regulation of CIITA genes. We 
hypothesize that the 19S ATPase S6a and the histone methyltransferase EZH2 each play critical 
roles in regulating transcriptional expression of CIITA genes. Understanding expression of CII-
TA and MHC II genes will allow us to reach new horizons of understanding the mechanisms 
which determine the immune response to pathogen, to self and to tumors.  
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2.1 ABSTRACT: 
 
Class II transactivator (CIITA) is the master regulator of the major histocompatibility class 
II transcription complex (MHC II) and is critical for initiation of adaptive immune responses. We 
have previously demonstrated that the 19S proteasome ATPase Sug1 plays a significant role in 
regulating CIITA activity and MHC-II expression. We now show that an additional component 
of the 19S complex, the 19S ATPase S6a (S6′/Tat-binding protein 1), is crucial for regulating 
cytokine-inducible transcription of CIITA. Lack of S6a negatively impacts CIITA activity and 
CIITA expression. Decreased expression of S6a significantly diminishes the recruitment of tran-
scription factors to the CIITA interferon-γ-inducible promoter IV (CIITApIV) and significantly 
decreases CIITApIV histone H3 and histone H4 acetylation, with a preferential loss of acetyla-
tion at H3 lysine 18 and H4 lysine 8. In addition, we provide evidence for the involvement of the 
19S AAA (ATPases associated with diverse cellular activity) ATPase hexamer as the 19S     
ATPase S6b binds CIITApIV in an S6a dependent fashion and has effects similar to S6a on  
CIITApIV histone acetylation. These analyses demonstrate the importance of 19S ATPases in 
the assembly of CIITApIV transcription machinery and provide additional insight into the regu-
latory mechanisms of the 19S proteasome in mammalian transcription.  
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2.2 BACKGROUND 
 
Major histocompatibility class II (MHC II) molecules are cell surface glycoproteins 
which present antigenic peptides to CD4
+
 T lymphocytes and play important roles in initiating, 
maintaining and terminating adaptive immune responses against invading pathogens and tumors.  
MHC II genes are induced by the inflammatory cytokine interferon gamma (IFN-) (Cresswell 
and Howard 1997; Ferdous, Gonzalez et al. 2001) and the expression of MHC II molecules is 
primarily regulated at the level of transcription.  Class II transactivator (CIITA) is a master regu-
lator that drives activation of MHC II genes (Chang, Fontes et al. 1994; Mach, Steimle et al. 
1996).  CIITA does not bind DNA, but interacts with the MHC II promoter via direct binding to 
the requisite MHC II transcription factors Regulatory Factor X (RFX), cAMP Response Element 
Binding (CREB) and Nuclear Factor Y (NF-Y) at the respective X1, X2 and Y promoter ele-
ments of MHC-II genes.  Once bound, CIITA stabilizes this enhanceosome complex and recruits 
other components of the basal transcriptional machinery (Moreno, Beresford et al. 1999; Master-
nak, Muhlethaler-Mottet et al. 2000; Zhu, Linhoff et al. 2000).  Transcription of CIITA itself is 
regulated in a cell specific manner by four distinct promoters: pI, pII, pIII and pIV (Muhlethaler-
Mottet, Otten et al. 1997; Morris, Beresford et al. 2002).  CIITA promoter IV (pIV) is the prima-
ry IFN-γ responsive form of CIITA and is predominantly induced in non-antigen presenting cells 
in response to IFN-γ stimulation via the JAK-signal transducer and activator of transcription 
(STAT) signal transduction pathway (Morris, Beresford et al. 2002; Piskurich, Gilbert et al. 
2006).   
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Epigenetic analysis of CIITApIV has shown that, prior to IFN-γ stimulation, acetylation 
of histones H3 and H4 occur at low to moderate levels (Ni, Karaskov et al. 2005). Following cy-
tokine stimulation, transcription of CIITA is induced at CIITApIV and is correlated with in-
creased acetylation of histones H3 and H4 (Morris, Beresford et al. 2002) and recruitment of his-
tone acetyltransferases, CIITApIV specific transcription factors, and the basal transcription ma-
chinery (Ni, Karaskov et al. 2005).  
 
The 26S proteasome is a large, multimeric complex made of a 19S regulatory particle and 
a 20S proteolytic core (Baumeister, Walz et al. 1998).  The 19S regulator is further divided into 
two parts: a lid and a base.  The lid is composed of eight non-ATPase subunits which are re-
quired for protein degradation (Coux, Tanaka et al. 1996; Baumeister, Walz et al. 1998).  The 
19S base contains six ATPases termed S4, S6a (S6‟, TBP1), S6b, S7, Sug1 (S8), and Sug2 
(S10b), and three non-ATPase subunits (Gorbea, Taillandier et al. 1999; Adams 2003).  During 
protein degradation, the 19S regulatory base contacts the 20S catalytic core and regulates the 
access of substrates to the core by recognizing and hydrolyzing ubiquitin from polyubiquitinated 
proteins (Coux, Tanaka et al. 1996; Glickman, Rubin et al. 1999; Rabl, Smith et al. 2008).  Re-
cent evidence in yeast and mammalian cells has supported novel, non-degradative functions for 
components of the 26S proteasome in regulating gene transcription (Baumeister, Walz et al. 
1998; Ciechanover 1998; Muratani and Tansey 2003; Lee, Ezhkova et al. 2005; Sulahian, 
Johnston et al. 2006).  In yeast, the 19S regulatory complex directly associates with the Gal4 ac-
tivator and is recruited to the GAL responsive promoter (Chang, Gonzalez et al. 2001; Gonzalez, 
Delahodde et al. 2002; Archer, Burdine et al. 2008).  Knockout studies in yeast and mammalian 
cells have shown that the 19S is essential for initiation and elongation by RNA polymerase II, 
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while the proteolytic activity of the 26S is not required (Ferdous, Kodadek et al. 2002).  Our pre-
vious studies have demonstrated that the 19S ATPase Sug1 associates with MHC II proximal 
promoter where it plays an important role in regulating CIITA recruitment to the HLA-DRA 
MHC II promoter and in subsequent MHC II gene expression (Bhat, Turner et al. 2008).  We 
have further shown that Sug1 plays a role in recruitment of multiple histone modifying enzymes 
where Sug1 positively regulates histone acetylation and methylation of MHC II and CIITApIV 
(Koues, Dudley et al. 2008; Koues, Dudley et al. 2009).   
 
Despite these findings, it remains unclear if additional 19S ATPases regulate mammalian 
gene expression and whether or not the regulatory mechanisms we have seen at the MHC-II 
promoter occur at additional genes.  S6a (S6‟/TBP-1) was first isolated through direct interac-
tions with the human immunodeficiency virus type 1 (HIV-1) Tat transactivator (Nelbock, Dillon 
et al. 1990) and has subsequently been shown to directly interact with multiple other proteins in-
cluding TBP-1-interacting protein (GT198/Hop2), the von Hippel-Lindau protein, rat α-
synuclein and the human ARF tumor suppressor.  S6a was recently shown to cooperate with TBP 
interacting protein to cooperatively enhance nuclear receptor (NR)-mediated transactivation, 
however the mechanisms that support the activating effects of S6a on NR transcription (Satoh, 
Ishizuka et al. 2009) remain unknown.  We demonstrate here that S6a plays critical roles in the 
initiation of transcription from CIITApIV. S6a is critical for the recruitment of requisite tran-
scription factors STAT-1and interferon regulatory factor 1 (IRF-1) to CIITApIV and for the ace-
tylation of histones H3 and H4 preceding transcription factor recruitment.  These results are nov-
el, as they indicate previously uncharacterized roles for the 19S ATPases in regulating transcrip-
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tion of inducible genes and provide further insight into the roles of the 19S proteasome in mam-
malian transcription.  
 
2.3 RESULTS 
 
The 19S ATPase S6a associates with CIITApIV and MHC II proximal promoters. 
 
We have recently shown that the 19S ATPase Sug1 positively regulates MHC II tran-
scription by stabilizing CIITA binding (Bhat, Turner et al. 2008) and by regulating histone H3 
acetylation at the MHC II proximal promoter (Koues, Dudley et al. 2008).  Specific roles for ad-
ditional 19S subunits in mammalian transcription remain largely unknown.  As the 19S ATPase, 
S6a has recently been shown to enhance transcription, we first investigated roles of S6a in MHC 
gene regulation by determining if S6a binds to MHC II promoter element and to the promoter of 
CIITApIV. HeLa cells were stimulated with IFN-γ, subjected to immunoprecipitation (IP) with 
antibody to endogenous S6a, and were analyzed by real-time PCR with primers spanning the 
proximal promoters of MHC II HLA-DRA and CIITApIV. Upon IFN- stimulation, S6a demon-
strated rapid and robust association with both the MHC-II proximal promoter (Figure 2.1 A) and 
with CIITApIV (Figure 2.1 B).  ChIP analyses in yeast have determined association of the pro-
teasome with elongation and coding regions of transcribed genes (Gillette, Gonzalez et al. 2004). 
Likewise, we observed the robust binding of S6a to MHC II exon III (Supplementary Figure 
2.11 B), MHC II exon V (Supplementary Figure 2.10 C) and CIITA coding region (Supple-
mentary Figure 2.10 E) indicating a strong potential for parallel pathways in mammalian cells.  
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Figure 2.1  The 19S ATPase S6a associates with MHC-II and CIITApIV proximal promo-
ters.  
(A-B)  ChIP assays were carried out in HeLa cells stimulated with IFN-γ for 0 to 18 hours.  Ly-
sates were immunoprecipitated (IP) with control antibody, antibody to endogenous S6a and as-
sociated DNA was isolated and analyzed via real-time PCR using primers spanning the W-X-Y 
box of the MHC-II HLA-DRA (A) and primers spanning IRF-E-GAS box of CIITApIV (B) pro-
moter.   Real-time PCR values were normalized to the total amount of promoter DNA added to 
the reaction (input). Input values represent 5% of the total cell lysate.  IP values are presented as 
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fold increase in the MHC-II and CIITA promoter DNA relative to unstimulated S6a IP samples.  
Control IP values for (A) and (B) were 0.5 ± 0.05.  Values for control IPs and S6a IPs represent 
mean ± SEM of five independent experiments.   
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Decreased expression of S6a decreases CIITA expression and activity. 
 
As S6a inducibly bound MHC II and CIITA promoters, we next investigated the role of 
S6a in regulating activation of these cytokine inducible genes by using short interfering RNA 
(siRNA) duplexes to specifically knockdown endogenous S6a.  siRNA mediated reduction of 
endogenous S6a decreased S6a protein expression by 90% relative to control siRNA transfected 
cells, but did not impact the expression of any of the other five 19S ATPases (Figure 2.2 A).  
We next addressed the role of S6a in regulating MHC II expression by using real-time PCR to 
measure endogenous levels of mRNA in S6a siRNA transfected cells.  Decreased expression of 
S6a dramatically reduced the IFN- inducible levels of endogenous MHC II mRNA (Figure 2.2 
B, white bars), in comparison to cells transfected with control siRNA (Figure 2.2 B, black 
bars).   
 
CIITA expression and activity drives MHC II expression.  In order to determine if deple-
tion of S6a affected CIITA transactivation, we employed dual luciferase reporter assays.  Trans-
fecting cells with control siRNA, CIITA and HLA-DRA-Luc resulted in increased MHC II HLA-
DRA promoter activity (Figure 2.2 C, black bars).  By comparison, in cells similarly transfected 
with S6a siRNA or predesigned MISSION Vérité S6a siRNA, CIITA mediated activation of the 
MHC II HLA-DRA promoter was significantly reduced (Figure 2.2 C, white bars).  Notably, 
levels of CIITA activity in S6a siRNA and MISSION Vérité S6a siRNA treated samples were 
comparable indicating that our predesigned S6a siRNA is very specific with minimum of off tar-
get effects. As an additional control for siRNA specificity, we knocked down S6a, reconstituted 
S6a expression by over expression of Myc-S6a, and restored the MHC-HLA-DRA promoter ac-
tivity in these cells (Figure 2.2 C, grey bars).  
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Figure 2.2  The 19S ATPase S6a is required for optimal CIITA activity and CIITA gene 
expression.  
(A)  S6a siRNA specifically and efficiently decreases S6a protein expression in the absence or 
presence of cytokine stimulation.  HeLa cells were transfected with control or S6a siRNA, un-
treated or stimulated with IFN-γ, harvested and subjected to Western Blot analysis of endogen-
ous expression of 19S ATPases S4, S6a, S6b, S7 Sug1 and S10b.  Western Blot analysis shows 
90% knockdown of S6a and stable expression of the other 19S ATPases.  Results reported are 
representative data of three independent experiments.   
(B)  Reduced expression of S6a in siRNA transfected cells decreases endogenous MHC-II 
mRNA expression.  Experimental cells were transfected with S6a specific siRNA and control 
cells were transfected with scrambled control siRNA.  Twenty four hours following siRNA 
transfection, HeLa cells were left unstimulated or were stimulated with IFN-γ for 0 to 18 hours.  
Fractions of cell lysates were analyzed for S6a expression by Western blot (not shown) or for 
levels of MHC-II mRNA.  Levels of mRNA were measured by real-time PCR and were norma-
lized to 18S mRNA.  Real-time PCR was performed in triplicate and results represent the mean ± 
SD of six independent experiments.   
(C)  Lack of S6a specifically decreases CIITA transcriptional activity.  HeLa cells were trans-
fected with MHC-II HLA-DRA-Luc reporter construct, Renilla, 100ng of Myc-S6a and 100ng of 
CIITA as indicated.  Controls were transfected with the Luc reporter, empty pCDNA3 vector and 
were transfected with control siRNA (black bars), with S6a specific siRNA (white bars) or ver-
site S6a specific siRNA (grey bars).  Luciferase assays were performed in triplicate and data are 
presented as fold increase in the luciferase activity.  Results presented represent the mean ± SD 
of three independent experiments.   
(D and E)  Reduced expression of S6a in siRNA transfected cells decreases endogenous CIITA 
mRNA (D) and does not affect GAPDH mRNA (E) expression levels.  As above, cells were 
transfected with S6a specific or scrambled control siRNA and were stimulated with IFN-γ for 0 
to 18 hours.  Fractions of cell lysates were analyzed for S6a expression by Western blot (not 
shown) or for levels of CIITA normalized to 18SmRNA (D) or as a control for GAPDH (E) 
mRNA level.  Real-time PCR was performed in triplicate and results represent the mean ± SD of 
six independent experiments.  ***P < 0.001, **P < 0.005, *P < 0.05 versus control siRNA  
(F) S6a siRNA decreases CIITA protein expression.  HeLa cells were transfected with control or 
S6a siRNA, stimulated as indicated, harvested and subjected to IB for S6a (top), CIITA (middle) 
and tubulin (bottom).  Immunoblots shows 95% decrease of S6a in stimulated and unstimulated 
cells, 60% decrease of CIITA (lane 6) 4hrs post cytokine stimulation and 35% decrease of CIITA 
(lane 8) 18hrs post stimulation. Results reported are representative of five independent experi-
ments.  
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 As S6a binds to CIITApIV, we next sought to determine if S6a was important for driving 
CIITA expression from the IFN- inducible CIITApIV.  Reduced expression of S6a had a signif-
icant negative impact on CIITA transcript levels (Figure 2.2 D, white bars) and protein level 
(Figure 2.2 F) in comparison to cells transfected with control siRNA (Figure 2.2 D, black 
bars).  As controls for the specificity of the knockdown effects on CIITA and MHC II gene ex-
pression, we investigated the role of S6a in regulating expression of constitutively expressed gly-
ceraldehyde-3-phosphate dehydrogense GAPDH (Figure 2.2 E).  Real-time PCR analysis indi-
cated that transcript levels of GAPDH were not affected by siRNA mediated depletion of S6a, 
indicating that the effects of decreased expression of S6a were specific to these inducible genes.  
 
S6a knockdown decreases transcription factor recruitment to the CIITApIV proximal 
promoter. 
 
CIITApIV contains three cis acting elements which are required for transcription in re-
sponse to IFN-γ: an IFN-γ activated sequence (GAS), an IRF element (IRF-E), and an E-box. 
Ligand-induced dimerization of the IFN-γ receptor activates JAK1 and JAK2 tyrosine kinases 
which phosphorylate STAT-1 allowing STAT-1 to translocate to the nucleus where it induces the 
expression of the IRF-1 gene (Muhlethaler-Mottet, Di Berardino et al. 1998; Morris, Beresford et 
al. 2002; Ni, Karaskov et al. 2005).  STAT-1 is also recruited to the CIITApIV GAS sequence, 
while a constitutively expressed dimer of USF-1 is recruited to the CIITApIV E-box 
(Muhlethaler-Mottet, Di Berardino et al. 1998).  A heterodimer of transcribed and translated in-
terferon regulatory factor 1 (IRF-1) and inducibly expressed IRF-2 is recruited to the IRF-E 
(Piskurich, Linhoff et al. 1999; Morris, Beresford et al. 2002) to assemble a transcription initia-
tion complex with USF-1 and STAT-1.  We therefore sought to determine if S6a interacts with 
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transcription factors critical for CIITA expression.  Endogenous S6a and STAT-1 co-
immunoprecipitated from HeLa cells with and without cytokine stimulation (Figure 2.3, upper 
panel lane 3 and 4).  Positive control samples were immunoprecipitated with endogenous 
STAT-1 (Figure 2.3, upper panel lane 1) or a negative control IgG antibody (Figure 2.3, up-
per panel lane 2).  Equal loading of cell lysates was confirmed by immunoblot analysis of total 
STAT-1 protein (Figure 2.3, lower panel).   
 
To further address the role of S6a in regulating IFN- inducible CIITA expression, ChIP 
assays were performed to determine the level of STAT-1 and IRF-1 binding to CIITApIV in the 
absence of S6a expression.  As previously demonstrated, (Morris, Beresford et al. 2002) initial 
ChIP mapping experiments show that STAT-1 rapidly and stably binds CIITApIV in an eighteen 
hour timecourse of IFN-γ stimulation (Figure 2.4 A).  In cells transfected with S6a siRNA, 
STAT-1 binding to CIITApIV was significantly decreased when compared to cells transfected 
with scrambled siRNA (Figure 2.4 B).  ChIP mapping experiments further demonstrated that 
IRF-1 transiently associated with CIITApIV following four hours of IFN-γ stimulation (Figure 
2.4 C).  Similar to the effects of S6a depletion on STAT-1 binding, upon transfection with S6a 
siRNA, there was a significant decrease in IRF-1 binding to CIITApIV upon transfection with 
S6a siRNA (Figure 2.4 D).   
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Figure 2.3 19S ATPase S6a associates with STAT-1 
S6a associates with STAT-1.  HeLa cells were stimulated with IFN-γ for 30 min, lysed and sub-
jected to IP with STAT-1 (lane 1) as a positive control, with mouse isotype control IgG (lane 2), 
with S6a (lane 3) and with S6a under stimulation with IFN-γ (lane 4).  IP and lysate control sam-
ples (bottom) were subjected to IB for STAT-1.  Results reported are representative data of three 
independent experiments. 
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Figure 2.4  STAT-1 and IRF-1 recruitment to the CIITApIV proximal promoter is dramat-
ically decreased in the absence of S6a.  
(A and C)  STAT-1 and IRF-1 are recruited to CIITApIV upon IFN-γ stimulation. ChIP assays 
were carried out in HeLa cells stimulated with IFN-γ for 0 to 18 hours.  Lysates were immuno-
precipitated (IP) with control antibody, with antibody to endogenous STAT-1 (A) or with anti-
body to IRF-1 (C), and associated DNA was isolated and analyzed via real-time PCR using pri-
mers spanning CIITA isoform IV proximal promoter (as described in Figure 1).  IP values are 
presented as fold increase in CIITApIV promoter DNA relative to unstimulated STAT-1(A) and 
IRF-1(C) IP samples. Control IP values for (A) and (C) were 0.9 ± 0.4.  Values for control IPs, 
STAT-1 and IRF-1 IPs represent mean ± SEM of two independent experiments.  
(B and D) S6a knockdown decreases recruitment of STAT-1 and IRF-1 to the proximal promoter 
of CIITApIV.  ChIP assays were carried out in HeLa cells stimulated with IFN-γ for 0.5hr (B) 
and 4 hours (D).  Lysates were immunoprecipitated (IP) with control antibody, with antibody to 
endogenous STAT-1 (B) or with antibody to IRF-1 (D), and associated DNA was isolated and 
analyzed as above.  IP values are presented as fold increase in CIITApIV DNA relative to unsti-
mulated CIITA IP samples.  Control IP values for (B) and (D) were 0.7 ± 0.5. Values for control 
IPs, STAT-1 and IRF-1 IPs represent mean ± SEM of four independent experiments.   
(E) S6a knockdown does not significantly affect the protein level of phosphorylated STAT-1 
(pSTAT-1).  HeLa cells transfected with control or S6a specific siRNA were stimulated with 
IFN-γ, harvested and subjected to Western Blot analysis of endogenous expression of pSTAT-1 
(bottom) and S6a (top).  Immunoblots show 90% decrease of S6a that slightly affects expression 
of pSTAT-1. Protein levels were quantified by Multi Gauge V3.1. Results reported are repre-
sentative data of three independent experiments.  
(F) Reduced expression of S6a in siRNA transfected cells does not decrease endogenous levels 
of IRF-1 mRNA.  As described in Figure 2, cells were transfected with S6a specific siRNA and 
control cells were transfected with scrambled control siRNA.  Following IFN-γ stimulation cell 
lysates were analyzed for S6a expression by Western blot (not shown) or for levels of IRF-1 
mRNA.  Real-time PCR was performed in triplicate and results represent the mean ± SD of three 
independent experiments.  *** P < 0.001 versus control siRNA. 
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Upon IFN- stimulation, phosphorylated STAT-1 dimerizes and moves rapidly into nuc-
leus where it binds to GAS elements of promoters of IFN-γ responsive genes including IRF-1 
and CIITA (Hobart, Ramassar et al. 1997; Piskurich, Linhoff et al. 1999).  To determine if S6a 
siRNA affected nuclear levels of phosphorylated STAT-1, we performed a Western Blot analysis 
to detect levels of phosphorylated STAT-1 in cells transfected with control or S6a specific siR-
NA (Figure 2.4 E).  As expected, phosphorylated STAT-1 was undetectable in unstimulated 
cells.  In INF- stimulated cells, decreased expression of S6a did not significantly impact the lev-
el of phosphorylated STAT-1, indicating STAT-1 was phosphorylated and appropriately targeted 
in the absence of S6a.  We next assayed IRF-1 transcript levels in S6a siRNA transfected cells.  
Real-time PCR analysis indicated that transcript levels of IRF-1 were not affected by depleting 
S6a (Figure 2.4 F, white bars), indicating that STAT-1 was functional at the IRF-1 promoter in 
the absence of S6a expression.  In total, these results demonstrate that the 19S ATPase S6a plays 
important and specific roles in recruiting the crucial transcription factors STAT-1 and IRF-1 to 
CIITApIV.  
 
S6a knockdown diminishes the levels of histone H3 and histone H4 acetylation at the    
CIITA isoform IV proximal promoter. 
 
 
Epigenetic studies of the IFN-γ inducible CIITApIV indicate that prior to cytokine stimu-
lation; histone H3 and histone H4 are moderately acetylated (Morris, Beresford et al. 2002; 
Wright and Ting 2006).  This basal acetylation correlates with promoter recruitment of ubiquit-
ously expressed USF-1 (Muhlethaler-Mottet, Di Berardino et al. 1998).  Following IFN-γ stimu-
lation, STAT-1 and IRF-1bind to the CIITA proximal promoter, recruit the basal transcription 
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machinery and initiate CIITA transcription of CIITA (Morris, Beresford et al. 2002; Wright and 
Ting 2006).  As STAT-1 and IRF-1 recruitment to CIITApIV is diminished in S6a depleted cells, 
we sought to determine if S6a is involved in regulating chromatin modifications to CIITApIV.  
To investigate the role of S6a in initial CIITApIV chromatin modifications, we analyzed promo-
ter IV levels of acetylated histone H3 and acetylated histone H4 in cells transfected with either 
S6a or control siRNA. In order to stimulate maximum acetylation in the presence of S6a knock-
down, cells were simultaneously treated with histone deacetylase (HDAC) inhibitors and IFN- 
and results were graphed as percent input to demonstrate levels of histone modification.  S6a 
siRNA transfected HeLa cells lacked inducible enhancement of H3 or H4 acetylation (Figure 
2.5, A-B white bars) compared to similarly treated control siRNA transfected cells (Figure 2.5, 
A-B, black bars).   
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Figure 2.5 S6a knockdown decreases CIITApIV histone H3 and histone H4 acetylation.   
(A and B) Lack of S6a decreases histone H3 and H4 acetylation at CIITApIV.  ChIP assays were 
carried out in HeLa cells transfected with S6a specific or control siRNA.  Cells were treated with 
HDAC inhibitors for 20hrs and were stimulated with IFN-γ for 0 to 18 hours.  Lysates were im-
munoprecipitated (IP) with control antibody, antibody to acetylated histone H3 (A) or with anti-
body to acetylated histone H4 (B), and associated DNA was isolated and analyzed via real-time 
PCR using primers spanning the proximal promoter CIITA isoform IV proximal promoter. Real-
time PCR values were normalized to the total amount of promoter DNA added to the reaction 
(input).   IP values are presented as increase in CIITApIV promoter DNA relative to unstimu-
lated samples.  Control IP values for (A) and (B) were 0.04 ± 0.01.  Values for control IPs, acety-
lated histone H3 and acetylated histone H4 IPs represent mean ± SEM of three independent ex-
periments.  
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 (C and D) S6a knockdown does not impact levels of histone H3 and histone H4 at CIITApIV.  
As above ChIP assays were carried out in HeLa cells transfected with S6a specific or control 
siRNA and stimulated with IFN-γ for 0-18 hours.  Lysates were subjected to IP with control an-
tibody or antibody to endogenous histone H3 (C) or H4 (D).  Associated DNA was isolated and 
analyzed via real-time PCR using primers spanning CIITApIV.  IP values are presented as in-
crease in CIITApIV DNA relative to unstimulated histone H3 (C) and histone H4 (D) IP sam-
ples.  Control IP values for (C) and (D) were 0.002 ± 0.001. Values for control IPs, histone H3 
and histone H4 IPs represent mean ± SEM of three independent experiments. *** P < 0.001 ver-
sus control siRNA. 
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Additional ChIP assays were performed to ensure that the loss of H3 and H4 acetylation 
observed at CIITApIV is not indicative of a total loss of H3 or H4 in the cells.  Cells treated with 
S6a specific siRNA showed no significant changes in levels of histones H3 or H4 compared to 
the levels observed in control siRNA treated and untreated cells (Figure 2.5, C-D).  In sum, 
these data indicate that the 19S ATPase S6a plays important and specific role in regulating acti-
vating epigenetic modifications at the CIITApIV proximal promoter.  
 
S6a knockdown decreases acetylation of histone H3 lysine 18 and histone H4 lysine 8 at the 
CIITA isoform IV proximal promoter.  
 
 
Acetylation takes place on lysine residues of histone tails. Histone code of CIITA promo-
ter has shown that only lysines (K) 9 and 18 of histone H3 and lysine 8 of histone H4 are acety-
lated (Ni, Karaskov et al. 2005). We have previously shown that Sug1 is crucial for regulating 
histone H3 acetylation at the MHC II proximal promoter. In the absence of Sug1, histone H3 
acetylation is significantly decreased with a preferential loss of acetylation at H3K18 (Koues, 
Dudley et al. 2008). Next, we wanted to determine if lack of S6a will mirror the affect of Sug1 
siRNA studies at MHC II promoter. 
 
 To evaluate H3K9, H3K18 and H4K8 acetylation levels at the CIITApIV proximal pro-
moter in the presence and absence of 19S ATPase S6a, HeLa cells were transfected with control 
or S6a specific siRNA, were treated with HDAC inhibitor, stimulated with IFN-γ as indicated, 
and immunoprecipitated with antibodies specific for H3K9 (Figure 2.6 A), H3K18 (Figure 2.6 
B), and H4K8 (Figure 2.6 C) acetylation. ChIP assay showed elevated levels of acetylated 
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H3K9 (Figure 2.6 A) upon cytokine stimulation that were not affected is S6a siRNA treated 
samples (Figure 2.6 A white bars) when comparing to control siRNA samples (Figure 2.6 A 
black bars). Similarly, when evaluating levels of H3K18 and H4K8 acetylation, HeLa cells were 
transfected, stimulated and IP with antibody to endogenous acetylated H3K18 (Figure 2.6 B) 
and H4K8 (Figure 2.6 C). Real time PCR analysis showed elevated levels of H3K18 and H4K8 
upon IFN-γ stimulation that were significantly decreased in S6a siRNA treated samples (Figure 
2.6 B-C, white bars) when comparing to control samples (Figure 2.6 B-C, black bars). These 
data indicate that S6a acts similarly to Sug1 and affects the acetylation levels of similar and spe-
cific lysine residues.  
 
The role of S6a in transcription initiation is gene specific and independent of degradation 
 
To ensure that decreased acetylation at the CIITApIV in the presence of S6a siRNA is 
not indicative of a global decrease in acetylated H3 and H4, S6a and control siRNA transfected 
cells were lysed and lysates were immunoblotted for endogenous levels of acetylated H3 and 
acetylated H4.  Although levels of S6a were successfully reduced (Figure 2.7 A, bottom panel, 
lane 2), the levels of acetylated H3 and acetylated H4 remained unchanged when compared to 
control siRNA treated and untreated cells (Figure 2.7 A top panels, lane 1 and 3 versus lane 
2).  To determine if S6a knockdown influences histone acetylation at additional genes, ChIP as-
says were performed to determine the levels of acetylated H3 and H4 at the GAPDH promoter.  
S6a knockdown had no impact on levels of acetylated H3 (Figure 2.7 B) or acetylated H4 (Fig-
ure 2.7 C) at the GAPDH promoter.   
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Figure 2.6 S6a knockdown decreases histone H3K18 and H4K8 acetylation but has no ef-
fect on H3K9 acetylation.  
(A) Histone H3K9 acetylation at CIITApIV is enhanced upon IFN-γ stimulation and HDAC in-
hibition and unaffected by the loss of S6a expression. HeLa cells were transfected with scambled 
control or S6a specific siRNA. 24 hrs later were treated with HDAC inhibitor and stimulated 
with IFN-γ from 0-18hrs. Lysates were subjected to IP with control antibody or antibody to en-
dogenous acetylated H3K9, and associated DNA was isolated and analyzed as described in Fig-
ure 5. 
 (B and C) S6a knockdown specifically decreases H3K18 (B) and H4K8 (C) acetylation at CII-
TApIV. HeLa cells were transfected with scrambled or S6a specific siRNA and 24 hrs later were 
treated with HDAC inhibitor and stimulated with IFN-γ for 0 to 18hrs. Lysates were subjected to 
IP with control antibody or antibody to endogenous acetylated H3K18 (B) and H4K8 (C). DNA 
was isolated and analyzed as described in Fig. 5. Data are presented as increase in the CIITApIV 
DNA relative to unstimulated IP samples. 
Control IP values were 0.1 ± 0.09. Control and acetylated histone H3K9, H3K18 and H4K8 IP 
values represent mean ± SEM of three independent experiments. *** P < 0.001 versus control 
siRNA. 
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Figure 2.7  S6a knockdown decreases histone H3 and H4 acetylation in a promoter specific 
manner.   
(A) Global histone H3 and H4 acetylation is unaffected by S6a siRNA knockdown.  HeLa cells 
were left untreated (NT), (lane 1) or were transfected with either S6a specific siRNA (lane 2) or 
with control siRNA (lane 3).  Lysates were subjected to IB for acetylated histone H3 (top), acety-
lated histone H4 (middle) or for endogenous S6a (bottom).  Results reported are representative 
data of three independent experiments.   
 (B and C) Lack of S6a does not affect levels of acetylated histone H3 (B) and acetylated histone 
H4 (C) at the GAPDH promoter.  ChIP assays were carried out in HeLa cells transfected with 
S6a specific or with control siRNA.  Cells were treated with HDAC inhibitors for 20hrs and 
were stimulated with IFN-γ for 0 to 18 hours. Lysates were immunoprecipitated (IP) with control 
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antibody, with antibody to acetylated histone H3 (B) or to acetylated histone H4 (C), and asso-
ciated DNA were analyzed via real-time PCR using primers spanning GAPDH promoter.  IP 
values are presented as increase in GAPDH promoter DNA relative to unstimulated samples.  
Control IP values for (B) and (C) were 0.05 ± 0.02.  Values for control IPs, acetylated histone H3 
and acetylated histone H4 IPs represent mean ± SEM of three independent experiments.  
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Figure 2.8  S6a dependent regulation of CIITApIV histone acetylation is independent of the 
proteolytic activity of 26S proteasome.  
 (A)  S6a is essential for 26S mediated protein degradation.  HeLa cells were transfected with 
S6a specific (middle panel) or with control siRNA (top and bottom panel) and were treated with 
proteasome inhibitor MG132 (bottom panel).  Following cyclohexamide treatment cells were 
harvested and analyzed for p53 degradation.  Results are representative of three independent ex-
periments.   
(B and C)  ChIP assays were carried out in HeLa cells stimulated with IFN-γ for 0 to 18 hours 
and treated with proteasome inhibitor MG132.  Lysates were immunoprecipitated (IP) with con-
trol antibody or antibody to acetylated histone H3 (B) and acetylated histone H4 (C).  Associated 
DNA was isolated and analyzed via real-time PCR using primers spanning CIITApIV.  Real-
time PCR values were normalized to the total amount of promoter DNA added to the reaction 
(input).  Input values represent 5% of the total cell lysate.   IP values are presented as increase in 
CIITApIV promoter DNA relative to unstimulated samples.  Control IP values for (A) and (B) 
were 0.002 ± 0.001.  Values for control IPs and for acetylated histone H3 IPs represent mean ± 
SEM of three independent experiments.  
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S6a is a critical component of the 19S proteasome whose primary function is to recruit 
and degrade polyubiquitinated proteins.  In a p53 half-life assay described previously (Koues, 
Dudley et al. 2008), we observed that cells transfected with S6a siRNA showed elevated levels 
of p53 expression upon cyclohexamide treatment when compared with control siRNA treated 
samples, indicating an expected decrease in 26S proteasome activity in the presence of S6a   
siRNA (Figure 2.8 A). These data indicate that S6a knockdown blocks the degradative function 
of the proteasome, we next questioned if the opposite was true as well:  Does proteasome inhibi-
tion affect activating histone modifications in similar manner to S6a siRNA?  To answer this 
question, we determined if the loss of histone H3 and histone H4 acetylation in S6a knockdown 
samples was independent of proteolysis.  Cells were treated with the proteasome inhibitor 
MG132 and ChIP experiments were performed to detect endogenous levels of CIITApIV H3 and 
H4 acetylation.  MG132 treated samples showed elevated levels of acetylated H3 (Figure 2.8 B) 
and acetylated H4 (Figure 2.8 C) at CIITApIV upon IFN-γ stimulation.  Therefore, although S6a 
function is required for degradation mediated by the 26S proteasome, the proteasome is not re-
quired for inducing activating transcription marks on CIITApIV.  These data indicate specific, 
proteolysis independent roles for the 19S ATPase S6a in regulating transcriptional activation of 
CIITApIV.  
 
S6b knockdown also decreases CIITA specific histone H3 and H4 acetylation.  
 
As a component of the 26S proteasome, S6a works with other 19S ATPases (S4, S6b, S7, 
Sug1 and S10b) to recruit polyubiquitinated proteins for degradation (Glickman, Rubin et al. 
1999). It is therefore feasible that the intact 19S holoenzyme complex-not the individual ATPas-
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es acts to regulate chromatin dynamics, independent of roles for the 19S in degradation. First, we 
have determined the binding pattern of the additional 19S ATPase, S6b to CIITApIV (Figure 2.9 
A). HeLa cells were stimulated with IFN-γ, subjected to chromatin immunoprecipitates (IP) with 
antibody to endogenous S6b, and analyzed by real time PCR with primers spanning the proximal 
promoters of CIITApIV. Upon cytokine stimulation, S6b has shown robust association to CII-
TApIV (Figure 2.9 A). Therefore, next we sought to determine the contribution of the additional 
19S ATPase, S6b to histone H3 (Figure 2.9 B) and histone H4 (Figure 2.9 C) acetylation. 
Treatment of HeLa cells with S6b specific siRNA decreased S6b proteins levels by 90% (Sup-
plementary Figure 2.11 A top) relative to control siRNA transfected cells, but did not impact 
protein level of S6a (Supplementary Figure 2.11 A middle) nor tubulin (Supplementary Fig-
ure 2.11 A bottom). Similar to our prior observations in S6a knockdown cells (Fig. 2.5 A-B), 
acetylated H3 and H4 ChIPs performed in the presence or absence of S6b exhibited significantly 
decreased acetylation of histone H3 (Figure 2.9 B, white bars) and acetylation of histone H4 
(Figure 2.9 C, white bars) at CIITApIV when compared to control siRNA transfected cells 
(Figure 2.9, B-C black bars). Additional ChIP assays were performed to make sure that the loss 
of acetylation of histone H3 and H4 was not caused by the total loss of histone H3 and histone 
H4 in the cells (Supplementary Fig. 2.11 B-C). Cells treated with siRNA specific against S6b 
showed no changes in levels of histones H3 and H4 when compared to control siRNA treated 
cells.  
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Figure 2.9  S6b dependent regulation of CIITApIV histone acetylation.  
(A)  ChIP assays were carried out in HeLa cells stimulated with IFN-γ for 0 to 18 hours.  Lysates 
were immunoprecipitated (IP) with control antibody, antibody to endogenous S6b and associated 
DNA was isolated and analyzed via real-time PCR using primers spanning IRF-E-GAS box of 
CIITApIV promoter.   Real-time PCR values were normalized to the total amount of promoter 
DNA added to the reaction (input). Input values represent 5% of the total cell lysate.  IP values 
are presented as fold increase in the CIITA promoter DNA relative to unstimulated S6a IP sam-
ples.  Control IP values were 0.7 ± 0.05.  Values for control IPs and S6a IPs represent mean ± 
SEM of four independent experiments.  
 (B and C) Lack of S6b 19S ATPase decreases histone H3 and H4 acetylation at CIITApIV.  
ChIP assays were carried out in HeLa cells transfected with S6b specific or control siRNA.  
Cells were treated with HDAC inhibitors for 20hrs and were stimulated with IFN-γ for 0 to 18 
hours.  Lysates were immunoprecipitated (IP) with control antibody, antibody to acetylated his-
tone H3 (B) or with antibody to acetylated histone H4 (C), and associated DNA was isolated and 
analyzed via real-time PCR using primers spanning the proximal promoter CIITA isoform IV 
proximal promoter. Real-time PCR values were normalized to the total amount of promoter 
DNA added to the reaction (input).   IP values are presented as increase in CIITApIV promoter 
DNA relative to unstimulated samples.  Control IP values for (B) and (C) were 0.05 ± 0.02.  
Values for control IPs, acetylated histone H3 and acetylated histone H4 IPs represent mean ± 
SEM of two independent experiments.  *** P < 0.001, **P < 0.005 versus control siRNA.  
(D) S6a siRNA decreases S6b binding to CIITApIV. As described above, ChIP assays were car-
ried out in HeLa cells with S6a specific or control siRNA and stimulated with IFN-γ for 0 to 18 
hours. Lysates were immunoprecipitated (IP) with control antibody, antibody to endogenous 
S6b, ad associated DNA was isolated and analyzed via real-time PCR using primers spanning 
IRF-E-GAS box of CIITApIV promoter. IP values are presented as fold increase in CIITApIV 
promoter DNA relative to unstimulated samples. The control IP values for (D) were 0.1 ± 0.05. 
Values for control IPs and S6b IPs represent mean ± SEM of two independent experiments.     
*** P < 0.001 versus control siRNA. 
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Figure 2.10 (Supplementary figure 1) The 19S ATPase S6a associates with MHC-II exon 
III, exon V and CIITA coding regions upon IFN-γ stimulation.  
(A) Location of MHC II primer/probe sets.  
(B-C)  ChIP assays were carried out in HeLa cells stimulated with IFN-γ for 0 to 18 hours.  Ly-
sates were immunoprecipitated (IP) with control antibody, antibody to endogenous S6a and as-
sociated DNA was isolated and analyzed via real-time PCR using primers spanning exon III (B), 
exon V (C) of the MHC-II HLA-DRA.   Real-time PCR values were normalized to the total 
amount of promoter DNA added to the reaction (input). Input values represent 5% of the total 
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cell lysate.  IP values are presented as fold increase in the MHC-II DNA relative to unstimulated 
S6a IP samples.  Control IP values for (B) and (C) were 0.4 ± 0.06.  Values for control IPs and 
S6a IPs represent mean ± SEM of three independent experiments.   
(D) Location of CIITA primer/probe sets.  
(E) ChIP assays were carried as above. DNA was isolated and analyzed using primers spanning 
coding region of CIITA. IP values are represented as fold increase in CIITA DNA relative to un-
stimulated samples. Control values were 0.5 ± 0.04. Values represent mean± SEM of three inde-
pendent experiments.  
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Figure 2.11 (Supplementary figure 2) The 19S ATPase S6b siRNA specifically and efficient-
ly decreases S6b protein expression and does not influence levels of histone H3 and histone 
H4 at CIITApIV. 
(A) S6b siRNA specifically and efficiently decreases S6b protein expression in the presence or 
absence of cytokine stimulation. HeLa cells were transfected with control or S6b specific siRNA, 
untreated or stimulated with IFN-γ for 0 to 18hrs, harvested and subjected to Western Blot analy-
sis of endogenous expression of S6a, S6b and tubulin. Western Blot analysis shows 90% knock-
down of S6b and stable expression of S6a and tubulin. Results reported are representative data of 
four independent experiments.  
(B and C) S6b knockdown does not impact levels of histone H3 and histone H4 at CIITApIV.  
As above ChIP assays were carried out in HeLa cells transfected with S6b specific or control 
siRNA and stimulated with IFN-γ for 0-18 hours.  Lysates were subjected to IP with control an-
tibody or antibody to endogenous histone H3 (B) or H4 (C).  Associated DNA was isolated and 
analyzed via real-time PCR using primers spanning CIITApIV.  IP values are presented as in-
crease in CIITApIV DNA relative to unstimulated histone H3 (B) and histone H4 (C) IP sam-
ples.  Control IP values for (B) and (C) were 0.001 ± 0.002. Values for control IPs, histone H3 
and histone H4 IPs represent mean ± SEM of two independent experiments.  
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To determine whether S6bbinds to CIITApIV in the absence of S6a, we performed S6b ChIP as-
say in S6a siRNA treated cells. As previously described, initial ChIP experiment showed that 
S6b rapidly binds to CIITApIV (Figure 2.9 A). However in cells transfected with S6a siRNA, 
S6b binding to CIITApIV was significantly decreased (Figure 2.9 A white bars), when com-
pared to cells transfected with control siRNA (Figure 2.9 A white bars). In sum these data and 
published Sug1 studies (Bhat, Turner et al. 2008; Koues, Dudley et al. 2009) indicate that the 
19S ATPases play important and similar roles in regulating epigenetic modifications at CIITA-
pIV and indicate intermolecular promoter interactions between 19S ATPases.  
 
2.4 DISCUSSION 
 
The 19S regulator of the 26S proteasome contains six proteasomal ATPases which be-
long to the AAA (ATPases associated with diverse cellular activity) superfamily of ATPases 
(Kinyamu, Chen et al. 2005). The 19S ATPases assemble into a hexameric ring that contacts the 
20S core particle where it likely functions in substrate unfolding and translocation (Coux, Tana-
ka et al. 1996; Glickman, Rubin et al. 1999).  The precise roles for the ATPases in ubiquitin me-
diated degradation remain unclear, but multiple studies have suggested that one or more of the 
19S ATPases functions to unfold ubiquitinated substrates as they are targeted into the 20S cata-
lytic core of the proteasome (Ciechanover 1998; Strickland, Hakala et al. 2000). 
 
 Recent studies have identified transcriptional activities of the 19S on yeast chromatin 
(Ferdous, Gonzalez et al. 2001; Ferdous, Kodadek et al. 2002; Gonzalez, Delahodde et al. 2002; 
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Morris, Kaiser et al. 2003; Lee, Ezhkova et al. 2005; Sikder, Johnston et al. 2006; Sulahian, 
Johnston et al. 2006) Roles for 19S ATPases in mammalian transcription have likewise been 
previously reported (Lassot, Latreille et al. 2007; Zhu, Wani et al. 2007; Bhat, Turner et al. 2008; 
Koues, Dudley et al. 2008), and the mechanisms of how 19S ATPases regulate transcription init-
iation of various genes remain similarly unclear.  Transcriptional activity of eukaryotic genes is 
regulated at multiple levels, including modifications to histone tails, recruitment of transcription-
al machinery and the assembly of preinitiation complexes (Lee and Young 2000).  We have pre-
viously demonstrated that following IFN- stimulation, the 19S ATPase Sug1 rapidly binds the 
MHC-II proximal promoter and that diminished expression of Sug1 substantially inhibits MHC-
II promoter histone acetylation and decreases recruitment of the transactivator CIITA, resulting 
in diminished MHC-II expression (Koues, Dudley et al. 2008).  Despite these advances, evidence 
of roles for the remaining 19S ATPases in regulating mammalian chromatin structure remains to 
be demonstrated. 
 
S6a is a critical ATPase subunit of the 19S regulator which we have previously reported 
to bind the promoter of the MHC II gene HLA-DRA (Koues, Dudley et al. 2008). As a part of the 
26S proteasome complex, S6a has been shown to bind with the polyubiquitin chain of substrates 
targeted for proteasome mediated degradation (Lam, Lawson et al. 2002).  Although the 19S 
ATPases likely form a ring structure, the fact that only the S6a subunit directly binds ubiquitin 
suggests delegation of specific tasks to specific ATPases and highlights the functional diversity 
of the 19S ATPase subunits (Rubin, Glickman et al. 1998; Kohler, Cascio et al. 2001).  The aim 
of the present work was therefore to determine the role of the 19S ATPase S6a in two key 
processes preceding transcriptional initiation of IFN- inducible genes: acetylation of core his-
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tones and recruitment of the general transcription factors.  Our current study indicates that the 
19S ATPase S6a rapidly and robustly binds the IFN- inducible promoters of MHC II HLA-DRA 
and CIITApIV and that in the absence of S6a, MHC II message levels and CIITA transactivation 
and expression levels are substantially decreased.  S6a siRNA resulted in a 70% reduction of 
MHC-II message level and a 30-40% decrease of CIITA message and protein level.  The CIITA 
result is likely more severe than indicated as the primers used to detect CIITA message levels 
detect CIITA expressed from any of the three CIITA promoters.  As IFN- stimulation results in 
expression of CIITA isotype III and IV (Piskurich, Gilbert et al. 2006), the smaller percent de-
crease in CIITA message level is likely due to the fact that we are assaying for a combination of 
both IFN- inducible isotypes of CIITA: CIITApIII and CIITApIV. Importantly, the effects of 
S6a
 
siRNA are specific, as reconstituting S6a expression in S6a siRNA transfected cells restores 
CIITA driven HLA-DRA promoter activity and GAPDH message levels are not impacted by S6a 
knockdown.  
 
The expression of CIITApIV upon IFN- stimulation depends on the binding of the tran-
scription factor STAT1 to a GAS sequence, of IRF-1 and IRF-2 to an IRF-E element, and of the 
ubiquitously expressed USF-1 to an E box.  Initial studies demonstrated that endogenous S6a and 
STAT-1 co-immunoprecipitated, suggesting functional interaction between these proteins.  Roles 
for S6a in binding and recruiting coactivators are likely. Ishizuka et al have previously indicated 
that S6a is capable of enhancing transactivation via HAT activity containing steroid receptor 
coactivator 1 (Ishizuka, Yamaya et al. 2001) and we have shown that 19S ATPase Sug1 to play 
an important role in the initial binding of HAT CBP to the MHC II proximal promoter (Koues, 
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Dudley et al. 2008; Koues, Dudley et al. 2009). Cytokine inducible association of STAT-1 and 
IRF-1 with CIITApIV further correlates with significant increases in the levels of acetylated H3 
and acetylated H4 at the CIITApIV proximal promoter.  Binding of STAT-1 and IRF-1 was sig-
nificantly reduced in the presence of S6a knockdown as was CIITApIV H3K18 and H4K8 acety-
lation, suggesting that S6a plays an important role in chromatin remodeling, recruitment of tran-
scription factors and in assembly of the preinitiation complex on CIITApIV. Observed effects of 
S6a knockdown are also lysine specific, as acetylation of histone H3K18 and histone H4K8 at 
CIITApIV are diminished in cells transfected with S6a siRNA, whereas acetylation of histone 
H3K9 are unaffected at CIITApIV proximal promoter.  
 
The 19S ATPases recognize ubiquitinated substrates for proteolysis and are therefore 
critical components of the 26S proteasome (Ciechanover 1994; Glickman, Rubin et al. 1999).  
To determine the effect of S6a knockdown on proteasome function, we assayed p53 half life in 
the presence of S6a knockdown and cyclohexamide treatment.  As S6a is an important regulatory 
protein of the 19S proteasome, it was not surprising that S6a knockdown negatively impacted 
proteasome activity.   However, when cells were treated with the proteasome inhibitor MG132 
and assayed for levels of H3 and H4 acetylation, the acetylation values were comparable to those 
of untreated cells.   Thus, the loss of CIITApIV histone acetylation observed in S6a deficient 
cells was not due to a lack of proteasome function.  These experiments further emphasize that 
although S6a is required for the proteolytic functions of the 26S proteasome, the effects of S6a 
on CIITApIV acetylation are proteolysis independent.  Furthermore, the effects on H3 and H4 
acetylation mediated by S6a siRNA are specific as whole cell lysates show no global changes in 
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H3 or H4 acetylation upon S6a knockdown and as acetylation levels at the GAPDH promoter are 
likewise unaffected by S6a knockdown. 
 
We show here that additional 19S ATPase, S6b inducibly binds CIITApIV and modulates 
histone H3 and histone H4 acetylation similarly to S6a. In data not shown, we have further seen 
that each of the 19S ATPases rapidly binds CIITApIV following IFN-γ stimulation. In fact, 
many of the above observations in regard to roles for S6a in chromatin remodeling and transcrip-
tion factor recruitment correlate with our previous observations that the 19S ATPase Sug1 regu-
lates specific activating chromatin marks and transcription factor recruitment at the MHC II 
proximal promoter (Koues, Dudley et al. 2009). Likewise, promoter binding of the 19S ATPases 
might be interdependent, as decreased exoression of S6a significantly decreased promoter re-
cruitment of S6b. It is therefore likely that 19S AAA ATPase play overlapping and similar roles 
in initiating CIITA transcription, where they potentially bind CIITApIV as AAA ATPase hex-
imeric complexes. That the 19S ATPase S6a robustly binds to the coding region gene HLA-DRA 
and CIITA indicates role in elongation processes at these genes, and it has been proposed that the 
19S AAA ATPases play roles in the coding regions of yeast genes by remodeling paused RNA 
polymerase II (Ferdous, Kodadek et al. 2002; Gonzalez, Delahodde et al. 2002). However, 
among the 19S ATPases, only S6a was shown to crosslink to the coding region of the human 
immunodeficiency virus type 1 gene in the presence of transcription factor Tat (Lassot, Latreille 
et al. 2007). Therefore, conflicting evidence remains as to individual and hexameric functions 
and the contributions of 19S ATPases to transcriptional processes. Despite mounting evidence 
for the roles of the 19S ATPases in the regulation of mammalian transcription, it remains unclear 
how these proteins may regulate multiple stages of transcriptional processes. A full understand-
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ing of the roles played by the 19S ATPases in mammalian transcription will require studies of 
the molecular events occurring at these and additional promoters.  
 
2.5 MATERIAL AND METHODS 
 
Cells 
 
HeLa (human epithelial) cells from ATCC (Manassas, VA) were maintained using high 
glucose Dulbecco modified Eagle (DMEM) medium (Mediatech Inc., Herndon, VA) supple-
mented with 10% fetal calf serum (FCS), 5mM L-glutamine and 5mM penicillin-streptomycin at 
37
◦
C with 5% carbon dioxide.  
 
Antibodies 
 
S4, S7, S6a, S6b and S10b antibodies were from Biomol International, L.P. (Plymouth 
Meeting, PA). Sug1 antibody was from Novus Biologicals (Littleton, CO).  IRF-1 and STAT-1 
antibodies were from Santa Cruz (Santa Cruz, CA). Phosphorylated STAT-1 (pY701) was from 
BD Biosciences (San Jose, CA). Histone H3, acetylated histone H3, histone H4, acetylated his-
tone H4 and rabbit and mouse immunoglobulin G (IgG) isotype control antibodies were from 
Millipore (Lake Placid, NY). Histone 3 (acetyl K9) and histone 3 (acetyl K18) antibodies were 
from Abcam (Cambridge, MA); histone H4 (acetyl K8) was from Millipore (Lake Placid, NY).  
p53 antibody was from Abcam (Cambridge, MA).  Tubulin and CIITA antibody was from Santa 
Cruz (Santa Cruz, CA). HRP conjugated mouse antibody was from Promega (Madison, WI) and 
HRP conjugated rabbit antibody was from Pierce (Rockland, IL).  
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Plasmids 
 
The following plasmids were previously described:  Flag-CIITA, pcDNA3 and HLA-
DRA-Luc (Cressman, Chin et al. 1999; Cressman, O'Connor et al. 2001; Greer, Zika et al. 2003).  
The Renilla luciferase control vector (E2231) was from Promega (Madison, WI). pBluescript 
(pBS)-S6a was kindly provided by  Dr. Martin Rechsteiner  (Richmond, Gorbea et al. 1997; 
Gorbea, Taillandier et al. 1999) and subcloned into Myc tagged pCMV-3 using EcoRI restriction 
sites.  
 
Endogenous Co-Immunoprecipitations 
 
HeLa cells were plated at a cell density of 2x10
6
 in 15 cm tissue culture plates.  Thirty 
minutes prior to harvesting, cells were stimulated with IFN-γ (500U/ml), lysed in RIPA lysis 
(1M Tris pH 8.0, 10% Nonidet P-40, 5% DOC, 10% SDS, 5M NaCl, 5mM EDTA, 1M DTT) 
supplemented with Complete EDTA-free protease inhibitors (Roche) buffer and were precleared 
with 30μl IgG beads (Sigma). Cell lysates were immunoprecipitated (IP) overnight with 5μg of 
anti S6a (Biomol), anti STAT-1 (Santa Cruz), or mouse isotype control IgG (Upstate).  Immune 
complexes were isolated with 50μl protein G beads, denatured with Leammli buffer, boiled and 
subjected to SDS-PAGE. Co-immunoprecipitated complexes were detected by immunoblotting 
(IB) with anti STAT-1 (Santa Cruz).  HRP conjugates were detected with Supersignal West Pico 
Chemiluminescent substrate (Pierce).  Equal transfection and loading was determined in non-
immunoprecipitated lysates by immunoblot of total protein.   
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siRNA Constructs and Transient Transfections 
 
Short interfering RNA (siRNA) duplexes predesigned against human PSMC3 (Qiagen) 
were previously described (Koues, Dudley et al. 2008) and were used for transient knockdown of 
the 19S ATPase S6a.  Versite specific siRNA was predesigned against human S6a (Sigma) to 
control the specificity of our siRNA complex.  S6b siRNA sequence was designed with a G+C 
content of 35 to 55% containing dTdT overhangs and was compared to the NCBI BLAST nuc-
leotide database. The target sequences of S6b siRNA used was 5′- CACG-
CATTTCGAGCTCTACAA-3′ (Qiagen). HeLa cells were transfected with 0.7µg of S6a or S6b 
specific siRNA, versite specific or scrambled sequence control using RNAiFect transfection rea-
gent (Qiagen) according to the manufacturer‟s instructions and were treated with IFN-γ 
(500U/ml) as indicated.  Cells were lysed in NP-40 lysis buffer (1M Tris pH 8.0, 1M KCl, 10% 
NP-40, 0.5M EDTA, 5M NaCl, 1M DTT, dH2O) with EDTA free protease inhibitor (Roche) and 
analyzed by western blot for knockdown efficiency and specificity. 
 
Luciferase Reporter Assays 
 
HeLa cells were plated in 6 well plates at a density of 5x10
4
 cells/well and transfected 
with 0.7μg of siRNA using RNAi transfection reagent (Qiagen) according to the manufacturer‟s 
instructions.  Following twenty-four hours of siRNA transfection, Flag-CIITA, HLA-DRA-Luc, 
Renilla, Myc-S6a and pCDNA3 plasmids were transfected as indicated using Fugene 6 (Roche, 
Indianapolis, IN).  Eighteen hours following transfection, cells were subjected to dual luciferase 
assays (Promega) according to the manufacturer‟s instructions. 
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RNA Expression 
 
HeLa cells were plated at a cell density of 8x10
5
 cells, transfected with S6a siRNA and 
twenty four hours later were stimulated with IFN-γ (500U/ml) as indicated.  Cells were harvested 
and 10% of the cells were lysed with 1% Nonidet P-40 lysis buffer and subjected SDS PAGE to 
determine the efficiency of the knockdown.  The remaining fraction of cells was subjected to 
RNA extraction with 1ml of Trizol reagent (Invitrogen) as previously described (Bhat, Turner et 
al. 2008).  The Omniscript Reverse Transcription Kit (Qiagen) was used to generate cDNA from 
extracted RNA.  Isolated DNA was analyzed by Real-time PCR on an ABI prism 7900 (Applied 
Biosystems) using primers and probes for MHC-II (Bhat, Turner et al. 2008; Koues, Dudley et 
al. 2008) and GAPDH (Medhurst, Harrison et al. 2000).  Primers sequences for CIITA and IRF-1 
were as follows:  CIITA sense GGGAGAGGCCACCAGCAG, CIITA antisense GCTCCAGG-
TAGCCACCTTCT and CIITA probe FAM-CTGTGAGCTGCCGCTGTTCCC-TAMRA, IRF-1 
sense TGGCCAAGGGTGTGATACTG, IRF-1 antisense CCACTCCGACTGCTCCAAGA and 
IRF-1 probe FAM-AGTTGATAGCCTCTTGCTCTTCTGTCCC-TAMRA. Values generated 
from Real-time PCR reactions were calculated on the basis of standard curves generated. 
 
Histone Immunoblotting 
 
HeLa cells were transfected with 0.7µg S6a siRNA or control siRNA using RNAiFect 
transfection reagent (Qiagen).  Forty eight hours following siRNA transfection, 10% of the total 
cell volume was lysed with 1% Nonidet P-40 lysis buffer and was analyzed by western blot for 
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knockdown efficiency. The remaining cell volume was lysed in SDS lysis buffer (1% SDS, 
10mM EDTA, 50mM Tris pH 8.0, dH20) for 30 minutes and sheared by sonication.  Lysate sam-
ples were normalized for protein concentration, denatured with Leammli Buffer (BioRad) and 
were separated by SDS PAGE. Gels were transferred to nitrocellulose and were immunoblotted 
with anti acetylated H3 (Millipore) and anti acetylated H4 (Millipore).  Secondary HRP conju-
gated anti-rabbit was detected with SuperSignal West Pico Chemiluminescent substrate (Pierce).  
 
Chromatin Immunoprecipitation (ChIP) 
 
ChIP assays were performed as previously described (Bhat, Turner et al. 2008; Koues, 
Dudley et al. 2008).  Briefly, HeLa cells were plated at a cell density of 2x10
6
.  Following IFN-γ 
stimulation (500U/ml), cells were crosslinked with 1% formaldehyde for 10 minutes at room 
temperature.  Crosslinking was stopped by the addition of 0.125M glycine for 5 minutes at room 
temperature.  Cells were lysed in SDS lysis buffer and were sonicated at constant pulse to gener-
ate an average of 500-750bp sheared DNA.  Sonicated lysates were precleared with salmon-
sperm coated agarose beads (Upstate) and half of the lysate was immunoprecipitated with 5μg of 
indicated antibody overnight at 4°C.  The remaining half of the lysate was used as a control and 
was immunoprecipitated with isotype control antibody (Upstate).  Following an additional 
twelve hour immunoprecipitation with 50μl of salmon-sperm coated agarose beads, samples 
were washed for 3 minutes at 4°C with the following buffers:  low and high salt buffer, LiCl  and 
1xTE buffer and were eluted with SDS elution buffer .  Following elution, cross-links were re-
versed overnight with 5M NaCl at 65°C and immunoprecipitated DNA was isolated using phe-
nol:chloroform:isopropanol mix (Invitrogen) as per the manufacturer‟s instructions.  Isolated 
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DNA was analyzed by real-time PCR using previously published primers spanning the W-X-Y 
box of the MHC-II HLA-DRA promoter (Bhat, Turner et al. 2008).  Primers spanning the GAS-
IRF-E box of CIITApIV were as follows:  sense CAGTTGGGATGCCACTTCTGA, antisense 
TGGAGCAACCAAGCACCTACT and probe FAM-AAGCACGTGGTGGC-TAMRA. Primers 
spanning exon III and exon V of MHC II were previously published (Koues, Dudley et al. 2009) 
and primers spanning. Values were calculated based on standard curves generated.  
 
Chromatin Immunoprecipitation with siRNA 
 
HeLa cells were plated at a cell density of 8x10
5
 and transfected with 0.7µg S6a, S6b 
specific or control siRNA (Qiagen).  Cells were stimulated with IFN-γ (500U/ml), 5mM HDAC 
inhibitor sodium butyrate (Upstate) and 5.2µM proteasome inhibitor MG132 (EMD Biosciences, 
San Diego, CA) as indicated and 10% of the total cell volume was lysed with 1% Nonidet P-40 
lysis buffer and was analyzed by western blot for knockdown efficiency.  The remaining cell vo-
lume was lysed in SDS lysis buffer and was subjected to sonication and the above described 
ChIP assay. 
 
In vivo proteolytic activity 
 
 Hela cells were transfected with S6a specific or control siRNA (Qiagen) and treated with 
5.2µM MG132 proteasome inhibitor (EMD Bioscience) and 100µM cyclohexamide (Sigma) as 
indicated.  Cells were lysed with 1% NP-40 buffer with protease inhibitor and total cell lysates 
were analyzed for p53 degradation and S6a knockdown efficiency.  
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3.1 ABSTRACT 
 
RNA polymerase II (Pol II) mediated elongation has recently emerged as a critical control 
step in gene expression.  We and others have shown that components of the 26S proteasome act 
as mediators of transcriptional initiation and play important roles in gene expression. We have 
previously demonstrated the 19S proteasome ATPase S6a (S6‟/TBP1) plays significant roles in 
transcriptional initiation of CIITApIV.  We now demonstrate RNAi mediated knockdown of S6a 
significantly diminishes occupancy of Pol II at both proximal promoter and coding regions of 
CIITA genes.  We further demonstrate S6a is bound at elevated levels at CIITApIV coding re-
gions where Pol II binding is markedly increased.  Further linking the 19S to elongation are 
demonstrated interactions of 19S ATPases S6a, S7, and Sug1 with critical regulators of elonga-
tion, the CDK9 and Hexim-1components of the inactive form of positive transcription elongation 
factor (P-TEF-b). Decreased expression of S6a significantly diminishes recruitment of Cyclin T1 
to CIITApIV promoter and coding region, indicating S6a contributes to efficient elongation. 
Transcriptional regulation by the 19S represents a novel mechanism of regulating mammalian 
gene expression and presents the proteasome as a therapeutic target for manipulating MHC II 
expression in cancer and in adaptive immune responses. 
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3.2 BACKGROUND 
 
Major Histocompatibility class II (MHC II) genes encode cell surface glycoproteins that 
bind and present antigens to CD4
+ 
T cells. Cell surface expression of MHC II molecules is 
tightly regulated to ensure rapid activation of the immune response (Glimcher and Kara 1992; 
Gerloni and Zanetti 2005). MHC II is expressed constitutively on antigen presenting cells, but 
can be induced on nucleated cells that are stimulated with the inflammatory cytokine interferon 
gamma, (IFN- γ) (Kaufman, Auffray et al. 1984; Boss 1997). Following IFN-γ stimulation, a 
large ubiquitously expressed multi-protein enhanceosome complex binds the MHC II proximal 
promoter and recruits the Class II Transactivator, (CIITA) (Reith and Mach 2001; Ting and 
Trowsdale 2002). Transcription of CIITA is regulated in a cell specific manner by four distinct 
promoters: pI, pII, pIII, and pIV. CIITA promoter IV (CIITApIV) is the CIITA promoter that 
responds to IFN-γ stimulation via the Janus kinase signal transducer and activator of transcrip-
tion (JAK-STAT) transduction pathway (Piskurich, Linhoff et al. 1999; Piskurich, Gilbert et al. 
2006). Once bound to MHC II promoter complexes, CIITA stabilizes the enhanceosome and re-
cruits basal transcription components, including the cyclin dependent kinase 7 (CDK7) subunit 
of transcription factor II H (TFIIH) and the cyclin dependent kinase (CDK9) subunit of positive 
transcription elongation factor (P-TEF-b).  CDK7 and CDK9 phosphorylate serine residues on 
RNA polymerase II (RNA pol II) and are thus critical regulators of the switch from initiation to 
elongation (Mach, Steimle et al. 1996; Masternak, Barras et al. 1998; Kanazawa, Okamoto et al. 
2000; Boss and Jensen 2003).    
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Recent studies from our lab and others have highlighted the central role played by CIITA 
in controlling MHC II expression by regulating transcriptional initiation and elongation through 
stabilizing the recruitment and phosphorylation of RNA Pol II (Bhat, Truax et al. ; Truax, Koues 
et al. ; Ting and Trowsdale 2002; Bhat, Turner et al. 2008; Koues, Dudley et al. 2008; Koues, 
Dudley et al. 2009). Transcription in eukaryotes is initiated by the recruitment of RNA polyme-
rase II (Pol II) to promoter localized start sites. RNA Pol II initiates transcription upon associa-
tion with basal transcription factors, P-TEF-b and via its C terminal domain (CTD) phosphoryla-
tion. The CTD of mammalian RNA Pol II consist of a series of 52 heptad repeats of YSPTSPS 
located on the large subunit of pol II (Dahmus 1996; McCracken, Fong et al. 1997). Once the 
preinitiation compex is formed, RNA Pol II initiates synthesis of mRNA that is accompanied by 
phosphorylation at serine 5 on the RNA pol II CTD. Eukaryotic genes often stall after synthesiz-
ing only 20-50 bases of RNA, when bound by negative elongation factor (NTE-F) and 5.6-
dichloro 1-β –D-ribofuranosylbenzimidazole (DRB) sensitivity inducing factor (DSIF) (Hirose, 
Tacke et al. 1999; Hirose and Manley 2000). To enable elongation, the active form of P-TEF-b 
phosphorylates N-TEF and serine 2 of RNA pol II CTD and releases the paused complex, lead-
ing to transcriptional elongation (Mancebo, Lee et al. 1997; Zhu, Pe'ery et al. 1997).  
 
P-TEF-b is a heterodimer composed of CDK9 and C type cyclins: cyclin T1 (Cyc T1) 
and cyclin T2 (Cyc T2) or cyclin K (Cyc K) (Price 2000) and exists in two distinct molecular 
forms as an active or inactive complex (Nguyen, Kiss et al. 2001; Yang, Zhu et al. 2001).  P-
TEF-b predominantly exists as an inactive complex composed of CDK9, cyclins, and small nuc-
lear RNA (sn7SK) bound to dimers of hexamethylene bisacetamide (HMBA) inducible protein 1 
(Hexim-1) and Hexim-2 (Price 2000; Michels, Fraldi et al. 2004). Upon initiation of transcrip-
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tion, P-TEF-b dissociates from Hexim-1 and 7SK through unknown mechanisms and forms the 
small active form of P-TEF-b that is recruited to transcription initiation complexes (Yik, Chen et 
al. 2003; Peterlin and Price 2006). The switch from transcriptional initiation to elongation is thus 
a dynamic process regulated by multiple protein-protein interactions. In addition to negatively 
regulating P-TEF-b, Hexim-1suppresses the transcriptional activity of transcriptional regulators 
including the glucocorticoid receptor, the estrogen receptor, and the p65 subunit of NF-κB 
(Ouchida, Kusuhara et al. 2003; Shimizu, Ouchida et al. 2005; Wittmann, Fujinaga et al. 2005). 
Important to this study, recent findings demonstrate Hexim-1 sequesters P-TEF-b from CIITA 
(Kohoutek, Blazek et al. 2006).  
 
Increasing evidence indicates the ubiquitin proteasome system (UPS) is involved in tran-
scriptional regulation. The 26S proteasome is a large, multimeric complex composed of a 19S 
regulatory particle and a 20S proteolytic core (Coux, Tanaka et al. 1996; Gorbea, Taillandier et 
al. 1999; Pickart 2004).  The 19S regulator is further divided a lid and a base.  Within the 19S 
base are six ATPases termed S4, S6a (S6‟, TBP1), S6b, S7, Sug1 (S8), and Sug2 (S10b), and 
three non-ATPase subunits (Gorbea, Taillandier et al. 1999; Adams 2003). Observations in yeast 
that ATPase components of the 19S proteasome associate with actively transcribed genes and 
facilitate recruitment of various transcription factors first established non- proteolytic involve-
ment for the proteasome in transcription (Ciechanover 1998; Ferdous, Kodadek et al. 2002; 
Gonzalez, Delahodde et al. 2002; Muratani and Tansey 2003; Lee, Ezhkova et al. 2005; 
Sulahian, Johnston et al. 2006; Archer, Burdine et al. 2008). Additional studies have indicated 
the 19S ATPase subunits Rpt6 (homolog of Sug1) and Rpt4 (homolog of Sug2 or S10b) partici-
pate in chromatin remodeling in yeast (Ezhkova and Tansey 2004; Lee, Ezhkova et al. 2005). In 
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addition, the 19S proteasome associates with RNA pol II (Ferdous, Gonzalez et al. 2001) and is 
critical for efficient RNA pol II mediated elongation in yeast cells (Ferdous, Gonzalez et al. 
2001; Lassot, Latreille et al. 2007).   While the proteasome has been demonstrated to regulate 
transcription at multiple yeast promoters, the role of the proteasome in initiation and elongation 
during mammalian transcription remains unclear.  
 
Our previous studies have demonstrated the19S ATPase S6a associates with the CIITA-
pIV proximal promoter, where it plays an important role in recruiting the requisite transcription 
factors STAT-1 and IRF-1 which are required for efficient transcription of CIITA. We have 
shown S6a regulates the addition of activating epigenetic modifications to CIITApIV, indicating 
the 19S ATPases play important roles in initiating transcription of inducible mammalian genes. 
We show here that the 19S ATPase S6a associates with regulatory components of P-TEF-b and 
plays novel roles in recruiting RNA pol II and cyclin T1 to CIITA coding regions. These data 
offer new insights into non proteolytic roles of the proteasome in regulating transcription elonga-
tion. 
 
3.3 RESULTS   
 
The 19S ATPase S6a associates with the promoter and coding regions of CIITApIV genes.  
We have shown the 19S ATPase Sug1 positively regulates MHC II transcription by regu-
lating CIITA binding and histone H3 acetylation at the MHC II proximal promoter (Bhat, Turner 
et al. 2008; Koues, Dudley et al. 2008). We have further demonstrated that the 19S ATPase S6a 
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plays similar roles in regulating transcriptional initiation at CIITApIV (Truax, Koues et al.) Each 
of the six 19S ATPases are recruited to the coding region of HIV-1 genes in the presence of the 
transactivator Tat, with S6a binding at significantly higher levels (Lassot, Latreille et al. 2007).  
As we have previously noted the 19S ATPase S6a binds to CIITA and MHC II coding regions 
(Truax, Koues et al.), we sought here to investigate the binding of the 19S ATPase S6a through-
out the coding region of CIITA genes.  
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Figure 3.1 The 19S ATPase S6a binds to both promoter and coding region of CIITA.  
 
(A) Schematic representation illustrating location of primers in the CIITA proximal promoter 
and coding regions.  
 
(B) S6a binds robustly to multiple CIITA coding regions. ChIP assays were carried out in HeLa 
cells stimulated with IFN-γ for 0 to 18 hours.  Lysates were immunoprecipitated (IP) with con-
trol antibody or antibody to endogenous S6a and associated DNA was isolated and analyzed via 
real-time PCR using primers spanning the IRF-E-GAS box of CIITApIV, exon IV, exon XI, ex-
on XVII or the polyA site.  Real-time PCR values were normalized to the total amount of promo-
ter DNA added to the reaction (input). Input values represent 5% of the total cell lysate.  IP val-
ues are presented as a relative increase in the CIITA DNA.  Control IP values for (A) and (B) 
were 1700 ± 500.  Values for control IPs and S6a IPs are representative data of 3 independent 
experiments. 
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To investigate S6a binding to CIITA coding sequences, we designed sets of primers and 
probes spanning the exons of CIITA (Figure 3.1 A). We performed chromatin immunoprecipita-
tion (ChIP) assays in HeLa cells which were stimulated with IFN-γ as indicated, and crosslinked 
and sonicated lysates were subjected to immunoprecipitation (IP) with antibody against endo-
genous S6a.  Following immunoprecipitation, associated DNA was isolated and analyzed by real 
time PCR with primers spanning the proximal promoter, exon IV, exon XI, exon XVIII, and the 
polyA site of CIITA. While S6a was inducibly recruited to CIITApIV, S6a demonstrated robust 
occupancy at CIITA exon IV in the absence cytokine stimulation that decreased with extended 
cytokine stimulation (Figure 3.1 B). Constitutive S6a binding was also observed at CIITA exons 
XI and XVIII and no S6a binding was observed at the CIITA polyA site. These data indicate 
marked differences in S6a binding in CIITA genes, robust binding in CIITA exon IV, and repro-
duce our previous observation of inducible S6a CIITApIV binding.  
 
S6a knockdown decreases RNA pol II occupancy at the CIITA proximal promoter and at 
exon IV.  
 
Expression of protein coding genes is carried out by RNA pol II and various transcription 
factors (Buratowski 1994) and is controlled at multiple levels (Conaway and Conaway 1993; 
Roeder 1996). In addition to the mechanisms that control recruitment of RNA pol II to promo-
ters, RNA pol II escape from promoter regions and the transition of RNA pol II to an elongating 
complex is also highly regulated (Saunders, Core et al. 2006; Chiba, Yamamoto et al. 2010).  
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Figure 3.2  S6a knockdown reduces RNA pol II occupancy on CIITA promoters and coding 
regions. 
(A-B) Timeline of RNA pol II binding to the promoter and coding regions of CIITA. ChIP as-
says were performed in HeLa cells stimulated with IFN-γ as indicated. Lysates were IP with con-
trol rabbit antibody or with antibody to endogenous RNA pol II. Associated DNA was isolated 
and analyzed using via Real Time PCR using primers spanning CIITA proximal promoter (A) 
and exon IV. Real-time PCR values were normalized to the total amount of promoter DNA add-
ed to the reaction (input). Input values represent 5% of the total cell lysate.  IP values are pre-
sented as a relative increase in CIITA DNA.  Control IP values for (A) and (B) were 2000.  Real-
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time PCR was performed in triplicate and results represent the mean ± SD of three independent 
experiments.   
 
(C) S6a siRNA specifically and efficiently decreases S6a protein expression but does not affect 
endogenous levels of RNA pol II. HeLa cells were transfected with control or S6a specific siR-
NA, stimulated with IFN-γ as indicated, harvested and subjected to Western Blot analysis of en-
dogenous expression of 19S ATPase S6a (top blot) and RNA pol II (bottom blot).  Western Blot 
analysis shows 90% knockdown of S6a and stable expression of RNA pol II.  Results reported 
are representative data of three independent experiments.  
 
(D-E) S6a siRNA decrease RNA pol II occupancy at CIITA proximal promoter (D) and coding 
region (E). HeLa cells were transfected with S6a specific (white bars) or with control siRNA 
(black bars), stimulated as indicated, lysed, and IP with antibody against endogenous RNA pol II 
or control antibody. Associated DNA was analyzed via Real time PCR using primers and probe 
specific for the CIITA proximal promoter (D) or CIITA exon IV (F). IP values were normalized 
against the total DNA added to the reaction and are graphed as relative increase in CIITA DNA. 
Control IP values for (D) and (E) were 2300± 500. Experiments were performed in triplicate and 
graphed results are presented as a mean ± SD of three independent experiments.  ***P < 0.001, 
**P < 0.005, *P < 0.05 versus control siRNA.  
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Figure 3.3  Proteasome inhibition and its effect RNA pol II occupancy at either the proxim-
al promoter (A) or exon IV (B) of CIITA.  
 
(A-B) ChIP assays were carried in HeLa cells stimulated with IFN-γ for 0-18 hrs (black bars) 
and pretreated with proteasome inhibitor MG132 (white bars) for 4 hrs prior harvesting. Lysates 
were subjected to IP with control antibody or with antibody against endogenous RNA pol II and 
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associated DNA was isolated and analyzed via Real time PCR using primers and probes span-
ning the proximal promoter (A) and exon IV (B) of CIITA. IP values are presented as a relative 
increase in CIITA DNA. Control values for (A) and (B) were 1800±300. Experiments were per-
formed in triplicate and graphed results are presented as a mean ± SD of two independent expe-
riments.  *P < 0.05 MG132 treated samples versus IFN-γ treated only.  
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To determine if S6a plays roles in RNA pol II promoter escape from CIITApIV, ChIP as-
says were performed to assess levels of RNA pol II binding to CIITApIV in the absence of S6a.  
Initial experiments to map baseline RNA pol II occupancy at CIITApIV and CIITA exon IV 
showed RNA pol II binding inducibly the CIITApIV proximal promoter (Figure 3.2 A) and con-
stitutive, elevated binding in the CIITA coding region (Figure 3.2 B) over a time course of IFN-
γ stimulation.  Having established baseline RNA pol II binding to the CIITApIV promoter and to 
exon IV, we next investigated roles of the 19S ATPase S6a in RNA pol II recruitment and occu-
pancy. As shown in (Figure 3.2 C), siRNA mediated reduction of endogenous S6a decreased 
S6a protein expression by 90% relative to control siRNA transfected cells, but did not impact the 
expression of the endogenous RNA pol II. In cells transfected with S6a siRNA, RNA pol II bind-
ing was decreased at the CIITA proximal promoter (Figure 3.2 D). However, the lack of S6a had 
a more pronounced effect on RNA pol II occupancy in CIITA exon IV where cells treated with 
S6a specific siRNA (Figure 3.2 D white bars) demonstrated significant decreases in RNA pol II 
occupancy when compared with control siRNA treated samples (Figure 3.2 D black bars).  To-
gether these studies strongly indicate the 19S ATPase S6a plays roles in both recruitment and 
processivity of RNA pol II at CIITA genes.   
  
The role of S6a in RNA pol II occupancy is independent of proteasomal degradation.   
 
As S6a an ATPase of the 19S proteasome, S6a plays important roles in the degradation of 
polyubiquitinated proteins (Ciechanover 1994; Ciechanover 1998).  While we have previously 
demonstrated that S6a siRNA does not block protein degradation, we have shown that S6a siR-
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NA moderately decreases 26S mediated degradation (Truax, Koues et al.). To determine the ef-
fects on RNA pol II occupancy of complete inhibition of proteasome mediated degradation, we 
treated IFN-stimulated cells with the proteasome inhibitor MG132 and assayed by ChIP for 
RNA pol II occupancy on CIITA genes. Cells were either mock treated or were treated with the 
proteasome inhibitor MG132 in the presence or absence of cytokine stimulation and ChIP assays 
were performed to detect endogenous level of RNA pol II at CIITA proximal promoters (Figure 
3.3 A) and coding regions (Figure 3.3 B). MG132 treated cells showed slight decreases in the 
levels of RNA pol II at both the proximal promoter and coding region of CIITA. Therefore, al-
though S6a plays roles in 26S mediated degradation (Truax, Koues et al.), proteasome inhibition 
does not prevent RNA pol II occupancy at CIITA promoters or coding regions, indicating the 
effects of S6a siRNA on RNA pol II occupancy are degradation independent.  
 
The 19S ATPase S6a interacts with P-TEF-b components CDK9 and Hexim-1  
 
Studies in yeast demonstrate components of the 19S proteasome associate with actively 
transcribing genes where they facilitate recruitment of various transcription factors (Ferdous, 
Gonzalez et al. 2001). As the 19S ATPase S6a binds both CIITA promoters and coding regions 
and impacts RNA pol II occupancy in these regions, we next sought to determine if S6a interacts 
with basal transcription factors required for elongation. RNA pol II is recruited to the CIITA 
proximal promoter and coding regions within hours of cytokine stimulation. It is known that spe-
cific phosphorylations of the RNA pol II CTD are required for transcription initiation and elon-
gation (Sims, Belotserkovskaya et al. 2004; Hager, McNally et al. 2009). RNA pol II Ser 5 phos-
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phorylation is required for the transition from initiation to elongation whereas Ser 2 phosphoryla-
tion is required for elongation (Hager, McNally et al. 2009). Phosphorylation is mediated by ki-
nase TFIIH (CDK7), the mediator complex, and the kinase P-TEF-b (CDK9). P-TEF-b exists in 
two forms, active and inactive, where the inactive form of P-TEF-b is bound to Hexim1 and 
7SK. We therefore investigated the interaction of the 19S ATPase S6a with components of P-
TEF-b (CDK9) by transfecting HeLa cells with Myc S6a and either Flag-Hexim-1 or HA-CDK9. 
As shown in Figure 4, S6a co-immunoprecipitated with Hexim-1 (Figure 3.4, lane 3 and 5) and 
with CDK9 (Figure 3.4, lane 4 and 6). Positive control was immunoprecipitated with Myc con-
jugated beads (Figure 3. 4, lane 1) and negative control with mouse IgG antibody (Figure 3. 4, 
lane 2).  
 
Efficient transfections and equal loading of cell lysates was confirmed by immunoblot 
analysis of Myc, HA, and Flag tagged proteins. The association of S6a with Hexim-1 and CDK9 
increases upon IFN-γ stimulation indicating that S6a may be important in the switch from the 
inactive to active form of P-TEF-b. (Figure 3.6 Supplementary Figure 1) demonstrates the 19S 
ATPases Sug1 and S7 also associate with Hexim-1 and CDK9, suggesting all 19S ATPases may 
promote the switch from inactive to active form of P-TEF-b.  
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Figure 3.4 The 19S ATPase S6a associates with Hexim-1 and CDK9.   
 
HeLa cells were transfected with Myc-S6a, Flag  Hexim-1, and HA-CDK9,  stimulated with 
IFN-γ for 4hrs as indicated, and were lysed and subjected to IP with Myc beads (lane 1) as a pos-
itive control, with mouse isotype control IgG (lane 2), with Flag Beads  (lane 3 and 5), and with 
HA beads (lane 4 and 6).  IP and lysate control samples (bottom) were subjected to IB for Myc, 
HA, and Flag as indicated.  Results reported are representative data of three independent experi-
ments.  
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Figure 3.5 Decreased expression of S6a decreases occupancy of cyclin T1 at CIITA proxim-
al promoter and coding region 
 
(A-B) Cyclin T1 inducibly binds the CIITA proximal promoter (A) and coding region (B). ChIP 
assays were carried out in HeLa cells as described in Fig 2 (A-B). Lysates were stimulated with 
IFN-γ for 0-18 hrs and subjected to IP against endogenous cyclin T1. Associated DNA was iso-
lated and analyzed via Real Time PCR with primers spanning CIITA proximal promoter (A) and 
coding region exon IV (B). Control IP values for (A) and (B) were 1350±500. Control and IP 
values represent the mean ±SD of two independent experiments.  
 
(C) S6a siRNA treatment significantly and specifically decreases S6a expression. HeLa cells 
were transfected with either control or S6a specific siRNA duplexes and were stimulated with 
IFN-γ as indicated.  Lysates were subjected to IB for endogenous S6a (top blot) or endogenous 
cyclin T1 (bottom blot).  Results reported are data representative of 2 independent experiments. 
Western blot shows specific 90-95% knockdown of S6a and stable expression of cyclin T1.  
 
(D-E) S6a knockdown significantly decrease cyclin T1 occupancy at the CIITA proximal promo-
ter (D) and CIITA exon IV coding region (E). ChIP analysis were carried out in HeLa cells that 
were stimulated as indicated with IFN-γ and transfected with control siRNA (black bars) or S6a 
specific siRNA (white bars). Lysates were subjected to IP with antibody against endogenous cyc-
lin T1. Associated DNA was analyzed via Real Time PCR with primers specific for the CIITA 
proximal promoter (D) and CIITA coding region (E). IP values are presented as a relative in-
crease in the CIITA DNA. Control IP values for (D) and (E) were 900±500. Control and cyclin 
T1 IP values represent the mean ±SD of 2 independent experiments. ***P < 0.001, **P < 0.005, 
*P < 0.05 versus control siRNA. 
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S6a knockdown decreases Cyclin T1 occupancy at the CIITA proximal promoter and cod-
ing region.   
 
Studies have shown that P-TEF-b is recruited to an early elongation complex on the HIV 
long term repeats (LTR) and forms a complex with Tat trans-activator protein  (Kanazawa, 
Okamoto et al. 2000) (Ping and Rana 1999) (Zhou, Chen et al. 1998). CIITA also recruits P-
TEF-b containing cyclin T1 to the promoter of MHC II (Kohoutek, Blazek et al. 2006).  P-TEF-b 
is also present at the transcribed regions of the HSP70 genes during heat shock activation (Lis, 
Mason et al. 2000) . Upon stimulation, P-TEF-b dissociates from the large inactive complex and 
forms a small complex that is recruited to transcriptional machinery (Nguyen, Kiss et al. 2001; 
Yang, Zhu et al. 2001). ChIP analyses were performed to assess cyclin T1 occupancy at the CII-
TA proximal promoter (Figure 3.5 A) and coding region (Figure 3.5 B).  Initial ChIP mapping 
experiments demonstrated cyclin T1 is inducibly recruited to both regions of CIITA. Levels of 
cyclin T1 at CIITA exon IV are significantly higher than at the proximal promoter, indicating 
cyclin T1 is an important elongation regulator at CIITA genes.  
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Figure 3.6 (Supplementary Figure 1) The 19S ATPase Sug1 (A) and S7 (B) associates with 
Hexim-1 and CDK9.   
 
(A-B) HeLa cells were transfected with Myc-Sug1, Myc-S7 Flag  Hexim-1, and HA-CDK9 as 
indicated, and were lysed and subjected to IP with Myc beads (lane 1) as a positive control, with 
mouse isotype control IgG (lane 2), with Flag Beads  (lane 3), and with HA beads (lane 4).  IP 
and lysate control samples (bottom) were subjected to IB for Myc, HA, and Flag as indicated.  
Results reported are representative data of three independent experiments.  
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To investigate roles for S6a in regulating occupancy of cyclin T1 at CIITA proximal 
promoters and coding regions, we utilized S6a siRNA specific duplexes to specifically knock-
down endogenous expression of S6a in HeLa cells and then performed ChIP experiments to 
detect levels of cyclin T1 at the CIITA proximal promoter (Figure 3.5 D) and coding regions 
(Figure 3. 5 E). Although S6a was sufficiently reduced via S6a specific siRNA, level of endo-
genous cyclin T1 were unaffected (Figure 3.5 C). S6a siRNA significantly impacted the re-
cruitment of cyclin T1 to the CIITA proximal promoter and coding region, indicating S6a plays 
important roles in recruiting cyclin T1 to CIITA genes.  
 
3.4 DISCUSSION 
 
Critical roles in transcription initiation of various mammalian genes have been demon-
strated for ATPases of the 19S proteasome (Truax, Koues et al. ; Kinyamu, Chen et al. 2005; 
Lassot, Latreille et al. 2007; Bhat, Turner et al. 2008; Koues, Dudley et al. 2008). We have pre-
viously demonstrated that upon cytokine stimulation, the 19S S6a is rapidly recruited to CIITA 
proximal promoters (Truax, Koues et al.).  Promoter binding of S6a mediates initiation of tran-
scription by stabilizing promoter binding of activating histone modifying enzymes and transcrip-
tion factors.  S6a, and other 19S ATPases, act as a critical regulator of the assembly of multi-
subunit complexes on promoters and thus regulate in large part the mechanics of transcription 
initiation.  
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Evidence also exists that 19S ATPases play important roles in RNA pol II dependent 
elongation  independent of the presence or function of the 20S core (Ferdous, Gonzalez et al. 
2001). The 19S ATPase Rpt 6 interacts with the yeast elongation factor CDc8 (human FACT) 
and a loss of Rpt 6 blocks elongation in yeast cells (Xu, Singer et al. 1995; Ferdous, Gonzalez et 
al. 2001). Recent studies have documented the existence of a holo RNA pol II complex com-
posed of a core RNA pol II and a mediator complex which functions to enable transcriptional 
activity of the core RNA pol II (Kim, Bjorklund et al. 1994). In these studies, the 19S ATPase 
Sug1 was identified as a subunit of mediator, indicting a mechanism by which Sug1 may regu-
late transcription initiation and elongation. We now provide evidence of novel roles for the 19S 
ATPase S6a in mediating transcriptional elongation of the critical mammalian gene CIITA. In 
the absence of S6a, RNA pol II binding to the CIITA promoter is decreased and RNA pol II 
binding to CIITA coding sequence is markedly reduced.  
 
As DNA is wrapped around histone proteins that are then condensed into chromatin 
(Luger, Mader et al. 1997; Richmond and Davey 2003), there must be additional regulation of 
the availability of DNA for transcription, however the exact mechanisms by how 19S ATPases 
regulate the accessibility of DNA remains to be determined. The role of S6a in binding RNA pol 
II to the coding region of CIITA genes is much more pronounced than at proximal promoter re-
gions. Perhaps 19S ATPases, which act as “unwindases” during proteasomal degradation, play 
similar roles in regulating the accessibility of coding region DNA. Evidence for roles of S6a in 
transcriptional elongation also comes from our observations that S6a associates with P-TEF-b 
components Hexim-1 and CDK9.  Upon cytokine stimulation, P-TEF-b is dissociated from the 
inactive complex that was bound by Hexim-1 and 7SK and is recruited to actively transcribing 
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genes (Nguyen, Kiss et al. 2001; Yang, Zhu et al. 2001; Michels, Fraldi et al. 2004). 19S ATPas-
es associate with components of the inactive (Hexim-1) and active (CDK9) form of P-TEF-b, 
indicating 19S ATPases may facilitate the switch from an inactive to active form of P-TEF-b. Of 
additional interest are our observations that S6a regulates CIITA promoter and coding region 
binding of the P-TEF-b component cyclin T1. However, the effects of S6a knockdown on cyclin 
T1 occupancy are more pronounced at CIITA coding regions than proximal promoters. Here 19S 
ATPases may play dual roles increasing DNA accessibility for elongation factors and in facilitat-
ing the switch from inactive to active P-TEF-b. The reduced levels of cyclin T1 in the absence of 
S6a are likely due to decreased release of Cyclin T1 from inactive P-TEF-b.  Additional experi-
ments will confirm and expand these findings.  While S6a is an important regulator of degrada-
tion, the roles played by S6a in elongation are independent of the proteolytic activity of the pro-
teasome, as proteasomal inhibition has minimal impact on RNA pol II promoter and coding re-
gion binding at CIITA genes. Studies in yeast using genome wide ChIP analyses indicate that 
while subunits of the 26S proteasome interact with a majority of genes, hundreds of genes asso-
ciate with either the 19S or 20s components of the proteasome, but not with both, thus protea-
some subunits have specific and independent function at different promoters (Sikder, Johnston et 
al. 2006).  
 
Our studies are the first to show the 19S ATPase S6a binds robustly within coding re-
gions of mammalian genes. S6a association is the strongest in CIITA exon IV while and is unde-
tectable at polyA regions of CIITA genes. We are the first one to demonstrate that RNA pol II 
occupancy at the proximal promoter and coding regions of CIITA is dependent on S6a. P-TEF-b 
is a critical regulator of mammalian elongation.  Our observation of S6a association with Hexim-
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1 1 and CDK9 suggests the actions of S6a are important in the activation of P-TEF-b. Dissocia-
tion of Hexim-1 and 7SK promotes formation of the active form of P-TEF-b which is in turn re-
cruited to actively transcribing genes (Nguyen, Kiss et al. 2001; Yang, Zhu et al. 2001; Michels, 
Fraldi et al. 2004). ChIP analyses demonstrated significantly reduced occupancy of the cyclin T1 
component of P-TEF-b at CIITA coding regions in the absence of S6a.  
 
In sum, we are the first to demonstrate 19S ATPases regulate transcriptional elongation 
of a mammalian gene. The mechanisms supporting this regulation remain unknown and the pos-
sibility remains that S6a regulates transcriptional elongation by controlling epigenetic modifica-
tions throughout coding regions. Our findings that 19S ATPases play critical roles in the regula-
tion of transcriptional elongation advance our knowledge of the functions of the proteasome in 
gene expression. Full understanding of the role of the 19S proteasome in regulating elongation of 
mammalian genes will require additional studies of the molecular mechanisms regulated by the 
ATPases of the 19S proteasome.  
 
3.5 MATERIAL AND METHODS 
 
Cells 
 
HeLa (human epithelial) cells were purchased from ATCC (Manassas, VA) and were 
maintained in high glucose Dulbecco modified Eagle (DMEM) medium (Mediatech Inc., Hern-
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don, VA) supplemented with 10% fetal bovine serum (FBS), 5mM L-glutamine, and 5mM peni-
cillin-streptomycin at 37
◦
C with 5% carbon dioxide.  
 
Antibodies 
 
Antibodies recognizing RNA pol II and cyclin T1 were purchased from Abcam (Cam-
bridge, MA). Mouse and rabbit immunoglobulin G (IgG) isotype control antibodies were pur-
chased from Millipore (Lake Placid, NY). S6a antibody was purchased from Biomol Internation-
al, L.P. (Plymouth Meeting, PA). HRP conjugated mouse antibody was purchased from Promega 
(Madison, WI); and HRP conjugated rabbit antibody was purchased from Pierce (Rockland, IL).  
 
Plasmids: 
 
Flag-Hexim-1 was kindly provided by Dr. David Price (Li, Price et al. 2005) and HA-
CDK9 was a generous gift from Dr. Lou (Zhou, Chen et al. 1998). The pBluescript (pBS)-S6a 
and S7 plasmids were kindly provided by Dr. Martin Rochesteiner (Richmond, Gorbea et al. 
1997; Rabl, Smith et al. 2008) and subcloned into Myc tagged pCMV-3 using EcoRI restriction 
sites. The Myc Sug-1 was kindly provided by Dr. A.A.Wani (Zhu and Ting 2001) and has been 
previously described (Koues, Dudley et al. 2008).  
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 Co-Immunoprecipitations:  
 
HeLa cells were plated at a cell density of 7x10
5
.  Following adhesion, cells were trans-
fected as indicated with 5 μg of Myc-S6a, Myc-S7, Myc Sug-1, pcDNA, Flag Hexim-1 and HA-
CDK9 plasmids using Fugene 6 (Roche, Indianapolis, IN) according to manufacturer‟s instruc-
tions. Twenty four hours post transfections cells were harvested and lysed in RIPA lysis buffer 
(1M Tris pH 8.0, 10% Nonidet P-40, 5% DOC, 10% SDS, 5M NaCl, 5mM EDTA, 1M DTT) 
supplemented with Complete EDTA-free protease inhibitors (Roche) buffer and were precleared 
with 30μl IgG beads (Sigma). Cell lysates were immunoprecipitated (IP) overnight with 30ul of 
Myc conjugated beads (Sigma), Flag conjugated beads (Sigma), HA conjugated beads (Sigma), 
or mouse IgG beads (Sigma).  Immune complexes were denatured with Leammli buffer, boiled 
and subjected to SDS-PAGE. Co-immunoprecipitated complexes were detected by immunoblot-
ting (IB) with anti Myc horseradish peroxidase (HRP) conjugated antibody (Sigma), Flag HRP 
antibody (Sigma), and HA antibody (Santa Cruz).  HRP conjugates were detected with Supersig-
nal West Pico Chemiluminescent substrate (Denville).  Bradford Assays were used to normalize 
the total protein in the sample. Equal transfection and loading was determined in non-
immunoprecipitated lysates by immunoblot.    
 
siRNA Constructs and Transient Transfections 
 
Short interfering RNA (siRNA) duplexes predesigned against human S6a (Qiagen) were 
used for transient knockdown of S6a as previously described (Truax, Koues et al.).  Cells were 
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transfected with 1ug of S6a specific siRNA,or All Star scrambled sequence control (Qiagen), 
using RNAiFect transfection reagent (Qiagen) according to the manufacturer‟s instructions and 
were treated with IFN-γ (500U/ml) as indicated.  Cells were lysed in NP-40 lysis buffer (1M Tris 
pH 8.0, 1M KCl, 10% NP-40, 0.5M EDTA, 5M NaCl, 1M DTT, dH2O) with EDTA free pro-
tease inhibitor (Roche) and were analyzed by western blot for knockdown efficiency and speci-
ficity. 
 
Chromatin Immunoprecipitation (ChIP) 
 
ChIP assays were performed as previously described (Truax, Koues et al. ; Bhat, Turner 
et al. 2008; Koues, Dudley et al. 2008; Mehta, Truax et al. 2011).  Briefly, cells were plated at a 
cell density of 3x10
6
, stimulated with IFN-γ as indicated (500U/ml), and were crosslinked with 
1% formaldehyde for 10 minutes at room temperature.  Crosslinking was stopped by the addition 
of 0.125M glycine for five minutes at room temperature.  Cells were lysed in SDS lysis buffer 
and were sonicated at constant pulse to generate an average of 500-750bp sheared DNA.  Soni-
cated lysates were precleared with salmon-sperm coated agarose beads (Millipore) and half of 
the lysate was immunoprecipitated with 5μg of indicated antibody overnight at 4°C.  The re-
maining half of the lysate was immunoprecipitated with mouse or rabbit isotype control antibody 
(Millipore).  Following a two hour immunoprecipitation with 60μl of salmon-sperm coated aga-
rose beads, samples were washed for 3 minutes at 4°C with each of the following buffers:  low 
salt buffer, high salt buffer, LiCl, and 1xTE and were eluted with SDS elution buffer.  Following 
elution, cross-links were reversed overnight with 5M NaCl at 65°C and immunoprecipitated 
DNA was isolated using phenol:chloroform:isopropanol mix (Invitrogen) as per the manufactur-
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er‟s instructions.  Isolated DNA was analyzed by real-time PCR using previously published pri-
mers spanning the GAS-IRF-E box of CIITApIV and exon IV of CIITA (Truax, Koues et al. ; 
Bhat, Turner et al. 2008; Koues, Dudley et al. 2008). Primers for the exon regions of CIITA cod-
ing region were as follows: CIITA exon XI sense GGGAAAGCTTGTGCAGACTC, antisense 
GGACAGATTGAGGGTTTCCA, and probe FAM- CTGCTGTTCGGGACCTAAAG-TAMRA; 
CIITA exon XVIII sense AACAGGATTCACGGATCAGC, antisense GCAGAGCAA-
GATGTGGTTCA, and probe FAM- GGACACAGCTCTTCTCCAGG-TAMRA; and CIITA 
polyA  sense AGCCTGCTAATTCCCCAGAT, antisense TCCCATTAGCTGTTTCCCTG, and 
probe FAM- AGTGGCAGCTGCTTTTGTCT-TAMRA. Values generated from Real-time PCR 
reactions were calculated based on standard curves generated.  
 
Chromatin Immunoprecipitation with siRNA 
 
ChIP with siRNA were performed as previously described (Truax, Koues et al. ; Koues, 
Dudley et al. 2008).  Briefly, cells were plated at a density of 8x10
5
, transfected with 1µg S6a 
specific or control siRNA (Qiagen), and were stimulated as indicated with IFN-γ (500U/ml).  
10% of the cell volume was lysed with 1% Nonidet P-40 lysis buffer and was analyzed by west-
ern blot for knockdown efficiency and specificity.  The remaining cell volume was crosslinked, 
lysed in SDS lysis buffer, and subjected to sonication and the above described ChIP assay. 
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ABSTRACT 
 
Precise regulation of Major Histocompatibility class II (MHC II) genes plays important 
roles in initiation, propagation, and termination of adaptive immune responses by controlling an-
tigen presentation to CD4
+
 T cells.  MHC II genes are constitutively expressed in only a few cell 
types and are inducibly expressed by the inflammatory response cytokine interferon gamma 
(INF-γ) in all nucleated cells.  The regulation of MHC II is tightly controlled by a Master Regu-
lator, the class II transactivator (CIITA), which is a general regulator of both constitutive and 
inducible MHC II expression.  Although much is known about the transcription factors necessary 
for CIITA expression, less is known about the epigenetic modifications and the requisite en-
zymes needed to provide these transcription factors access to DNA.  We show here that multiple 
epigenetic changes occur at the IFN-γ inducible CIITA promoter within 20‟ of IFN-γ stimulation 
and that these changes correlate with the opening of the promoter and the initiation of transcrip-
tion.  Our study links these rapidly occurring epigenetic events at the inducible CIITA promoter 
to decreased promoter binding of the histone methyltransferase EZH2, and shows that decreased 
promoter binding of EZH2 transforms this previously tightly regulated and cytokine inducible 
promoter into a constitutively active and dysregulated gene. 
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4.1 BACKGROUND 
 
MHC is an important gene family, whose protein product is expressed on the cell surface 
of all jawed vertebrates.(Gelin, Sloma et al. 2009)  MHC II is constitutively expressed on antigen 
presenting cells, and is inducibly expressed on nucleated cells in response to pro-inflammatory 
cytokines.(Kaufman, Auffray et al. 1984; Chang, Fontes et al. 1994)  Precise regulation of MHC 
II genes plays important roles in the control of adaptive immune responses, and in limiting infec-
tion, autoimmune disease, and tumor growth.(Adamski, Ma et al. 2004; Handunnetthi, Ramago-
palan et al. 2010)  The regulation of MHC II is controlled by a Master Regulator, the class II 
transactivator (CIITA), with multiple studies demonstrating that CIITA regulated expression of 
MHC II is controlled and induced by IFN-γ.(Murphy, Choi et al. 2004)  As a functional CIITA 
gene is necessary for the expression of MHC II genes, CIITA is widely considered to be a re-
quired master regulator of both constitutive and inducible MHC II expression.(Collins, Korman 
et al. 1984; Boss and Jensen 2003; Reith, LeibundGut-Landmann et al. 2005).  
 
Four distinct promoters regulate expression of CIITA in a highly regulated and cell type 
specific manner.(Muhlethaler-Mottet, Otten et al. 1997; Piskurich, Linhoff et al. 1999) Promoter 
I drives CIITA expression in dendritic cells (Landmann, Muhlethaler-Mottet et al. 2001), CIITA 
promoter III is responsible for CIITA expression in B cells, (Lennon, Ottone et al. 1997) and 
promoter IV is responsible for the inducible expression of CIITA and is regulated by IFN-. 
(Piskurich, Gilbert et al. 2006)  To date, the function of CIITA promoter II remains unknown.  
CIITApIV is composed of three cis-acting elements: an IFN- activated sequence (GAS), an E-
box, and an IFN response element (IRE) site. (Piskurich, Linhoff et al. 1999)  IFN- stimulation 
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leads to the activation of the JAK/STAT pathway by triggering the phosphorylation of signal 
transducer and activator of transcription 1 (STAT-1) homo-dimers, which then translocate to the 
cell nucleus and regulate the expression of multiple genes, including that of interferon regulatory 
factor 9 (IRF-1) (Reith and Mach 2001).  Upon IFN-γ stimulation, STAT-1 and IRF-1 are re-
cruited, along with the ubiquitous factor 1 (USF-1), to CIITApIV.  STAT-1 binds to the GAS 
element, USF-1 localizes to the E-box, and IRF-1 is recruited to the IRE element. (Piskurich, 
France et al. 1993; Piskurich, Youngman et al. 1997; Piskurich, Linhoff et al. 1999; Piskurich, 
Gilbert et al. 2006) Following IFN-γ stimulation, CIITApIV histone acetylation is increased and 
the ATPase subunit of the SWI/SNF complex, Brahma-related gene 1 (BRG1), is necessary for 
chromatin remodeling. (Beresford and Boss 2001; Pattenden, Klose et al. 2002) Binding of these 
regulatory elements to CIITApIV leads to the appearance of CIITA transcripts, which have pre-
viously been observed two hours post IFN-γ stimulation.  
 
Despite the requirement for CIITA expression in MHC II transcription, strikingly few 
studies have investigated the remodeling events occurring at CIITApIV and the early regulatory 
epigenetic modifications to CIITApIV.   Increases in the levels of acetylation of histones H3 and 
H4 (Agalioti, Chen et al. 2002; Morris, Beresford et al. 2002) and tri-methylation of histone 
H3K4 has been observed upon prolonged cytokine stimulation.(Ni, Karaskov et al. 2005)  Pre-
vious studies have shown that two histone modifying enzymes are recruited to CIITApIV:  the 
HAT CBP/p300 and the ATP dependent chromatin remodeler BRG-1 which binds to the prox-
imal promoter prior to STAT-1 recruitment.  (Sisk, Gourley et al. 2000; Pattenden, Klose et al. 
2002; Ni, Karaskov et al. 2005)  Histone modification studies carried out at CIITApIV tradition-
ally assay two distinct conditions: unstimulated cells and then a significantly later time period 
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post IFN-γ stimulation.  In the case of CIITApIV expression, these later time points are less rele-
vant as dynamic and regulatory epigenetic changes occur quickly following IFN-γ stimula-
tion.(Morris, Spangler et al. 2000)  Our previous observations of rapid induction of CIITA mes-
sage levels from CIITAPIV demonstrate that this CIITA promoter is likely in an open conforma-
tion within two hours of IFN-γ stimulation (Truax, Koues et al. 2010)  thus, an important area of 
study are the epigenetic events occurring before these early CIITA transcripts appear.  The study 
of the epigenetic regulation of the Master Regulator CIITA is clinically relevant, as aberrant ex-
pression of CIITA leads to inappropriate expression of MHC II proteins. (Guy, Krajewski et al. 
1986; Santin, Hermonat et al. 1998; Ting and Trowsdale 2002)  Dysregulated expression of 
MHC II is associated with various disorders and diseases; in sum, over expression of MHC II is 
correlated with autoimmune diseases, while suppression of MHC II expression leads to tumor 
development and immune deficiency syndromes. (Guy, Krajewski et al. 1986; Santin, Hermonat 
et al. 1998). 
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4.2 RESULTS 
 
Rapid epigenetic changes occur at CIITApIV following IFN-γ stimulation. 
 
Acetylation of histone tails neutralizes the charge on histones and counters the natural 
tendency of DNA and histones to tightly interact.  Histone acetylation occurs on lysine residues 
and is often targeted to lysine (K) residue 18 of histone H3. (Jenuwein and Allis 2001; Roth, De-
nu et al. 2001; Gorisch, Wachsmuth et al. 2005)  Prior epigenetic studies of the IFN-γ inducible 
CIITA promoter, pIV, have shown weak to moderate acetylation of histones H3 and H4 in the 
absence of cytokine induction; (Morris, Beresford et al. 2002; Wright and Ting 2006) which al-
lows binding of ubiquitously expressed USF-1 to CIITApIV.  Following IFN-γ stimulation, CII-
TApIV is available for further transcription factor binding of STAT-1 and IRF-1, which in turn 
recruit the basal transcriptional machinery and, together with USF-1, drive robust transcription of 
CIITA. (Reith, LeibundGut-Landmann et al. 2005) 
 
As prompt CIITA expression is required in the initial stages of an adaptive immune re-
sponse, we sought to determine how quickly CIITApIV undergoes epigenetic remodeling in the 
presence of inflammatory cytokine.  To evaluate levels of H3K18 acetylation at various time 
points following IFN-γ stimulation, HeLa cells were stimulated with IFN-γ, crosslinked, lysed, 
immunoprecipitated with antibodies specific to H3K18 acetylation, and analyzed by real-time 
PCR with primers and probe spanning the CIITApIV proximal promoter.  ChIP assays showed 
elevated levels of H3K18 upon IFN-γ stimulation that were significantly increased within 20 mi-
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nutes and that remained significantly elevated through 120 minutes of cytokine stimulation (Fig-
ure 4.1 A, left panel).  Of note, although H3K18 acetylation at CIITApIV is immediately in-
creased by inflammatory cytokine, maximal levels of acetylation are not reached until 18h fol-
lowing IFN-γ stimulation (Figure 4.1 A, right panel). To determine if histone acetylation is in-
fluenced by IFN-γ at all genes, ChIP assays were performed to determine the levels of acetylated 
H3K18 at the GAPDH promoter. Figure 4.1 B demonstrates that cytokine stimulation had no 
significant impact on the levels of acetylated H3K18 at the GAPDH promoter as the levels of 
acetylation remains constant throughout the IFN-γ time course.  
 
We and others have previously reported that increases in acetylation of histone H3 fre-
quently overlap spatially and temporally with increases in an additional activating epigenetic 
modification at histone H3:  lysine 4 trimethylation (H3K4me3). (Wu, Wang et al. 2008; Koues, 
Dudley et al. 2009)  In order to more precisely determine the timeline of IFN-γ induced changes 
that occur in regards to H3K4me3 at CIITApIV, chromatin immunoprecipitation experiments 
were performed to determine levels of H3K4me3 at CIITApIV at time points immediately fol-
lowing IFN-γ stimulation.  As shown in Figure 4.1C, ChIP mapping experiments demonstrated 
that, similar to rapid changes in H3K18 acetylation, significant increases in H3K4me3 occur 
within 20 minutes of IFN-γ stimulation and continue to rise throughout the 120 minute time 
course. Additional ChIP experiments at the GAPDH promoter demonstrate the observed changes 
in Figure 1c are promoter specific as levels of H3K4me3 are not significantly altered by IFN-γ 
stimulation (Figure 4.1 D).  
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Figure 4.1   Rapid increases in histone 3 lysine 18 (H3K18ac) acetylation and in histone 3 
lysine 4 (H3K4me3) are observed at CIITA promoter IV following IFN-γ stimulation.  
 (A and C)  HeLa cells were stimulated with IFN-γ as indicated, crosslinked with formaldehyde, 
lysed and sonicated.  Lysates were immunoprecipitated (IP) with control antibody or with anti-
body to H3K18ac (A) or to H3K4me3 (C).  Associated DNA was isolated and analyzed via Real-
time PCR using primers spanning the IRF-1 binding site at CIITAPIV.  Real-time PCR values 
were normalized to the total amount of promoter DNA added to the reaction (input; 5% of the 
total cell lysate).  IP values are presented as a relative increase in CIITApIV DNA relative to un-
stimulated samples.  Control IP values for (A and C) were 350± 100.  Values for control IPs, 
acetylated histone H3K18 IPs and for trimethylated H3K4 IPs represent mean ± SEM of three 
independent experiments. ****P < 0.00005, ***P < 0.0005, **P < 0.005, *P < 0.05 versus un-
stimulated sample.  
(B and D) H3K18 acetylation and H3K4me3 levels at the GAPDH promoter are not affected by 
cytokine stimulation.  ChIPs were carried out as above in Hela cells stimulated with IFN-γ.  Ly-
sates were subjected to IP with control antibody or with antibody to endogenous H3K18ac (B) or 
H3K4me3 (D). Associated DNA was isolated and analyzed via real time PCR using primers 
spanning the GAPDH proximal promoter.  IP values are presented as a relative increase in 
GAPDH DNA relative to unstimulated samples.  Control IP values for (B and D) were 250± 50. 
Values for control IPs, acetylated histone H3K18 IPs, and for trimethylated H3K4 IPs represent 
mean ± SEM of three independent experiments. 
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Figure 4.2  Rapid decreases in histone 3 lysine 9 (H3K9me3) and histone 3 lysine 27 
(H3K27me3) trimethylation occur at CIITA promoter IV upon IFN-γ stimulation.    
(A and C)  HeLa cells were stimulated with IFN-γ, crosslinked with formaldehyde, and cells 
were lysed and sonicated.  Lysates were immunoprecipitated (IP) with control antibody or with 
antibody to H3K9me3 (A) or to H3K27me3 (C).  Associated DNA was isolated and analyzed via 
Real-time PCR using primers spanning the IRF-1 binding site at CIITAPIV.  Real-time PCR 
values were normalized to the total amount of promoter DNA added to the reaction (input; 5% of 
the total cell lysate).  IP values are presented as a relative increase in CIITApIV DNA relative to 
unstimulated samples.  Average control IP values for (A) and (C) were 400± 80.  Values for con-
trol IPs, for trimethylated H3K9 IPs, and for trimethylated H3K27 IPs represent mean ± SEM of 
three independent experiments. ****P < 0.00005, ***P < 0.0005, **P < 0.005, *P < 0.05 versus 
unstimulated sample.  
(B and D) H3K9me3 and H3K27me3 levels at the GAPDH promoter are not affected by IFN-γ 
stimulation.  ChIPs were carried out as above in Hela cells stimulated with IFN-γ.  Lysates were 
subjected to IP with control antibody or with antibody to endogenous H3K9me3 (B) or 
H3K27me3 (D).  Associated DNA was isolated and analyzed via real time PCR using primers 
spanning the GAPDH proximal promoter.  IP values are presented as a relative increase in 
GAPDH DNA relative to unstimulated samples.  Control IP values for (B and D) were 200± 50. 
Results reported are represented by mean ± SEM of three independent experiments. 
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Converse to gains in lysine 4 hypermethylation, losses in histone 3 lysine 9 hypermethy-
lation (H3K9me3) are associated with open chromatin structure and these losses are thus an indi-
cation of active transcription.(Agalioti, Chen et al. 2002) We next sought to determine levels of 
H3K9me3 at CIITApIV at early time points following IFN-γ stimulation. HeLa cells were stimu-
lated with IFN-γ, crosslinked, lysed, subjected to IP with antibody against endogenous trimethy-
lated H3K9, and analyzed by real-time PCR with primers and probe spanning the CIITApIV 
proximal region.  ChIP assays showed significant decreases in H3K9me3 at CIITApIV within 20 
minutes of IFN-γ stimulation (Figure 4.2 A).  Levels of H3K9me3 continued to decline until 
reaching baseline levels within 80 minutes, indicating that initial drops in H3K9me3 have 
marked effects on chromatin structure and transcriptional activity. ChIP assays and real time 
PCR analysis further indicated that promoter levels of H3K9me3 at GAPDH were not signifi-
cantly affected by cytokine stimulation (Figure 4.2 B). 
 
Previous studies suggest that the addition of activating H3K4 methylation events similar 
to those observed in Figure 1c frequently correlate with the depletion of silencing hypermethyla-
tion events on histone H3 lysine 27 (H3K27me3). (Ng, Robert et al. 2003)   To characterize 
changes in the levels of H3K27me3 at CIITApIV, we expanded our epigenetic map of this pro-
moter by performing ChIP assays in IFN-γ stimulated HeLa cells and isolating H3K27me3 mod-
ifications.  Stimulated HeLa cells were crosslinked, lysed and immunoprecipitated with antibody 
to endogenous H3K27me3, and isolated DNA was analyzed by real time PCR using primers and 
probe spanning proximal CIITApIV.  As shown in Figure 2c, ChIP results demonstrate a signifi-
cant decline in H3K27me3 at early time points post cytokine stimulation. In addition, further 
ChIP and real time PCR analysis indicate levels of H3K27me3 at the GAPDH proximal promo-
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ter region are not significantly affected by cytokine stimulation (Figure 4.2 D). In sum, these 
data indicate that following IFN-γ stimulation, significant regulatory epigenetic events occur at 
CIITApIV in rapid succession.  
 
CIITApIV is rapidly activated for transcription by the inflammatory cytokine IFN-γ. 
 
Following IFN-γ treatment, dimerization of the IFN-γ receptor activates JAK1 and JAK2 
which phosphorylate STAT-1 and subsequently promote STAT-1 nuclear localization and bind-
ing to target promoters.(Chang, Fontes et al. 1994) STAT-1 binds the GAS element of CIITApIV 
and, along with USF-1, IRF-1, and the basal transcriptional machinery, assembles the transcrip-
tional initiation complex necessary to promote transcription from CIITApIV. (Chang, Fontes et 
al. 1994; Muhlethaler-Mottet, Di Berardino et al. 1998; Morris, Beresford et al. 2002)  As bind-
ing of STAT-1 to CIITApIV occurs when the promoter is in an open conformation, we addressed 
the effectiveness of early activating epigenetic modifications to CIITApIV by performing ChIP 
assays to determine levels of STAT-1 bound to CIITApIV following IFN-γ stimulation.   ChIP 
mapping assays demonstrate significant localization of STAT-1 to CIITApIV within 20 minutes 
of IFN-γ stimulation (Figure 4.3 A).  These data indicate the rapid alterations in CIITApIV 
chromatin structure are effectively opening the promoter and allowing assembly of initiation 
complexes on the proximal promoter of CIITApIV. Based on these observations, we conclude 
that significant activating epigenetic events occur at CIITApIV within the first 20 minutes of 
INF-γ stimulation.   
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Figure 4.3  Figure 3.  Transcriptional activation of CIITApIV occurs within 20’ of IFN-γ 
stimulation.   
(A)  STAT1 binds CIITA promoter IV within 20‟ of IFN-γ stimulation.  HeLa cells were stimu-
lated with IFN-γ, crosslinked with formaldehyde, and cells were lysed and sonicated.  Lysates 
were immunoprecipitated (IP) with control antibody or with antibody to STAT1.  Associated 
DNA was isolated and analyzed via Real-time PCR using primers spanning the IRF-1 binding 
site at CIITAPIV.  Real-time PCR values were normalized to the total amount of promoter DNA 
added to the reaction. IP values are presented as a relative increase in CIITApIV DNA relative to 
unstimulated samples.  Average control IP values were 532± 32.  Values for control IPs and for 
STAT1 represent mean ± SEM of three independent experiments.  
 (B)  Rapid increases in CIITA message levels occur within 40‟ post IFN-γ stimulation.  CIITA 
and GAPDH mRNAs were prepared using TRIzol reagent and cDNA was generated using gene 
specific antisense primers for CIITA and GAPDH.  cDNA was quantitated by real time PCR us-
ing gene specific antisense primers for CIITA and GAPDH.  Data are graphed as relative value 
of CIITA mRNA and were determined after normalization to GAPDH mRNA.  Values represent 
mean ± SEM of three independent experiments. ***P < 0.0005, **P < 0.005, *P < 0.05 versus 
unstimulated sample. 
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Figure 4.4   EZH2 binding to CIITApIV decreases significantly following IFN-γ stimula-
tion.   
HeLa cells stimulated with IFN-γ were crosslinked with DSG and formaldehyde and were then 
lysed and sonicated to generate fragments of approximately 750bp.  Lysates were IP with control 
antibody or with antibody to EZH2.  Associated DNA was isolated and analyzed via Real-time 
PCR using primers spanning the IRF-1 binding site at CIITAPIV.  IP values are presented as 
amount of CIITApIV DNA relative to unstimulated samples and have been normalized to the 
total amount of promoter DNA added to the reaction.  Data are presented as the relative number 
of associated molecules analyzed in three cell lysate preps with each sample analyzed in tripli-
cate.  Control IP values were 435±30. **P < 0.005, *P < 0.05 versus unstimulated sample. 
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To address the effectiveness of these modifications in activating expression of CIITA, we as-
sayed CIITA transcript levels in HeLa cells stimulated with IFN-γ at various time points.  In con-
trast to previous studies demonstrating delayed CIITA mRNA expression; (Morris, Beresford et 
al. 2002; Boss and Jensen 2003) real-time PCR results in Figure 4.3 B indicate CIITA transcript 
levels increase to detectable levels as early as 40 minutes following IFN-γ stimulation.   
 
Increases in CIITApIV transcription correlate with decreased promoter binding of the 
regulatory histone methyltransferase EZH2. 
 
As a key epigenetic modifier, histone methylation frequently regulates other epigenetic 
alterations by generating binding sites for various chromatin remodeling complexes and histone 
modifying enzymes.  Histone methyltransferases (HMTs) are chromatin remodeling enzymes 
capable of adding one, two, or three methyl groups to lysine residues on histones H1, H2A, H3, 
and H4, (Bannister and Kouzarides 2004; Schubeler, MacAlpine et al. 2004) and can activate 
(H3K4) or suppress (H3K27) transcriptional processes(Morris, Spangler et al. 2000). The HMT 
enhancer of Zeste homolog 2 (EZH2) is part of the Polycomb repressive complex 2, and is 
known to play important roles in gene silencing (Simon and Lange 2008) by catalyzing the tri-
methylation of H3K27 (Martinez-Garcia and Licht 2010) and H3K9 and has previously been 
shown to interact with CIITApIV. (Holling, Bergevoet et al. 2007)  In order to determine if the 
loss of H3K9me3 and H3K27me3 observed at CIITApIV was consistent with changes in EZH2 
binding to the promoter, we performed dual crosslinking ChIP assays by immunoprecipitating 
endogenous EZH2 from IFN-γ stimulated HeLa cells.  Data in Figure 4.4 demonstrates an abun-
dance of EZH2 at CIITApIV that rapidly declines upon treatment of cells with IFN-γ and ap-
proaches base line levels 40 minutes following treatment.  The drop in the level of EZH2 corre-
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lates with our previous observations of decreases in H3K9me3 and H3K27me3, and with in-
creases in activating modifications, promoter availability and CIITA transcript levels.   
 
Loss of EZH2 leads to aberrant CIITA expression. 
 
As EZH2 binding to CIITApIV was significantly and immediately decreased in the pres-
ence of  IFN-γ, we next investigated the role of EZH2 in regulating activation of CIITApIV 
genes by using siRNA duplexes to specifically knockdown endogenous EZH2.  siRNA mediated 
reduction of endogenous EZH2 decreased EZH2 protein expression by 90% relative to control 
siRNA transfected cells (Figure 4.5 A, upper blots) but did not impact the expression of tubulin 
(Figure 4.5 A, lower blots).  Analyis of EZH2 transcripts in EZH2 siRNA treated cells demon-
strated 80-90% reduction of EZH2 mRNA (Figure 4.5 B, white bars) in comparison to control 
siRNA treated cells (Figure 4.5 B black bars).  As an additional control for specificity of the 
knockdown, we investigated the role of EZH2 in regulating expression of constitutively ex-
pressed GAPDH (Figure 4.5 C).  Real time PCR analysis indicated that transcript levels of 
GAPDH were unaffected by siRNA mediated depletion of EZH2.  We next assayed CIITA tran-
script levels in EZH2 siRNA transfected cells.  Real time PCR analysis indicated that transcript 
levels of CIITA were significantly increased in EZH2 depleted samples (Figure 4.6, white bars) 
in comparison to control siRNA samples (Figure 4.6, black bars).   
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Figure 4.5  Figure 5. The EZH2 knockdown is specific. 
(A) EZH2 siRNA efficiently and specifically decreases EZH2 protein expression.  HeLa cells 
transfected with scrambled control or with EZH2 specific siRNA were stimulated with IFN-γ. 
Cells were harvested and were subjected to Western blot analysis for endogenous expression of 
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EZH2 and for tubulin.  Western Blot analysis shows 90% knockdown of EZH2 and stable ex-
pression of tubulin.   
(B-C) Reduced expression of EZH2 in siRNA transfected cells does not affect mRNA expression 
of GAPDH.  EZH2 (B) and GAPDH (C) mRNA was prepared using TRIzol reagent and cDNA 
was generated using gene specific antisense primers for EZH2 and GAPDH.  cDNA was quanti-
tated by real time RT-PCR using gene specific primers for EZH2 and for GAPDH.  Data are 
graphed as relative value of EZH2 mRNA in (B) determined after normalization to GAPDH 
mRNA in (D).  Values represent mean ± SEM of three independent experiments. ***P < 0.0005, 
**P < 0.005 versus unstimulated sample. 
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Figure 4.6  EZH2 knockdown significantly increases CIITA mRNA in the presence or absence of 
cytokine stimulation. 
HeLa cells transfected with scrambled control or with EZH2 specific siRNA were stimulated with IFN-γ.  
Cells were harvested and CIITA mRNA was prepared using TRIzol reagent as described in Figure 5.  Da-
ta are graphed as relative values of CIITA mRNA normalized against GAPDH mRNA. Values represent 
mean ± SEM of three independent experiments. ***P < 0.0005, **P < 0.005 versus unstimulated sample. 
.  
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The results in Figure 6 demonstrate that decreased expression of EZH2 results in the loss 
of suppression of CIITA.  
The molecular mechanisms regulating EZH2 removal from CIITApIV, and other induci-
ble promoters, is not well understood and the point at which EZH2 is actually removed from 
promoters remains unknown.  As removal of EZH2 from CIITApIV strongly correlates with ac-
tivation of transcription at CIITApIV, we addressed two mechanisms potentially involved in re-
gulating removal of EZH2 from CIITApIV:  degradation of EZH2 and BRG-1 binding.  Sup-
plementary Figure 4.7 A demonstrates that EZH2 has a 4 hour half life in HeLa cells and Sup-
plementary Figure 4.7 B shows that EZH2 remains stable over the course of a 120 minute IFN-
γ time course.  Thus, EZH2 degradation in response to IFN-γ stimulation is an unlikely mechan-
ism of regulating EZH2 binding to CIITApIV.  Binding of Brahma-related gene 1 (BRG-1) to 
CIITApIV has previously been shown to be required for IFN-γ inducible pIV binding of STAT-1 
and IRF and for increased chromatin accessibility of CIITApIV upon IFN-γ stimulation.  (Ni, 
Karaskov et al. 2005)  Supplementary Figure 4.8 demonstrates that EZH2 is released from 
IFN-γ stimulated CIITApIV in the absence of BRG-1, indicating that BRG-1 binding is not re-
quired to regulate EZH2 removal from this inducible promoter. 
  
142 
 
 
 
Figure 4.7  (Supplementary Figure) EZH2 half life is unchanged during a 120 minute IFN-γ 
time course. 
(A) HeLa cells were treated with cycloheximide for 0-15hrs.  Following cyclohexamide treat-
ment, cells were lysed in 1% NP40 and western blot analysis was performed to determine the 
half life of endogenous EZH2.  (B) HeLa cells were treated with IFN-γ for the indicated time 
points. Cells were harvested after stimulation and western blot analysis was performed to deter-
mine the level of endogenous EZH2 protein in whole cell lysates.  Results shown are representa-
tive of two experiments.  
 
 
 
 
143 
 
                                                                                                                                                      
144 
 
Figure 4.8  (Supplementary Figure) BRG-1 binding to CIITAPIV is not required for re-
moval of EZH2 from CIITAPIV.  
(A) Timecourse of BRG-1 binding to CIITApIV.   HeLa cells were stimulated with IFN-γ, cros-
slinked with formaldehyde, lysed and sonicated.  Lysates were IP with control antibody or with 
antibody to BRG-1.  Associated DNA was isolated and analyzed via Real-time PCR using pri-
mers spanning the IRF-1 binding site at CIITAPIV.  IP values are presented as increases in CII-
TApIV DNA relative to unstimulated samples and have been normalized to the total amount of 
promoter DNA added to the reaction.  Data are presented as the relative number of associated 
molecules analyzed in three cell lysate preps with each sample analyzed in triplicate. Control IP 
values were 650±50.  
 (B) BRG-1 siRNA efficiently decreases endogenous BRG-1 protein expression.  HeLa cells 
transfected with scrambled control or BRG-1 specific siRNA were stimulated with IFN-γ for the 
time points indicated. Cells were harvested and subjected to Western blot analysis for endogen-
ous expression of BRG-1.  Western Blot analysis shows 90% knockdown of BRG-1.   
(C) Binding of EZH2 to CIITApIV is unchanged in the absence of BRG-1.  HeLa cells were 
transfected with BRG-1 specific siRNA or with control siRNA and were stimulated with IFN-γ 
for 0 to 18 hours.  Double crosslinked lysates were IP with control antibody or with antibody to 
endogenous EZH2 and associated DNA was isolated and analyzed via real-time PCR using pri-
mers spanning IRF-1box of CIITApIV.  Real-time PCR values were normalized to the total 
amount of promoter DNA added to the reaction (input).  IP values are presented as relative in-
crease in CIITA DNA relative to unstimulated samples.  Control IP values were 95±30.  Values 
shown are representative data. 
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4.3 DISCUSSION 
 
Our study provides an in depth description of the early epigenetic events occurring at 
IFN-γ stimulated CIITApIV.  As the master regulator of MHC II genes, CIITA controls MHC II 
expression and is therefore tightly regulated. (Kaufman, Auffray et al. 1984; Guy, Krajewski et 
al. 1986; Adamski, Ma et al. 2004; Gerloni and Zanetti 2005)  Previous studies from our lab and 
others have shown that epigenetic events play an important role in controlling activation of CII-
TApIV. (Boss and Jensen 2003; Morimoto, Toyota et al. 2004; Koues, Dudley et al. 2009; 
Truax, Koues et al. 2010) We observe here that following IFN-γ stimulation regulatory epigenet-
ic events occur in rapid succession at CIITApIV.  Although H3K18 acetylation levels rise post 
IFN-γ stimulation, the increase in H3K18 acetylation is non-linear, indicating an immediate, but 
non-maximal, loosening of the chromatin template following IFN-γ stimulation.  Steady increas-
es in the activating addition of methyl groups to histone H3 lysine 4 also occur at CIITApIV fol-
lowing IFN-γ stimulation.  The levels of H3K4me3 significantly increase throughout the 120 
minute time course, indicating an accumulation of epigenetic marks in addition to H3K18 acety-
lation for maximal methylation of lysine 4.   
 
 In contrast to K18 acetylation and K4 methylation is the silencing modification of 
H3K9me3, which is lost at CIITApIV upon IFN-γ stimulation.  Levels of H3K9me3 significantly 
decline over the 120 minute IFN-γ time course and then remain at baseline for the duration of 
IFN-γ stimulation.  A similar trend is observed in the case of H3K27me3 where loss of the inhi-
bitory H3K27me3 modification occurs upon IFN-γ stimulation, with the decline in K27me3 mir-
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roring gains in H3K4me3 and suggesting competitive targeting of lysines 27 and 4 in epigenetic 
regulation of CIITApIV.  
 
Rapid changes in regulatory epigenetic modifications to histone H3 at CIITApIV follow-
ing IFN-γ stimulation indicate chromatin is opened and transcription rapidly occurs following 
exposure of cells to inflammatory cytokine.  This assumption is confirmed by observations that 
STAT-1 binds CIITApIV and drives expression of CIITA transcripts within 40 minutes of IFN-γ 
stimulation.  Previous studies have demonstrated STAT-1 binding to the GAS sequence as one of 
the first trans-acting events occurring at CIITApIV, and have demonstrated STAT-1 binding 
within five minutes of IFN-γ stimulation.(Morris, Beresford et al. 2002)  Based on these previous 
studies, it was anticipated that STAT-1 would rapidly associate with CIITApIV following IFN-γ 
stimulation.  The present data demonstrate not only rapid STAT-1 binding, but also that binding 
is sustained at similar levels throughout IFN-γ induction, indicating initial chromatin remodeling 
events overcome critical thresholds required to activate CIITApIV expression.  Additionally, 
both STAT-1 binding and low, but significant CIITA expression correlate with the rapid rise in 
the levels of H3K18ac and H3K4me3 and with the rapid drop in the levels of H3K9me3 and 
H3K27me3.   Thus, the combination of rapidly occurring epigenetic modifications is sufficient to 
activate the CIITA gene. 
 
It is important to note that levels of STAT-1 binding to CIITApIV do not significantly 
change after 60 minutes of IFN-γ stimulation, indicating that beyond this point CIITApIV main-
tains an open chromatin structure and active levels of transcription, despite greatly enhanced le-
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vels of H3K18 acetylation at later time points.  Observations that levels of H3K18ac do not peak 
until after 120 minutes of IFN-γ stimulation are in contrast to the rapid decreases in suppressing 
levels of H3K9me3 and H3K27me3, and suggest that the removal of methyl groups from CII-
TApIV may play important roles in the initial control of CIITA activation.  Similar observations 
that strong binding of the HMT EZH2 to CIITApIV rapidly declines following IFN-γ stimulation 
add further support to the regulatory control histone methylation exerts at CIITApIV.   
 
           Decreased expression of CIITA, and of MHC II, has also been previously described as a 
mechanism utilized by tumors to escape the immune response.(Holling, van Eggermond et al. 
2006)  Relevant to our study are observations that changes in chromatin structure (Jones and 
Laird 1999; Jones and Baylin 2002)  and tissue specific changes in EZH2 expression are asso-
ciated with various types of cancers. (Jones and Laird 1999; Schulz and Hatina 2006; Simon and 
Lange 2008; Cooper and Foster 2009)  EZH2 was previously found to bind CIITAPIV chromatin 
in uveal melanoma cells where EZH2 siRNA resulted in increased CIITA expression in cells 
stimulated for 24h with IFN-γ.  In contrast to our observations in HeLa cells, CIITA transcripts 
were not observed in unstimulated uveal melanoma cells treated with EZH2 siRNA.(Holling, 
Bergevoet et al. 2007)  These differences could be due to several reasons including our increased 
efficiency of EZH2 knockdown and cell type specific differences.  In data not shown, we have 
observed significant levels of IFN-γ independent CIITA mRNA expressed in multiple EZH2 
siRNA treated human cancer cell lines, including variants of MDA MB 435, indicating cell type 
differences in the epigenetic status of the bivalent promoter CIITApIV.  Thus, differences in cell 
lines may contribute to differing levels of suppression by EZH2 and differing states of chromatin 
packaging of CIITApIV.   In addition, although DNA methyltransferases are known to associate 
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with EZH2 and the PRC2 complex, EZH2 mediated suppression in some cases may be sufficient 
to silence genes, as in the case of CIITApIV, where siRNA mediated depletion of EZH2 was 
successful in reactivating the silenced gene.   
 
           Few studies have been performed to determine how EZH2 is itself regulated and main-
tained in cells.  EZH2 phosphorylation by cyclin-dependent kinase 1 (CDK1) and cyclin-
dependent kinase 2 (CDK2) is required for EZH2 recruitment and H3K27me3 at target promo-
ters. (Chen, Bohrer et al. 2010)  As we and others have previously demonstrated the importance 
of prior phosphorylation in regulating ubiquitination of proteins, we sought to determine if EZH2 
phosphorylation established a pattern of sustained phosphorylation leading to ubiquitination and 
degradation in response to IFN-γ stimulation.  As the half life of EZH2 was unaltered in the 
presence of IFN-γ, it is unlikely that degradation is responsible for removal of EZH2 from CII-
TApIV in IFN-γ stimulated cells.  Alternatively, the ATPase BRG1 is needed for chromatin re-
modeling and STAT-1 binding at CIITApIV and could provide a means of EZH2 removal from 
CIITApIV.  However, the present study suggests that EZH2 is lost upon IFN-γ stimulation from 
CIITApIV in the absence of BRG-1, suggesting additional regulatory mechanisms are at play.  In 
regards to the epigenetic regulation of CIITA, our study implicates EZH2 in regulating the initial 
chromatin remodeling events at the cytokine-inducible CIITA promoter.  Knowledge that CII-
TApIV is rapidly released from surrounding chromatin following IFN-γ stimulation and depar-
ture of EZH2 strongly suggests that EZH2 is predominantly involved in initial chromatin re-
modeling in response to stimuli.  Our study suggests EZH2 is a „master regulator‟ of epigenetic 
modifications to histones and is the first to link the regulation of rapidly occurring epigenetic 
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changes to EZH2 and, as such, has strong implications for the regulation not only of CIITA, but 
for many other silenced but inducible genes.   
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MATERIALS AND METHODS 
 
Cell Lines:   
 
HeLa cells (human epithelial) from ATCC (Manassas, VA) were cultured  in Dulbecco's 
Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum, 5mM L-glutamine 
and 5mM penicillin-streptomycin at 37°C with 5% carbon dioxide. 
 
Antibodies:  
 
The ChIP antibodies recognizing H3K27me3, H3k9me3, and H3K18ac were from Active 
Motif (Carisbad, CA) and the H3K4me3 and EZH2 antibodies were from Abcam (Cambridge, 
MA).   STAT-1 and BRG-1 antibodies were from Santa Cruz (Santa Cruz, Ca).  Rabbit and 
mouse immunoglobulin G (IgG) isotype control antibodies were from Millipore (Lake Placid, 
NY). The antibodies recognizing EZH2 in western blots were from Millipore (Billerica, MA) 
and the anti-tubulin antibody was from Santa Cruz (Santa Cruz, Ca). HRP conjugated mouse an-
tibody was from Promega (Madison, WI) and HRP conjugated rabbit antibody was from Pierce 
(Rockland, IL).  
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siRNA constructs and transient transfection:   
 
Short interfering RNA (siRNA) duplexes were predesigned against human EZH2 (Qia-
gen) and BRG-1 (Qiagen) and were used for transient knockdown of EZH2 and BRG-1.  All Star 
scrambled siRNA (Qiagen) was used as the negative control siRNA. HeLa cells were transfected 
with 0.7µg of control, EZH2, or BRG-1 specific siRNA using RNAiFECT transfection reagent 
(Qiagen) according to the manufacturer‟s instructions and were treated with 500 U/ml of IFN-γ 
from Peprotech (Rocky Hill, NJ) as indicated.  Cells were lysed in NP-40 lysis buffer (1M Tris 
pH 8.0, 1M KCl, 10% NP40, 0.5 M EDTA, 5MNaCl, 1M DTT, dH20) supplemented with Com-
pete EDTA-free protease inhibitor from Roche (Florence, SC) and knock down efficiency and 
specificity was assessed by western blot or mRNA analysis.  
 
Chromatin immunoprecipitation (ChIP): 
 
ChIP assays were performed as described previously. (Truax, Koues et al. 2010) (Koues, 
Dudley et al. 2009; Koues, Mehta et al. 2010)   Briefly, HeLa cells were plated at a density of 
2×10
6 
cells/15 cm plate and were stimulated with 500 U/ml IFN-γ.  Formaldehyde cross-linking 
was performed with 1% formaldehyde for 10 minutes at room temperature and 0.125 M glycine 
was added for five minutes at room temperature to stop cross linking.  Cells were lysed using 
SDS lysis buffer (50mM Tris pH 8.0, 10mM EDTA, dH20, 1%SDS) with protease inhibitor 
(Qiagen, CA) for 20 minutes on ice.  Samples were sonicated at constant pulse to generate DNA 
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fragments of 500-800 bp.  Sonicated samples were run on 1% agarose gels and stained with 
Ethidium Bromide (EtBr) to determine sonication efficiency.   Sonicated lysates were precleared 
with salmon-sperm coated agarose beads (Millipore) and half of the lysate was immunoprecipi-
tated (IP) with 5μg of polyAb against H3K27me3, H3k9me3, H3K18ac, H3K4me3, STAT-1, or 
EZH2 overnight at 4°C.  The remaining half of the lysate was used as a control and was IP with 
isotype control antibody (Millipore, MA).  Following an additional one hour IP with 50μl of 
salmon-sperm coated agarose beads, samples were washed for three minutes at 4°C with the fol-
lowing buffers:  Low salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH 8.0, 
150mM NaCl, dH20), high salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris 
pH 8.0, 500mM NaCl, dH20), LiCl buffer (0.25M LiCl, 1% NP40, 1% DOC, 1mM EDTA, 
10mM Tris pH 8.0, dH20) and 1xTE buffer and were eluted with SDS elution buffer (1% SDS, 
0.1M NaHCO3, dH2O).  Following elution, crosslinks were reversed overnight with 5M NaCl at 
65°C and immunoprecipitated  DNA was isolated using phenol:chloroform:isoamyl alcohol mix 
(Invitrogen) as per the manufacturer‟s instructions.  Isolated DNA was analyzed by real-time 
PCR using primers spanning the GAPDH promoter and CIITApIV.(Morris, Beresford et al. 
2002; Truax, Koues et al. 2010) Values graphed were calculated based on standard curves gener-
ated.   
 
Dual Crosslinking Chromatin immunoprecipitation (Dual ChIP): 
 
 As described above for ChIP assays, HeLa cells were plated at a density of 2.5 × 10
6 
cells/15 cm 
plate and were stimulated with 500 U/ml IFN-γ at indicated time points.  Cells were harvested 
and washed with Phosphate Saline Buffer (PBS), and were resuspended in 10 ml of PBS (pH 
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8.0) containing 1mM MgCl2 and 1μM of Disuccinimidyl Glutarate (DSG) and were incubated at 
room temperature for 45 minutes.  0.1 mM of Tris pH 7.4 was added for five minutes at room 
temperature to stop cross-linking.  Cells were rinsed with PBS and resuspended in 10ml of PBS.  
Secondary formaldehyde cross-linking was performed with 1% formaldehyde for 10 minutes at 
room temperature, followed by the addition of 0.125 M glycine for five minutes at room temper-
ature to stop further cross linking.  Cells were lysed in SDS lysis buffer and were subjected to 
sonication and ChIP as above.   
 
RNA expression:  
 
HeLa cells were plated at a density of 8×10
5 
cells/10 cm plate and were stimulated with 500 
U/ml IFN-γ at experiment specific time points.  Cells were harvested and total RNA was pre-
pared using TRIzol reagent (Invitrogen, CA) according to the manufacturer's instructions and as 
previously described(Bhat, Turner et al. 2008; Koues, Dudley et al. 2008; Bhat, Truax et al. 
2010; Truax, Koues et al. 2010).  The Omniscript Reverse Transcription Kit (Qiagen, CA) was 
used to generate cDNA from extracted RNA.  Isolated DNA was analyzed by real time PCR us-
ing primers and probes for CIITA (Truax, Koues et al. 2010) and GAPDH (Truax, Koues et al. 
2010) mRNA.  Primer sequences for EZH2 were as follows: EZH2 sense TTCATGCAACACC-
CAACACT, EZH2 antisense GAGAGCAGCAGCAAACTCCT, EZH2 probe FAM- TTAC-
CAGCATTTGGAGGGAG - TAMRA.  Real-time PCR values were generated based on standard 
curves generated for each gene and levels of CIITA and EZH2 are presented as fold changes 
over GAPDH message levels.   
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RNA expression in cells treated with siRNA:  
 
HeLa cells were plated at a cell density of 8x10
5
 cells, transfected with EZH2 siRNA and twenty 
four hours later were stimulated with IFN-γ as indicated.  Cells were harvested and 10% of the 
cells were lysed with 1% NP-40 lysis buffer and subjected SDS PAGE to determine the efficien-
cy of the knockdown.  The remaining fraction of cells was subjected to RNA extraction with 1ml 
of Trizol as described above. 
 In vivo half life assay.  
HeLa cells were treated with 100 µM
 
cycloheximide (Sigma) for 0-15hrs. The total cell volume 
was
 
lysed with 1% NP-40 buffer with protease inhibitor and
 
analyzed by Western blotting for 
EZH2 degradation. 
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5.1 ABSTRACT 
 
One mechanism frequently utilized by tumor cells to escape immune system recognition 
and elimination is suppression of cell surface expression of Major Histocompatibility Class II 
(MHC II) molecules.  Expression of MHC II is regulated primarily at the level of transcription 
by a Master Regulator, the Class II Transactivator, CIITA.  Decreased expression of CIITA has 
been documented in multiple tumor cell types including breast tumors.  We investigate here con-
tributions of epigenetic modifications to transcriptional silencing of CIITA in variants of the hu-
man breast cancer cell line MDA MB 435.  Increased histone H3 lysine 27 trimethylation corre-
lated with significant reductions in RNA polymerase II recruitment to the interferon- inducible 
CIITA promoter, CIITApIV, and with increased CIITApIV occupancy by the histone methyl-
transferase enhancer of zeste homolog 2 (EZH2).  Decreased expression of EZH2 in MDA MB 
435 variants resulted in significant increases in CIITA and MHC II mRNA independent of cyto-
kine stimulation.  These data indicate EZH2 contributes critical regulatory marks to the silencing 
transcription of CIITA and to the regulation of MHC II expression.  
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5.2 BACKGROUND 
 
Major histocompatibility class II (MHC II) genes encode cell surface proteins responsible 
for presenting peptides from extracellular spaces to activate CD4
+ 
T cells.  As activated T cells 
are in turn responsible for driving adaptive immune responses, MHC II molecules play critical 
roles in regulating immune recognition of pathogens and tumors.  Constitutive expression of 
MHC class II is limited to professional antigen presenting cells, but MHC II expression can be 
induced in most other cell types by inflammatory cytokines, of which IFN-γ is the most potent 
(Kaufman, Auffray et al. 1984; Chang, Fontes et al. 1994).  Although CD8
+ 
T cells are more di-
rectly responsible for lysis of infected cells and tumor cells, recent studies have shown that pep-
tide immunization in the presence of CD4
+ 
T cells enhances CD8
+ 
T cell responses (Langlade-
Demoyen, Garcia-Pons et al. 2003).  Further, several murine tumor models have demonstrated 
that CD4
+ 
T cells are required for an effective anti-tumor immune response (Greenberg, Cheever 
et al. 1981; Fujiwara, Fukuzawa et al. 1984; Hock, Dorsch et al. 1991; Lauritzsen, Weiss et al. 
1994).  Loss of MHC II expression has also been associated with decreased numbers of tumor 
infiltrating T cells and with increased aggressiveness of colorectal and laryngeal carcinomas 
(Garrido and Ruiz-Cabello 1991; Warabi, Kitagawa et al. 2000).  These observations suggest that 
CD4
+ 
T cells are able to respond to tumor antigens presented via MHC II to induce an effective 
immune response and emphasize the importance of understanding the transcriptional regulation 
of MHC II genes in cancer cells.  
 
Tight regulation of MHC II transcription and expression is necessary for proper initiation, 
stabilization, and termination of adaptive immune responses.  MHC II genes are regulated by a 
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multi-protein enhanceosome complex that binds the W-X-Y region of the MHC II promoter, as-
sembly of which is stabilized by the Class II transactivator, CIITA (Boss 1997; Ting and 
Trowsdale 2002).  Although CIITA does not directly bind the MHC II promoter, its association 
with the pre-assembled enhanceosome complex is required for MHC II expression and serves to 
coordinate steps leading to transcriptional initiation (Fontes, Jiang et al. 1997; Mahanta, Scholl et 
al. 1997).  CIITA recruits to the MHC II proximal promoter components of the basal transcrip-
tional machinery, histone acetyltransferases (HATs), histone deacetylases (HDACs), chromatin 
remodeling complexes, and the kinases that phosphorylate RNA pol II (Fontes, Kanazawa et al. 
1999; Beresford and Boss 2001; Zika, Greer et al. 2003; Drozina, Kohoutek et al. 2005).  CIITA 
transcription is tightly regulated with multiple promoters regulating transcription of CIITA in a 
tissue specific manner (Muhlethaler-Mottet, Otten et al. 1997; Pai, Askew et al. 2002).  Promoter 
I drives expression of CIITA in dendritic cells (Landmann, Muhlethaler-Mottet et al. 2001), the 
function of promoter II is unknown, and promoter III drives constitutive CIITA expression in B 
cells (Lennon, Ottone et al. 1997).  Transcription of CIITA in non-antigen presenting cells is in-
duced by the inflammatory cytokine interferon gamma (IFN-γ) and is primarily achieved by 
coordinate binding of multiple transcription factors to the IFN-γ  inducible promoter, CIITA 
promoter IV (CIITApIV) (Piskurich, Gilbert et al. 2006).  Transcriptional activation of CIITA-
pIV by IFN-γ requires the assembly of the following transcription factors: interferon regulatory 
factor 1 (IRF-1), signal transducer and activator of transcription 1 (STAT-1), and ubiquitous fac-
tor 1 (USF-1) to conserved DNA sequences on CIITApIV.  STAT-1 directly binds ubiquitously 
expressed USF-1 at the E-box of the IFN- activated sequence (GAS).  STAT-1 also initiates 
transcription from the IRF-1 promoter; once IRF-1 is expressed, it subsequently binds the IFN 
response element (IRE) site at CIITApIV (Piskurich, Linhoff et al. 1999).   
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Previous studies from our lab and others indicate that epigenetic modifications to chro-
matin play important roles in regulating MHC II and CIITApIV transcription (Truax, Koues et 
al. ; Koues, Dudley et al. 2008).   In unstimulated cells, the MHC II proximal promoter exhibits 
low basal acetylation which allows for binding of the ubiquitously expressed components of the 
enhanceosome complex.  Following cytokine stimulation, acetylation of histones H3 and H4 sig-
nificantly increases, allowing for recruitment of CIITA, the basal transcription machinery and 
initiation of MHC II transcription (Beresford and Boss 2001; Wright and Ting 2006).   CIITA-
pIV is also regulated by proximal promoter epigenetic modifications and is characterized as a 
bivalent promoter with both activating and repressing chromatin marks.  In unstimulated cells, 
CIITApIV exhibits elevated trimethylation of histone H3 lysine 27 (H3K27me3) and low acety-
lation of histones H3 and H4.  In the presence of IFN-γ, changes in higher order chromatin struc-
ture are followed by increases in acetylation of histones H3 and H4 (Agalioti, Chen et al. 2002; 
Morris, Beresford et al. 2002), increased trimethylation of histone H3 lysine 4 (H3K4me3) (Ni, 
Karaskov et al. 2005), and a significant and rapid decrease in  H3K27me3 (Morris, Beresford et 
al. 2002; Holling, van Eggermond et al. 2006; Holling, Bergevoet et al. 2007).  The histone me-
thyltransferase (HMTase) largely responsible for the addition of methyl groups to H3K27 is the 
Enhancer of Zeste Homolog 2 (EZH2) (Cao, Wang et al. 2002; Cao and Zhang 2004), the cata-
lytic subunit of the Polycomb repressive complex 2 (PRC2) which is involved in maintaining 
epigenetic memory and transcriptional silencing (Cao, Wang et al. 2002; Kuzmichev, Nishioka 
et al. 2002).  While EZH2 has previously been demonstrated to bind CIITApIV in malignant 
uveal melanoma cells, mechanistic roles for EZH2 in regulating CIITA and MHC II expression 
remain to be elucidated.  Indeed, although studies have well demonstrated EZH2 is frequently 
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over expressed in a wide variety of cancers including tumors of the prostate and breast, mecha-
nistic links of EZH2 to cancer progression remain areas of intense investigation.   
 
Decreased expression of MHC II has been previously described in breast tumors (Garrido 
and Ruiz-Cabello 1991; Dadmarz, Sgagias et al. 1995).  Variants of the MDA MB 435 human 
breast cancer cell line differ in their metastatic ability (Zhang, Fidler et al. 1991) and have re-
cently been classified as members of the HER-2 over expressing subtype of breast carcinoma 
(Holen and Coleman 2010).  Previous work has demonstrated that among these variant lines, 435 
Brain 1 cells exhibit poor metastatic ability while 435 Lung 2 cells exhibit high metastatic ability 
(Zhang, Fidler et al. 1991; Shi, Vinyals et al. 2006).  In this study, we analyzed MHC II and CII-
TA expression patterns in variants of MDA MB 435.  Initial studies determined a loss of cell sur-
face MHC II in the MDA MB 435 variants which correlated with increased metastatic potential, 
decreased CIITA expression, and suppression of CIITApIV.  We provide evidence that in the 
MDA MB 435 variants, CIITApIV maintains a closed chromatin conformation in the presence or 
absence of IFN-γ stimulation.  Elevated levels of EZH2 at CIITApIV and the resulting increases 
in CIITApIV H3K27me3 leave the proximal promoter inaccessible for transcription factor bind-
ing or transcription initiation.  Decreased expression of EZH2 restores expression of CIITA and 
MHC II in unstimulated cells, with substantial impact on MHC II expression in each of the MDA 
MB 435 variants.  These observations suggest EZH2 is a pivotal regulator of CIITApIV silenc-
ing and further implicate this histone methyltransferase as a candidate target for use in activating 
immune responses against tumors. 
 
162 
 
5.3 RESULTS: 
 
Differential expression of MHC II by variants of MDA MB 435 human breast carcinoma 
correlates with decreased MHC II mRNA levels.   
 
Down regulation of cell surface expression of MHC II molecules is frequently noted on 
tumor cells.  Low level expression of MHC II impairs immune recognition of tumors and allows 
undetected tumor growth and tumor metastasis (Gobin, Peijnenburg et al. 1997; van den Elsen, 
Holling et al. 2004).  Flow cytometry was used to determine cell surface expression of MHC II 
molecules (versus mouse IgG2a κ isotype control antibody, (Supplementary Figure 5.9) in 
three variants of MDA MB 435 human breast cancer cells (Figure 5.1 A), in HeLa cells (Figure 
5.1 B) and in immortalized, but non-tumorigenic, epithelial breast MCF 10A cells (Figure 5.1 
C).  Figure 1A and C demonstrates that HeLa cells and MCF-10A cells respond similarly to IFN-
γ stimulation by increasing cell surface expression of MHC II molecules.  Levels of MHC II ex-
pression in MDA MB 435 cells were similar to HeLa cells upon 24 hours of  IFN- stimulation 
(Figure  5.1 A) while MHC II expression was reduced in poorly metastatic 435-Brain 1 cells 24 
hours post  IFN-γ.  Further reductions in cell surface expression of MHC II are seen in highly 
metastatic 435-Lung 2 cells similarly stimulated with IFN-γ (Figure 5.1 A).  These results are in 
agreement with our findings that MHC II mRNA levels are decreased in poorly metastatic 435-
Brain 1 and almost eliminated in highly metastatic 435-Lung 2 cancer cells (Figure 5.1 E). Ad-
ditionally, we have determined that MHC II mRNA levels in breast cancer cells (Figure 5.1 E) 
showed a significant 100 fold reduction in the MHC message levels while comparing to our con-
trol HeLa cells (Figure 5.1 D). 
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Figure 5.1  MHC II cell surface expression and mRNA expression is decreased in MDA MB 
435 cells. 
  (A-C)  Cell surface expression of MHC II on MDA MB 435 cells (A) on HeLa cells (B) and on 
non metastatic breast MCF 10A cells (C).  Cells were stimulated with IFN-γ for 24 hours, trypsi-
nized, washed, and incubated with PE-labeled anti-human HLA-DR antibody.  Following anti-
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body incubation, cells were fixed and PE cell surface staining was measured by FACS-Canto.  
Results shown are representative of three independent experiments.   
(D-E)  Reduced expression of endogenous MHC II mRNA in breast cancer cells (E) compared to 
HeLa cells (D).  Cells were left unstimulated or were stimulated with IFN-γ for 0 to 18 hours and 
levels of mRNA were measured by real-time PCR and were normalized to GAPDH mRNA.  Re-
sults shown represent the mean ± SD of four independent experiments.   
(F-G)  Levels of acetylated H3 (F) and acetylated H4 (G) at the MHC II HLA-DRA proximal 
promoter.  ChIP assays were carried out in cells stimulated with IFN-γ for 0 to 18 hours.  Lysates 
were immunoprecipitated (IP) with control antibody, antibody to endogenous acetylated H3 (F) 
or antibody to endogenous acetylated H4 (G) and associated DNA was isolated and analyzed via 
real-time PCR using primers spanning the W-X-Y box of the MHC II HLA-DRA promoter.  
Real-time PCR values were normalized to the total amount of promoter DNA added to the reac-
tion (input).  Input values represent 5% of the total cell lysate.  IP values are presented as the rel-
ative increase in MHC II DNA relative to unstimulated samples.  Control IP values for (E) and 
(F) were 950 ± 200.  Values for acetylated H3 (E) and acetylated H4 (F) IPs represent mean ± 
SEM of three independent experiments.   
. 
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 The above observations demonstrate significant reductions in expression of MHC II by 
MDA MB 435 breast cancer cell lines that correlate with increasing metastatic capability.  As 
MHC II cell surface expression is indispensable for T cell interaction and the presentation of tu-
mor derived peptides to helper T cells (Garrido and Ruiz-Cabello 1991; Warabi, Kitagawa et al. 
2000), the highly metastatic 435-Lung 2 breast cancer cells may down regulate MHC II genes to 
avoid immune recognition. 
 
Histone H3 and histone H4 are acetylated at the activated MHC II proximal promoter in 
MDA MB 435 cells. 
 
Transcription occurs within the highly ordered context of chromatin and an open chroma-
tin structure is required for transcription initiation.  To determine the availability of the MHC II 
promoter for transcription factors binding, we assayed levels of acetylation on histone H3 and 
H4 in MDA MB 435 cells.  Metastatic variants of MDA MB 435 cells were left untreated or 
were stimulated with IFN-γ for 0-18 hrs and were subjected to chromatin immunoprecipitation 
(ChIP) analyses.  Lysates were immunoprecipitated with antibody against acetylated H3 (Figure 
5.1 F) or acetylated H4 (Figure 5.1 G) and analyzed via real time PCR.  Following IFN-γ stimu-
lation, levels of acetylated H3 and H4 significantly increase in all MDA MB 435 variants, indi-
cating open MHC II promoter regions.  Previous studies demonstrated that histone H3 lysine 18 
(K18) is strongly acetylated at activated MHC II promoters (Rybtsova, Leimgruber et al. 2007).  
ChIP experiments were next performed to determine levels of MHC II promoter acetylation on 
H3K18 in MDA MB 435 variants.  Cells were stimulated with IFN-γ as indicated, were sub-
166 
 
jected to ChIP analyses with endogenous antibody against acetylated H3K18, and were analyzed 
by real time PCR with primers and probe spanning the MHC II proximal promoter.  Endogenous 
levels of H3K18 acetylation were rapidly elevated with cytokine stimulation and no significant 
changes in H3K18 acetylation were observed between different metastatic variants of MDA MB 
435 cells (Figure 5.2 A) or in comparison to HeLa cells (supplementary Figure 5.10 A).  The 
histone acetyltransferase (HAT) CREB binding protein (CBP/p300) interacts with CIITA 
(Kretsovali, Agalioti et al. 1998; Fontes, Kanazawa et al. 1999) and is known to both acetylated 
H3 and H4 at the MHC II proximal promoter and to enhance binding of CIITA to the MHC II 
enhanceosome complex (Chan and La Thangue 2001).  ChIP analysis indicated recruitment of 
CBP to the MHC II proximal promoter upon cytokine stimulation in each of the variants of 
MDA MB 435 cells (Figure 5.2 B) and a similar level of CBP was observed at the MHC II prox-
imal promoter in HeLa cells (supplementary Figure 5.10 B).  These data indicate neither his-
tone acetylation of the MHC II proximal promoter nor the recruitment of the HAT CBP are sig-
nificantly affected in the MDA MB 435 cells.  
 
Silencing epigenetic marks decrease at the activated MHC II proximal promoter in MDA 
MB 435 cells. 
 
As demonstrated above, although MDA MB 435 cells lose the ability to inducibly ex-
press MHC II on a cell surface as their metastatic ability increases; however, the MHC II prox-
imal promoter is inducibly acetylated in these cells.   
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Figure 5.2  Despite expected patterns of epigenetic modifications and enzyme recruitment 
at MHC II HLA-DRA, RNA pol II fails to inducibly bind the proximal promoter region.  
 Levels of acetylated H3K18 (A), CBP (B), H3K9me3 (C), H3K27me3 (D) and RNA pol II (E) 
at the MHC II HLA-DRA proximal promoter.  ChIP assays were carried out in MDA MB 435, 
MDA MB 435 Brain 1 and MDA MB 435 Lung 2 cells stimulated with IFN-γ for 0 to 18 hours.  
Lysates were IP with control antibody or antibody against indicated endogenous protein and as-
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sociated DNA was isolated and analyzed via real-time PCR using primers spanning the W-X-Y 
box of the MHC II HLA-DRA promoter.  Real-time PCR values were normalized to the total 
amount of promoter DNA added to the reaction (input).  Input values represent 5% of the total 
cell lysate.  IP values are presented as a relative increase in MHC II DNA relative to unstimu-
lated samples.  Control IP values were 800 ± 200 (A-B), 900 ± 150 (C-D), and 1000 ± 100 (E).  
Values represent mean ± SEM of three independent experiments.   
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Figure 5.3  Significantly decreased levels of CIITA mRNA in MDA MB 435 breast cancer 
cells in the presence of lower levels of promoter acetylation (A).  
 (A-B). HeLa (A) and MDA MB 435, MDA MB 435 Brain 1, MDA MB 435 Lung 2 cells (B) 
were treated with IFN-γ for 0 to 18 hours.  Levels of mRNA were measured by real-time PCR 
and normalized to GAPDH mRNA.  Real-time PCR was performed in triplicate and results 
represent the mean ± SD of four independent experiments.   
(C-D) Levels of acetylated H3 (C) and acetylated H4 (D) at CIITApIV in breast cancer cells 435 
Lung 2. ChIP assays were carried out in MDA MB 435, MDA MB 435 Brain 1 and MDA MB 
435 Lung 2 cells stimulated with IFN-γ for 0 to 18 hours.  Lysates were immunoprecipitated (IP) 
with control antibody, antibody to endogenous acetylated H3 (C) or antibody to endogenous ace-
tylated H4 (D) and associated DNA was isolated and analyzed via real-time PCR using primers 
spanning the GAS-IRF-E box of CIITApIV. Real-time PCR values were normalized to the total 
amount of promoter DNA added to the reaction (input). Input values represent 5% of the total 
cell lysate.  IP values are presented as a relative increase in CIITApIV DNA relative to unstimu-
lated samples.  Control IP values for (C) and (D) were 600 ± 150.  Values for control IPs and 
acetylated H3 (C) acetylated H4 (D) IPs represent mean ± SEM of three independent experi-
ments.   
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To determine parallel patterns of histone methylation at the MHC II proximal promoter, 
HeLa cells and MDA MB 435 cell variants were stimulated with IFN-γ and ChIP analysis was 
performed to determine levels of trimethylation at histone H3 lysine 9 (H3K9me3) and histone 
H3 lysine 27 (H3K27me3).  Levels of H3K9me3 and H3K27me3 were significantly reduced at 
the MHC II proximal promoter within 4hrs of cytokine stimulation and are eliminated 18 hrs 
post IFN-γ stimulation in MDA MB 435 cells (Figure 5.2 C-D).  Similar levels of H3K9me3 
(supplementary Figure 5.10 C) and H3K27me3 (supplementary Figure 5.10 D) were ob-
served at the MHC II proximal promoter in HeLa cells stimulated with IFN-γ for 0-18hrs.  These 
data indicate aberrant histone methylation at the MHC II proximal promoter is not responsible 
for suppressed cell surface expression of MHC II. 
 
RNA polymerase II fails to inducibly bind the MHC II promoter in MDA MB 435 cells.  
 
Following cytokine stimulation, levels of acetylation increase and levels of methylation 
levels decrease at the MHC II promoter in MDA MB 435 cells, indicating MHC II promoter as-
sociated chromatin is open and available for transcription.  To determine assembly of the basal 
transcription machinery at the MHC II proximal promoter, we investigated promoter recruitment 
of RNA polymerase II (RNA pol II) in MDA MB 435 cells.  Cells were stimulated with IFN-γ 
for 0-18hrs and subjected to ChIP analyses with antibodies against endogenous RNA pol II.  In 
each of the variants of MDA MB 435 cells, RNA pol II was constitutively bound to the MHC II 
proximal promoter, but no additional binding occurred in response to IFN- stimulation (Figure 
5.2 E).  By comparison, ChIP analyses in HeLa cells indicate robust inducible recruitment of 
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RNA pol II to the MHC II proximal promoter (supplementary Figure 5.10 E).  Thus, although 
the MHC II promoter is epigenetically available, RNA pol II is not inducibly recruited to the 
open MHC II promoter.   
 
Despite suppression of CIITA mRNA in MDA MB 435 variants, histone H3 and histone H4 
are inducibly acetylated at CIITApIV  
 
CIITA expression and subsequent binding to the MHC II proximal promoter is essential 
for transcriptional activation of MHC II genes.  To determine relative expression levels of CIITA 
mRNA in the MDA MB 435 variants, cells were stimulated with IFN-γ for 0-18hrs, subjected to 
Trizol extraction, and analyzed via real time PCR using primers specific for CIITA.  Levels of 
CIITA mRNA in each of the MDA MB 435 cell line variants was suppressed and decreased as 
metastatic ability increases (Figure 5.3 B).  Additionally, when comparing with CIITA mRNA 
levels in HeLa cells (Figure 5.3 A) MDA MB 435 breast cancer cells demonstrate about 80 fold 
decrease. We and others have previously demonstrated that epigenetic modifications play impor-
tant roles in the transcriptional regulation of CIITA (Truax, Koues et al. ; Koues, Dudley et al. 
2008) and in the silencing of MHC II genes in tumors (van den Elsen, van der Stoep et al. 2000; 
Holling, Schooten et al. 2004; Satoh, Toyota et al. 2004) (Magner, Kazim et al. 2000; Holtz, 
Choi et al. 2003; Kanaseki, Ikeda et al. 2003; Holling, Bergevoet et al. 2007).  To determine 
global acetylation levels of histone tails at CIITApIV in the MDA MB 435 variants, ChIP assays 
utilizing antibodies against endogenous acetylated H3 and acetylated H4 were performed.  Real 
time PCR analysis indicated levels of acetylated histone H3 (Figure 5.3 C) and acetylated his-
tone H4 (Figure 5.3 D) increase at CIITApIV upon stimulation with IFN-.  By comparison, in 
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HeLa cells levels of inducible acetylation on histone 3 and histone 4 at CIITApIV are more ro-
bust than the levels observed in each of the MDA MB 435 cell variants (Supplementary Figure 
5.11 A and C).  To analyze levels of acetylated H3K18 and association of the HAT CBP at CII-
TApIV in the MDA MB 435 variants, cells were left untreated or were stimulated with IFN-γ for 
0-18 hrs, subjected to IP with antibody to endogenous acetylated H3K18 (Figure 5.4 A) or CBP 
(Figure 5.4 B), and analyzed via real time PCR with primers and probe spanning the CIITApIV 
proximal promoter.  In each of the MDA MB 435 variants, levels of acetylated H3K18 and CBP 
binding to CIITApIV increased upon cytokine stimulation.  Similar to the above observations of 
global acetylation, levels of inducible acetylation on histone H3K18 and levels of CBP binding, 
are reduced at CIITApIV in the MDA MB 435 variants compared to HeLa cells (supplementary 
Figure 5.12 A and B).   
 
CIITApIV is specifically and inducibly hypermethylated at CIITApIV in MDA MB 435 
cell variants 
 
  To determine levels of histone H3 methylation in MDA MB 435 cell variants, ChIP expe-
riments utilizing antibodies against endogenous trimethylated (me3) histone H3 lysine 9 (K9) 
and lysine 27 (K27) were performed.  Real time PCR analysis indicated elevated basal levels of 
H3K9me3 at CIITApIV in MDA MB 435 cell variants that significantly decrease upon stimula-
tion with IFN- in the MDA MB 435 variants (Figure 5.4 C) and in HeLa cells (supplementary 
Figure 5.12 C).   Elevated basal levels of H3K27me3 were observed at CIITApIV in MDA MB 
435 cell variants; however following the IFN-γ stimulation, levels of H3K27me3 significantly 
increase with increasing metastatic potential of the MDA MB 435 cell variants (Figure 5.4 D). 
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Figure 5.4  Decreased CIITApIV levels of H3K18 acetylation and decreased CPB and RNA 
Pol II recruitment correlates with significantly elevated levels of H3K27me3 in metastatic 
cells.  
(A-E) Levels of acetylated H3K18, CBP, H3K9me3, H3K27me3 or RNA pol II at CIITApIV.  
ChIP assays were carried out in MDA MB 435, MDA MB 435 Brain 1 and MDA MB 435 Lung 
2 cells stimulated with IFN-γ for 0 to 18 hours.  Lysates were IP with control antibody or antibo-
dy to indicated endogenous proteins and associated DNA was isolated and analyzed via real-time 
PCR using primers spanning the IRF-E-GAS box of the CIITApIV proximal promoter.  Real-
time PCR values were normalized to the total amount of promoter DNA added to the reaction 
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(input). Input values represent 5% of the total cell lysate.  IP values are presented as a relative 
increase in CIITA isoform IV relative to unstimulated samples.  Control IP values were 800 ± 
200 (A); 750 ± 150 (B); 1000 ± 100 (C-D); and 600 ± 120 (E).  Values represent mean ± SEM of 
three to five independent experiments. 
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 The inducible hypermethylation of lysine 27observed at CIITApIV is cell line specific as ChIP 
assays performed in HeLa cells demonstrate elevated levels of H3K27me3 at CIITApIV that de-
crease upon IFN-γ stimulation (Supplementary Figure 5.12 D).  To determine if CIITApIV 
hypermethylation is sequence specific, ChIP experiments were performed to detect endogenous 
levels of H3K27me3, H3K9me3, and H3K18ac at the GAPDH promoter (supplementary Fig-
ure 5.13).  These data demonstrate low levels of methylation and high levels of acetylation at the 
GAPDH promoter that are unchanged by IFN- stimulation and do not significantly differ be-
tween the MDA MB 435 cell variants.  Gains in H3K27methylation at CIITApIV in the MDA 
MB 435 cell variants are not an indicative of increases in levels of histone H3 or histone H4 as 
ChIP assays demonstrate no significant changes in the level of histone H3 (supplementary Fig-
ure 5.11 B) and histone H4 (supplementary Figure 5.11 D) in the MDA MB 435 cell variants.  
In sum these data indicate the elevated levels of inducible H3K27me3 at CIITApIV are responsi-
ble for the suppressed levels of CIITA mRNA in the MDA MB 435 cell variants. 
 
IFN- inducible recruitment of RNA pol II, STAT-1, and IRF-1 to CIITApIV is diminished 
in MDA MB 435 cell variants 
 
An open chromatin confirmation is required for the initiation of transcription.  Data in 
Fig. 4D indicate that the CIITApIV proximal promoter is methylated and in a closed confirma-
tion in MDA MB 435 cell variants.  To further confirm the status of chromatin at CIITApIV in 
these cells, promoter recruitment of RNA pol II was analyzed by ChIP assay.  Cells were stimu-
lated with IFN-γ for 0-18hrs and were subjected to immunoprecipitation with antibody against 
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endogenous RNA pol II.  In each of the variants of MDA MB 435 cells, RNA pol II was consti-
tutively bound to CIITApIV, but only in the MDA-MB3435 Breast line was further significant 
binding induced by IFN- stimulation (Figure 5.4 E).  In the MDA-BR1 Brain and MDA-Lu2 
Lung lines, no additional significant RNA pol II binding occurred in response to IFN- stimula-
tion (Figure 5.4 E).  By comparison, ChIP analyses in HeLa cells demonstrate robust inducible 
recruitment of RNA pol II to CIITApIV (supplementary Figure 5.12 E).  
 
 The transcription factors STAT-1 and IRF-1 are required for CIITApIV transcription in 
response to IFN-γ stimulation (Piskurich, Linhoff et al. 1999).  Western blot analyses were per-
formed to determine if the lack of CIITA mRNA in MDA MB 435 cell variants was due to re-
duced expression of STAT-1 and IRF-1.  Levels of STAT-1 (Figure 5.5 A) and IRF-1 (Figure 
5.5 B) remain unchanged in the three variants of MDA MB 435 cells indicating both STAT-1 
and IRF-1 are expressed and available for binding CIITApIV.  Next, we performed ChIP assays 
to investigate binding of STAT-1 and IRF-1 to CIITApIV in each of the MDA MB 435 cell va-
riants and HeLa cells.   Cells were stimulated with IFN-γ for 0-18hrs and subjected to immuno-
precipitation with antibody against endogenous STAT-1 or endogenous IRF-1.  ChIP data indi-
cate low levels of STAT-1 IRF-1 are recruited to CIITApIV in each of the MDA MB 435 cell 
variants with minimal enhancement of binding upon IFN- stimulation (Figure 5.5 C-D). In ad-
dition MDA MB 435 breast cancer cells showed lower levels of STAT-1 (Figure 5.5 C) and 
IRF-1 (Figure 5.5 D) at CIITApIV in comparison to control HeLa cells (Figure 5.5 C and D 
upper panel). In sum, hypermethylation of CIITApIV results in significantly reduced recruit-
ment of STAT-1 and IRF-1 and prevents inducible binding RNA pol II in response to cytokine 
stimulation.   
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Figure 5.5   Although expressed, recruitment of STAT-1 and IRF-1 to CIITApIV decreases 
in metastatic breast cancer cells.  
 (A-B) Expression of STAT-1 (A) and IRF-1 in parental MDA MB 435 (left), in 435 Brain 1 
(middle), and in 435 Lung 2 cells (right). MDA MB 435, MDA MB 435 Brain 1, and MDA MB 
435 Lung 2 cells were left untreated or stimulated with IFN-γ as indicated.  Lysates were sub-
jected to IB for STAT-1 (A) or IRF-1 (B). Results reported are data representative of two inde-
pendent experiments.  (C-D) ChIP assays were carried out in MDA MB 435, MDA MB 435 
Brain 1 and MDA MB 435 Lung 2 and HeLa cells stimulated with IFN-γ for 0 to 18 hours.  Ly-
sates were immunoprecipitated (IP) with control antibody, with antibody to endogenous STAT-1 
(C) or IRF-1 (D), and associated DNA was isolated and analyzed via real-time PCR using pri-
mers spanning CIITA isoform IV proximal promoter.  IP values are presented as relative in-
crease in CIITApIV promoter DNA relative to unstimulated STAT-1(C) and IRF-1(D) IP sam-
ples. Control IP values for (C) and (D) were 0.8 ± 0.4.  Values for control IPs, STAT-1 and IRF-
1 IPs represent mean ± SEM of three independent experiments.   
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Figure 5.6  In MDA MB cells, IFN- stimulation results in specific and significantly in-
creased binding of EZH2 at CIITApIV.  
(A) EZH2 mRNA expression.  MB 435, MDA MB 435 Brain 1, and MDA MB 435 Lung 2 cells 
were stimulated with IFN-γ for 0 to 18 hours.  Cell lysates were analyzed for levels of EZH2 
mRNA by real-time PCR and were normalized to GAPDH mRNA.  Real-time PCR was per-
formed in triplicate and results represent the mean ± SD of three independent experiments.  (B) 
EZH2 protein expression.  MDA MB 435, MDA MB 435 Brain 1, and MDA MB 435 Lung 2 
cells were stimulated with IFN-γ, harvested and subjected to Western Blot analysis of endogen-
ous EZH2.  Results shown are representative data of three independent experiments.  (C -D) Le-
vels of EZH2 at MHC II (C) and CIITApIV (D) proximal promoters post cytokine stimulation.  
Double crosslinking ChIP assays were carried out in cells stimulated with IFN-γ for 0 to 18 
hours.  Lysates were IP with control antibody and antibody to endogenous EZH2 and associated 
DNA was isolated and analyzed via real-time PCR using primers spanning the W-X-Y box of the 
MHC-II HLA-DRA (C) and primers spanning IRF-E-GAS box of CIITApIV (D) promoters.  
Real-time PCR values were normalized to the total amount of promoter DNA added to the reac-
tion (input).  Input values represent 5% of the total cell lysate.  IP values are presented as relative 
increase in the MHC II (C) and CIITA (D) promoter DNA relative to unstimulated samples.  
Control IP values for (C and D) were 1500 ± 350.  Values for control and EZH2 IPs represent 
mean ± SEM of three independent experiments. 
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Lack of transcription factor and RNA pol II binding at CIITApIV leads to significantly 
reduced expression of CIITA and MHC II in the poorly metastatic 435 Brain 1 and highly metas-
tatic 435 Lung 2 cells.  
 
Binding of the histone methyltransferase EZH2 to CIITApIV is significantly and specifical-
ly increased in the MDA MB 435 cell variants 
 
Histone methyltransferases (HMTs) are chromatin remodeling enzymes that add one, 
two, or three methyl groups to lysine residues on histones (Bannister and Kouzarides 2004).  We 
have recently demonstrated the HMT enhancer of zeste homolog 2 (EZH2), a known regulator 
H3K9me3 and H3K27me3 (Humphreys, Lyle et al. 2000; Cao, Wang et al. 2002), to be a critical 
regulator of IFN- inducible transcription from CIITApIV (Mehta, Truax et al. 2011).  Initial 
analyses confirm that each of the MDA MB 435 variants express similar levels of EZH2 mRNA 
(Figure 5.6 A) and EZH2 protein (Figure 5.6 B).  To determine if EZH2 aberrantly binds CII-
TApIV in the MDA MB 435 cell variants, ChIP assays were performed.  Cells were stimulated 
with IFN-γ for 0-18hrs and were subjected to immunoprecipitation with antibody against endo-
genous EZH2.  Chromatin immunoprecipitations show that EZH2 binds the MHC II promoter 
(Figure 5.6 C) and CIITApIV (Figure 5.6 D) in unstimulated cells (note differences in Y axis).  
Four hours post cytokine stimulation, EZH2 occupancy decreases at the MHC II proximal and 
reaches baseline binding 18hrs following cytokine stimulation (Figure 5.6 C).  Similar patterns 
of EZH2 binding to the MHC II proximal promoter were observed in HeLa cells stimulated with 
IFN-γ for 0-18hrs (supplementary Figure 5.14 A).   Striking differences in EZH2 binding pat-
180 
 
terns were observed at CIITApIV in the MDA MB 435 variants.  In unstimulated cells, EZH2 
binds to CIITApIV at levels similar to that of the MHC II proximal promoter.  However, upon 
cytokine stimulation, EZH2 binding increases in each variant of MDA MB 435 cells at both four 
and 18 hrs post IFN-γ stimulation (Figure 5.6 D).   By comparison, in HeLa cells, patterns of 
EZH2 binding to CIITApIV (supplementary Figure 5.14 B) are similar to binding of EZH2 at 
the MHC II proximal promoter (supplementary Figure 5.14 A).   
 
 Knockdown of EZH2 significantly reduces H3K27me3 at CIITApIV in the MDA MB 435 
variants  
 
To investigate roles for EZH2 in the suppression of CIITApIV in the MDA MB 435 va-
riants, we utilized siRNA duplexes to specifically knock down endogenous expression of EZH2 
and then performed ChIP assays to detect levels of H3K27me3 at CIITApIV.  siRNA mediated 
knockdown of EZH2 resulted in a >90% decrease in endogenous EZH2 protein expression but 
did not impact endogenous tubulin expression (Figure 5.7 A).  To further determine efficiency 
of the siRNA duplexes, EZH2 mRNA levels were tested in each of the MDA MB 435 variants 
(Figure 5.7 B).  Cells treated with EZH2 specific siRNA (black bars) showed a 90% reduction in 
EZH2 mRNA levels when compared to cells treated with control siRNA (white bars), indicating 
EZH2 siRNA specifically and efficiently decreases EZH2 in the presence or absence of cytokine 
stimulation.   
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Figure 5.7   EZH2 knockdown decreases CIITApIV histone H3K27 trimethylation. 
  (A-B)  EZH2 knockdown is efficient and specific.  MDA MB 435, MDA MB 435 Brain 1, and 
MDA MB Lung 2 cells were transfected with either EZH2 specific or control siRNA. 10% of the 
lysates were subjected to IB for endogenous EZH2 or tubulin.  Results reported are representa-
tive data of three independent experiments.  The remaining lysates were subjected to EZH2 
mRNA isolation, quantization by real-time PCR, and normalization to GAPDH mRNA as above.  
Real-time PCR was performed in triplicate and results represent the mean ± SD of three inde-
pendent experiments.    
(C) Levels of trimethylated H3K27 in breast cancer cells.  ChIP assays were carried out in MDA 
MB 435, MDA MB 435 Brain 1, and MDA MB Lung 2 cells transfected with either EZH2 or 
control siRNA and stimulated with IFN-γ for 0 to 18 hours.  Lysates were IP with control anti-
body or antibody to endogenous H3K27me3 and associated DNA was isolated and analyzed via 
real-time PCR using primers spanning the IRF-E-GAS box of the CIITApIV promoter.  Real-
time PCR values were normalized to the total amount of promoter DNA added to the reaction 
(input).  Input values represent 5% of the total cell lysate.  IP values are presented as relative in-
crease in CIITA cDNA relative to unstimulated samples.  Control IP values were 950 ± 300.  
Values represent mean ± SEM of three independent experiments.  
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Figure 5.8   EZH2 knockdown significantly increases mRNA levels of CIITA and MHC II 
in MDA MB 435 (A), MDA MB 435 Br-1 (B), and MDA MB 435 Lu 2 cells (C).  
 MDA MB 435, MDA MB 435 Brain 1, and MDA MB 435 Lung 2 cells were transfected with 
either EZH2 specific or with control siRNA and were stimulated with IFN-γ for 0 to 18 hours.  
Levels of MHC II and CIITA mRNA were measured by real-time PCR and were normalized to 
GAPDH mRNA.  Real-time PCR was performed in triplicate and results represent the mean ± 
SD of three independent experiments.  . 
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To determine levels of H3K27me3 at CIITApIV in the EZH2 siRNA treated MDA MB 
435 cell variants, ChIP assays were performed.  As seen previously at CIITApIV in the MDA 
MB 435 variants, in cells treated with control siRNA, levels of H3K27me3 increase at CIITApIV 
upon IFN- stimulation (Figure 5.7 C, black bars).   
 
When specific siRNA was used to knockdown EZH2, significant decreases in CIITApIV 
H3K27me3 were observed in each of the MDA MB 435 variants upon IFN-γ treatment (Figure 
5.7C, white bars).  These data suggest EZH2 is responsible for the elevated levels of 
H3K27me3 in the MDA MB 435 variants.  
 
Knocking down EZH2 restores suppressed levels of CIITA and MHC II mRNA in each of 
the MDA MB 435 variants 
 
To determine if decreased expression of EZH2 and the resulting decrease in CIITApIV 
H3K27me3 regulates activation of CIITA and MHC II genes in the MDA MB 435 variants, 
mRNA experiments were performed.  Cells were transfected with EZH2 specific or control siR-
NA as indicated and were stimulated with IFN-γ for 0-18 hrs.  Following stimulation cells were 
lysed and CIITA and MHC II mRNA levels were quantified via real time PCR.  Both CIITA and 
MHC II mRNA levels are significantly elevated in cells treated with EZH2 specific siRNA (Fig-
ure 5.8 A-C, white bars) when compared to cells treated with control siRNA (Figure 5.8 A-C, 
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black bars).  Knocking down EZH2 restored CIITA and MHC II message levels in each of the 
MDA MB 435 variants, both with and without IFN-γ stimulation.   
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Figure 5.9  (Supplementary Figure 1) Control cell surface staining for variants of MDA 
MB 435 breast cancer cells (A) HeLa (B) and MCF 10A (C).  
(A-C) MDA MB 435, MDA MB 435 Brain 1, and MDA MB 435 Lung 2 cell (A) HeLa cells (B) 
and MCF 10A cells (C) were stimulated with IFN-γ as indicated.  Post stimulation cells were 
trypsinized, washed, and incubated with PE-labeled mouse control IgG.  Following antibody in-
cubation, cells were fixed and PE cell surface staining was measured by FACS-Canto.  Results 
shown are representative of three independent experiments. 
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Figure 5.10  (Supplementary Figure 2) IFN- induced levels of acetylated H3K18, CBP, 
H3K9me3, H3K27me3 and RNA pol II at MHC II HLA-DRA in HeLa cells.   
 (A-E)  Levels of H3K18 acetylation (A), CBP (B) trimethylated H3K9 (C), trimethylated 
H3K27 me3 (D), and RNA pol II (E) at MHC II. ChIP assays were carried out in HeLa cells sti-
mulated with IFN-γ for 0 to 18 hours.  Lysates were IP with control antibody or antibody to indi-
cated endogenous proteins and associated DNA was isolated and analyzed via real-time PCR us-
ing primers spanning the W-X-Y box of the MHC II HLA-DRA promoter. Real-time PCR values 
were normalized to the total amount of promoter DNA added to the reaction (input). Input values 
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represent 5% of the total cell lysate. IP values are presented as a relative increase in MHC II 
DNA relative to unstimulated samples. Control IP values were 550 ± 100 (A-B); were 450 ± 100 
(C-D); and 850 ± 150 (E).  Values represent mean ± SEM of two independent experiments.   
.  
190 
 
 
Figure 5.11  (Supplementary Figure 3) Levels of acetylated H3 and H4 increase in HeLa 
cells stimulated with IFN-γ and levels of histone H3 and H4 are unchanged in MDA MB 
435 cells.  
(A and C) Levels of acetylated H3 (A) and acetylated H4 (C) at CIITApIV increase upon IFN-γ 
stimulation in HeLa cells.  Cells were stimulated as indicated.  Following stimulation lysates 
were subjected to ChIP analyses and IP with control antibody or antibody against endogenous 
acetylated H3 (A) or acetylated H4 (C).  DNA was analyzed via real time PCR with primers and 
probes spanning CIITApIV proximal promoter.  IP values are graphed as increase over unstimu-
lated samples. Control IP values were 780 ± 200.  Values represent mean ± SEM of two inde-
pendent experiments.  (B and D)  Constant levels of H3 (B) and H4 (D) at CIITApIV in MDA 
MB 435 cells.  ChIP analyses were performed in MDA MB 435, MDA MB 435 Brain 1, and 
MDA MB 435 Lung 2 cells stimulated with IFN-γ for 0 to 18 hours.  Lysates were IP with con-
trol antibody or antibody to endogenous histone 3 (B) or endogenous histone H4 (D) and asso-
ciated DNA was isolated and analyzed via real-time PCR using primers for the CIITApIV pro-
moter.  Real-time PCR values were normalized as above and control IP values for (B and D) 
were 600 ± 100.  Values represent mean ± SEM of two independent experiments.   
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Figure 5.12  (Supplementary Figure 4) Levels of H3K18 acetylation, CBP, H3K9me3, 
H3K27me3, and RNA pol II at CIITApIV in HeLa cells.   
(A-E)  Levels of H3K18 acetylation (A), CBP (B) trimethylated H3K9 (C), trimethylated H3K27 
(D), and RNA pol II (E) at CIITApIV in HeLa cells.  HeLa cells were stimulated with IFN-γ for 
0-18hrs and subjected to ChIP assay as in supplementary Fig. 2 above.  Lysates were IP with iso-
type control antibodies or antibodies against indicated endogenous proteins.  DNA was analyzed 
via real time PCR as described in supplementary Fig. 2 using primers specific for CIITApIV.  
192 
 
Data are presented as relative increase in CIITA relative to unstimulated samples. Isotype control 
values were 540 ± 200 (A-B); 950 ± 200 (C-D) and 800± 200 (E). Values represent mean ± SEM 
of two independent experiments.   
193 
 
 
194 
 
Figure 5.13  (Supplementary Figure 5) Levels of H3K27me3, H3K9 me3, and H3K18 acety-
lation at the GAPDH proximal promoter are unaffected by cytokine in MDA MB 435 (top), 
MDA MB 435 Brain 1 (middle), and MDA MB 435 Lung 2 cells (bottom).  
 Cells were stimulated as indicated and were subjected to ChIP assay as above.  Lysates were IP 
with isotype control antibodies or antibodies against indicated endogenous.  Associated DNA 
was isolated and analyzed via real time PCR as described in supplementary Fig.2 using primers 
specific for the GAPDH proximal promoter.  Data are presented as relative increase in GAPDH 
DNA relative to unstimulated samples.  Isotype control values were 700 ± 200.  Values represent 
mean ± SEM of two independent experiments. 
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Figure 5.14  (Supplementary Figure 6) Levels of EZH2 decrease at MHC II and CIITApIV 
post cytokine stimulation.  
 (A-B)  Levels of EZH2 at MHC II (A) and CITApIV (B) decrease with cytokine stimulation in 
HeLa cells.  HeLa cells were stimulated with IFN-γ as indicated.  Lysates were IP with isotype 
control antibody or with antibody against endogenous EZH2.  Associated DNA was analyzed via 
real time PCR using primers for MHC II (A) or for the CIITApIV (B) proximal promoter.  
Graphed values were normalized to unstimulated samples.  Control IP values for A were 500 ± 
150 (A) and 950 ± 250 (B). Values represent mean ± SEM of two independent experiments.   
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5.4 DISCUSSION 
 
Our study reveals a mechanism by which the histone methyltransferase EZH2 promotes 
suppression of transactivation from CIITApIV and cell surface expression of MHC II.  In va-
riants of the breast cancer cell line MDA MB 435, metastatic potential negatively correlates with 
expression of MHC II and with active transcription of the MHC II master regulator, CIITA.  We 
found that in these cells, transactivation from CIITApIV was actively suppressed by increased 
binding of the histone methyltransferase EZH2 and by increased H3K27me3 in the presence of 
the inflammatory cytokine IFN-.  These findings support our recent observation that EZH2 is a 
master regulator of CIITA and, that by exerting critical control over CIITApIV H3K27me3, 
EZH2 regulates transactivation from CIITApIV (Mehta, Truax et al. 2011).  Together, these 
findings indicate therapies targeting EZH2 expression in breast cancer may directly impact the 
expression of CIITA by tumor cells resulting in increased cell surface expression of MHC II and 
increased tumor recognition by the adaptive immune response. 
 
Tumors which best avoid immune recognition are an increased risk for metastasis and 
tumor related mortality.  Tumors of the breast are no exception to this rule with the most com-
mon sites for breast cancer metastasis being the lung, liver, bone, brain, and auxiliary lymph 
nodes (Price 1990).  To achieve metastatic ability, tumor cells specifically alter immune gene 
expression patterns in order to escape host immune surveillance.  Multiple tumor types, includ-
ing colorectal and gastric tumors (Satoh, Toyota et al. 2004), trophoblastic tumors (Morris, 
Spangler et al. 2000), T cell leukemias, and developmental tumors (van den Elsen, Gobin et al. 
2001), accomplish specific decreases in MHC II expression by silencing IFN- inducible CIITA-
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pIV (Croce, De Ambrosis et al. 2003).  Additional studies indicate that many established tumor 
cells lack expression of cell surface MHC II (de Waard-Siebinga, Kool et al. 1995), further im-
plicating MHC cell surface expression as an important factor in predicting tumor metastasis and 
patient prognosis.  Decreased expression of MHC II has been observed in metastatic breast tu-
mors and in multiple breast cancer cell lines, indicating that suppression of MHC II may have 
causative, rather than correlative, relationships with immune evasion and with metastatic poten-
tial in breast tumors (Ruiz-Cabello, Klein et al. 1991; Gorelik, Kim et al. 1993; Dadmarz, 
Sgagias et al. 1995; Maiorana, Cesinaro et al. 1995; Walter, Lingnau et al. 2000; Sotiriadou, 
Perez et al. 2001).  The ramifications of our study to tumors of the breast are clear and support 
previous findings regarding suppression of CIITA in breast cancer (Shi, Vinyals et al. 2006):  
breast tumors may increase metastatic properties through epigenetically targeting suppression of 
cell surface expression of MHC II.   
 
We show here that silencing of MHC II molecules in metastatic breast cancer cell lines is 
associated with dysregulated epigenetic modifications at the proximal promoter of CIITApIV. 
Significant decreases in CIITA transcript levels in cells stimulated with IFN- resulted in both 
decreased MHC II transcripts and in decreased cell surface expression of MHC II.  Expression of 
MHC II genes correlates metastatic ability of the MDA MB 435 variants resulting in baseline 
expression of MHC II in the highly metastatic MDA MB 435 Lu2 cells.  The impairment in CII-
TA transcript levels correlates with elevated H3K27me3 at CIITApIV, while neither H3K9me3 
nor H3 or H4 acetylation demonstrate alterations in the MBD MB 435 variants.  These observa-
tions underline the dominance of H3K27me3 in regulating the transcriptional status of CIITApIV 
chromatin.  The lack of transactivation from CIITApIV is not due to defective IFN- signaling as 
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requisite CIITApIV transcription factors STAT-1 and IRF-1 are expressed in the nucleus (Shi, 
Vinyals et al. 2006) but exhibit limited capability to bind CIITApIV in the presence of IFN- 
stimulation.   
 
As the catalytic subunit of PRC2, EZH2 adds three methyl groups to lysine 27 resulting 
in chromatin condensation.  Converse to decreased MHC II expression in tumors is the overex-
pression of EZH2 which is observed in diverse tumors types including prostate, breast and blad-
der cancers and has been linked to enhanced tumor cell proliferation (Raman, Mongan et al. 
2005; Bachmann, Halvorsen et al. 2006; Collett, Eide et al. 2006).   Reports indicate elevated 
expression of EZH2 correlates with metastatic tumor growth and with clinically aggressive be-
haviors in prostate and breast cancer (Xiao 2011).  Elevated levels of EZH2 have been recog-
nized as a negative prognostic marker for a number of breast and prostate cancer patients 
(Varambally, Dhanasekaran et al. 2002; Kleer, Cao et al. 2003) and are associated with poor out-
comes to tamoxifen therapy in advanced breast cancer patients (Reijm, Jansen et al.).  In sum, 
accumulating evidence indicates EZH2 may be a primary culprit in metastatic tumor growth and, 
as such, is currently studied as a target for therapeutic intervention.  We demonstrate here a sig-
nificant association between high levels of EZH2 and H3K27me3 at CIITApIV and the metastat-
ic ability of human breast cancer cells.  Perhaps most striking is the observation that decreased 
expression of EZH2 resulted in constitutive expression of CIITApIV and MHC II transcripts in 
unstimulated cells.  These results provide increased evidence for EZH2 as a target for anti-tumor 
immunotherapies and provide additional mechanistic links to roles for EZH2 in tumor cell me-
tastasis.   
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Our results support a hypothesis that hypermethylation of histone tails by EZH2 represses 
CIITApIV gene expression in metastatic variants of MDA MB 435 cells.  It is noteworthy that 
the master regulator CIITA is in turn controlled by its own master regulator, EZH2.  One possi-
bility is that CIITA silencing, however critical, may be the nonspecific result of increased ex-
pression of EZH2.  Alternatively, and in agreement with previous findings that overexpression of 
CIITA in MDA MB 435 variants blocks lung metastasis (Yan, Shen et al. 2006), our data sug-
gests EZH2 is a pivotal and specific contributor to CIITApIV silencing, potentially be recruiting 
DNA methyltransferases to CIITApIV.  Indeed, EZH2 has been demonstrated to interact with 
DNA methyltransferases and EZH2 binding has been shown to be required for DNA methylation 
of EZH2 target promoters (Vire, Brenner et al. 2006).  Indeed, previous studies on MDA MB 
435 variants demonstrate only partial methylation of CIITApIV (Shi, Vinyals et al. 2006).  Sup-
pression of MHC II on tumor cells is critical for tumor cell survival, or at a minimum, for avoid-
ing immunosurveillance.  While the mechanisms responsible for the pronounced effects of over-
expression of EZH2 on tumor metastasis remain largely unknown, it seems likely to be targeted 
suppression, rather than coincidence, that results in elevated EZH2 binding and silencing CIITA-
pIV in metastatic breast cancer cells.   
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5.5 MATERIALS AND METHODS 
 
Cells 
 
  435-Lung 2 and 435-Brain 1 variants of the estrogen independent MDA MB 435 human 
breast cancer cell line were a gift from Dr. Janet Price (Shi, Vinyals et al. 2006).  MDA MB 435 
variants were maintained using modified Eagle (MEM) medium (Mediatech Inc., Herndon, VA) 
supplemented with 5% fetal bovine serum (FBS) with the exception of MDA MB 435 Brain 1 
which were supplemented with 10% FBS, 5mM L-glutamine and 5mM penicillin-streptomycin 
at 37
◦
C with 5% carbon dioxide.  MCF 10A (non tumorigenic human epithelial) and HeLa (hu-
man epithelial) cells were purchased from ATCC (Manassas, VA).  MCF 10A cells were main-
tained in Mammary Epithelial Cell Basal medium (MEBM) with the following supplements: 0.5 
ml hydrocortisone, bovine pituitary extract (BPE); 2 ml gentamicin sulfate amphotericin-B (GA-
1000); 0.5 ml human recombined epidermal growth factor in buffered BSA saline solution 
(rhEGF); and 0.5 ml human recombinant insulin.  HeLa cells were maintained in high glucose 
Dulbecco modified Eagle (DMEM) medium (Mediatech Inc., Herndon, VA) supplemented with 
10% fetal bovine serum (FBS), 5mM L-glutamine, and 5mM penicillin-streptomycin at 37
◦
C 
with 5% carbon dioxide.  
 
 
Antibodies 
 
Antibodies recognizing IRF-1 and STAT-1 were purchased from Santa Cruz (Santa Cruz, 
CA).  Antibodies recognizing Histone H3, acetylated histone H3, histone H4, acetylated histone 
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H4, and rabbit and mouse immunoglobulin G (IgG) isotype control antibodies were purchased 
from Millipore (Lake Placid, NY).  Antibodies recognizing Histone 3 (trimethyl K27), histone 3 
(trimethyl K9), histone 3 (acetyl K18), and EZH2 antibodies were purchased from Abcam 
(Cambridge, MA).  Antibody recognizing EZH2 was purchased from Millipore (Lake Placid, 
NY); antibody recognizing Tubulin was purchased from Santa Cruz (Santa Cruz, CA); HRP con-
jugated mouse antibody was purchased from Promega (Madison, WI); and HRP conjugated rab-
bit antibody was purchased from Pierce (Rockland, IL).  
 
Flow cytometry for MHC II cell surface expression  
 
Cells were plated at a density of 7 x10
5
, stimulated with IFN-γ (500U/ml) as indicated, 
and were trypsinized, washed with PBS and resuspended in 100 μl of incubation buffer (0.5% 
bovine serum albumin in PBS).  10μg Phycoerythrin (PE)-labeled anti-human HLA-DR (clone 
L243, Biolegend, San Diego, CA) or PE mouse IgG2a κ isotype control antibody (Biolegend) 
was added and the cell suspension was rotated at 4°C for 45 minutes.  Following antibody incu-
bation, cells were washed with PBS and fixed with 2% paraformaldehyde.  MHC II cell surface 
expression was measured by FACS-Canto (Becton Dickinson, San Jose, CA) and analyzed using 
FlowJo.  All samples were analyzed using 10,000 events per sample.   
 
siRNA Constructs and Transient Transfections 
 
Short interfering RNA (siRNA) duplexes predesigned against human EZH2 (Qiagen) 
were used for transient knockdown of EZH2.  Cells were transfected with 1ug of EZH2 specific 
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siRNA or All Star scrambled sequence control (Qiagen) using RNAiFect transfection reagent 
(Qiagen) according to the manufacturer‟s instructions and were treated with IFN-γ (500U/ml) as 
indicated.  Cells were lysed in NP-40 lysis buffer (1M Tris pH 8.0, 1M KCl, 10% NP-40, 0.5M 
EDTA, 5M NaCl, 1M DTT, dH2O) with EDTA free protease inhibitor (Roche) and analyzed by 
western blot for knockdown efficiency and specificity. 
 
RNA Expression 
 
Cells were plated at a density of 8x10
5
 cells and were stimulated as indicated with IFN-γ 
(500U/ml).  Cells were harvested and were subjected to RNA extraction with 1ml of Trizol rea-
gent (Invitrogen) as previously described (Truax, Koues et al. ; Bhat, Turner et al. 2008).  An 
Omniscript Reverse Transcription Kit (Qiagen) was used to generate cDNA from extracted 
RNA.  Isolated DNA was analyzed by Real-time PCR on an ABI prism 7900 (Applied Biosys-
tems) using primers and probes for CIITA, MHC II and GAPDH (Truax, Koues et al. ; Bhat, 
Turner et al. 2008).  Primers sequences for EZH2 were as follows:  EZH2 sense TTCATGCAA-
CACCCAACACT, EZH2 antisene GAGAGCAGCAGCAAACTCCT and EZH2 probe FAM- 
TTACCAGCATTTGGAGGGAG -TAMRA. Values generated from Real-time PCR reactions 
were calculated on the basis of standard curves generated. 
 
RNA expression in siRNA treated cells 
 
Cells were plated at a density of 8x10
5
 cells, transfected with EZH2 specific or control 
siRNA, and twenty four hours later were stimulated as indicated with IFN-γ (500U/ml).  Cells 
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were harvested and 10% of the cell volume was lysed with 1% Nonidet P-40 lysis buffer and 
subjected SDS PAGE.  RNA was extracted and analyzed from the remaining fraction of cell vo-
lume as above.  
 
Chromatin Immunoprecipitation (ChIP) 
 
ChIP assays were performed as previously described (Truax, Koues et al. ; Bhat, Turner 
et al. 2008; Koues, Dudley et al. 2008).  Briefly, cells were plated at a cell density of 3x10
6
, sti-
mulated with IFN-γ as indicated (500U/ml), and were crosslinked with 1% formaldehyde for 10 
minutes at room temperature.  Crosslinking was stopped by the addition of 0.125M glycine for 
five minutes at room temperature.  Cells were lysed in SDS lysis buffer and were sonicated at 
constant pulse to generate an average of 500-750bp sheared DNA.  Sonicated lysates were prec-
leared with salmon-sperm coated agarose beads (Upstate) and half of the lysate was immunopre-
cipitated with 5μg of indicated antibody overnight at 4°C.  The remaining half of the lysate was 
immunoprecipitated with isotype control antibody (Upstate).  Following a two hour immunopre-
cipitation with 50μl of salmon-sperm coated agarose beads, samples were washed for 3 minutes 
at 4°C with each of the following buffers:  low salt buffer, high salt buffer, LiCl, and 1xTE and 
were eluted with SDS elution buffer.  Following elution, cross-links were reversed overnight 
with 5M NaCl at 65°C and immunoprecipitated DNA was isolated using phe-
nol:chloroform:isopropanol mix (Invitrogen) as per the manufacturer‟s instructions.  Isolated 
DNA was analyzed by real-time PCR using previously published primers spanning the W-X-Y 
box of the MHC-II HLA-DRA promoter and the GAS-IRF-E box of CIITApIV (Truax, Koues et 
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al. ; Bhat, Turner et al. 2008; Koues, Dudley et al. 2008). Values generated from Real-time PCR 
reactions were calculated based on standard curves generated.  
 
Dual crosslinking Chromatin Immunoprecipitation (dChIP) Assay 
 
 Cells were plated at a density of 2.5 × 10
6 
cells and were stimulated as indicated with 500 
U/ml IFN-γ.  Cells were harvested and washed with PBS, resuspended in 10 ml of PBS (pH 8.0) 
containing 1mM MgCl2 and 1μM of Disuccinimidyl Glutarate (DSG) and were incubated at 
room temperature for 45 minutes.  Following crosslinking, 0.1 mM Tris pH 7.4 was added for 
five minutes at room temperature to block further cross-linking.  Cells were washed in PBS, re-
suspended in 10ml of PBS and Formaldehyde cross-linking was performed as described above 
for the ChIP assay.   
 
Chromatin Immunoprecipitation with siRNA 
 
ChIP with siRNA assays were performed as previously described (Truax, Koues et al. ; 
Koues, Dudley et al. 2008).  Briefly, cells were plated at a density of 8x10
5
, transfected with 1µg 
EZH2 specific or control siRNA (Qiagen), and stimulated as indicated with IFN-γ (500U/ml).  
10% of the cell volume was lysed with 1% Nonidet P-40 lysis buffer and was analyzed by west-
ern blot for knockdown efficiency and specificity.  The remaining cell volume was crosslinked, 
lysed in SDS lysis buffer, and subjected to sonication and the above described ChIP assay. 
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6 CHAPTER VI: CONCLUSIONS: 
 
The process of gene expression is utilized by all living organisms, including eukaryotes, 
prokaryotes, and viruses to generate macromolecules for life. There are several steps in which 
gene expression can be regulated including transcription, translation, and posttranslational mod-
ifications. Genes are organized as very long strands of DNA which carry genetic information and 
are tightly packed into nuclei (Ogbourne and Antalis 1998). DNA is wrapped around histone 
proteins which are then condensed into chromatin (Luger, Mader et al. 1997; Richmond and 
Davey 2003). Genes can be constitutively silenced or expressed, or belong to a group of induci-
ble genes which are expressed as needed (Nakayama, Rice et al. 2001; Agalioti, Chen et al. 
2002; Jacobs and Khorasanizadeh 2002; Plath, Fang et al. 2003; Sparmann and van Lohuizen 
2006).  To allow for these diverse modes of gene expression, chromatin is dynamic, allowing for 
rapid changes in gene expression in response to various stimuli. Both silenced and active chro-
matin structures are associated with specific histone modifications. These covalent modifications 
include acetylation, methylation, phosphorylation, sumoylation, and ubiquitination; each of 
which plays important roles in gene expression by determining the level of accessibility of chro-
matic DNA. Transcriptionally silenced heterochromatin is frequently methylated on histone H3 
at lysines 9 and 27 (Nakayama, Rice et al. 2001; Jacobs and Khorasanizadeh 2002; Plath, Fang et 
al. 2003; Sparmann and van Lohuizen 2006). Euchromatin is active chromatin and is heavily 
acetylated on lysine residues on histones H3 and H4 (Eberharter and Becker 2002; Gorisch, 
Wachsmuth et al. 2005). The addition and removal of histone modifications is mediated by a 
group of histone modifying enzymes termed histone acetyltransferases, histone deactetylases, 
207 
 
histone methyltransferases, and histone demethylases. The study of posttranslational modifica-
tions of histone tails has given rise to a “histone code” which, together with the “DNA code,” 
determines the availability of DNA for gene expression.   
 
 The ubiquitin proteasome system (UPS), largely known for its ability to degrade polyu-
biquitinated proteins, has recently emerged as a novel player in transcriptional regulation of vari-
ous genes (Ciechanover 1994; Hochstrasser 1996; Kinyamu, Chen et al. 2005). The 19S subunit 
of the 26S proteasome contains six ATPases which assemble into a hexameric ring to associate 
with the 20S proteasome. Full roles for 19S ATPases in proteasome mediated degradation re-
main unclear, but their roles in unfolding of ubiquitinated proteins directed towards the 20S core 
are critical for protein degradation (Coux, Tanaka et al. 1996; Glickman, Rubin et al. 1999). Ini-
tial observations that the 20S core and 19S regulatory particle also exist as independent com-
plexes in both nuclear and cytoplasmic components led to studies of independent contributions 
of these components to cellular activity (Brooks, Fuertes et al. 2000). These efforts resulted in 
observations that the 19S ATPases could separate from the 19S proteasome and associate with 
activation domains of transcription factors and with inducible promoters (Swaffield, Melcher et 
al. 1995; Rubin, Coux et al. 1996; Gonzalez, Delahodde et al. 2002; Sun, Johnston et al. 2002). 
Intense efforts have identified independent roles for 19S ATPases in regulating transcriptional 
activity of  multiple yeast genes (Ferdous, Gonzalez et al. 2001; Ferdous, Kodadek et al. 2002; 
Gonzalez, Delahodde et al. 2002; Morris, Kaiser et al. 2003; Lee, Ezhkova et al. 2005; Sulahian, 
Johnston et al. 2006). Studies in mammalian systems have lagged behind those in yeast, however 
interactions of the 19S proteasome with the tumor suppressor p53, the HIV- promoter and coding 
region, the retinoic acid receptor, the glucocorticoid receptor, and the viral transcription factor 
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E1A have driven further development of the field (Ferdous, Kodadek et al. 2002; Kinyamu, 
Chen et al. 2005; Rasti, Grand et al. 2006; Lassot, Latreille et al. 2007; Zhu, Wani et al. 2007).  
Despite these advances, the mechanism by which 19S ATPases regulates mammalian transcrip-
tion remains unknown.  
 
In order to understand functional involvement of the 19S proteasome in gene expression, 
we have investigated the role of the 19S ATPase S6a in regulating transcriptional initiation of 
CIITA. We choose CIITA for further investigation because, as the master regulator of MHC 
class II genes, CIITA is a critical and inducible gene (Wang 2003). We and others have previous-
ly demonstrated interactions between the UPS and mono and polyubiquitinated CIITA (Bhat, 
Truax et al. ; Greer, Zika et al. 2003; Schnappauf, Hake et al. 2003) and a dependence of CIITA 
activation on 19S ATPase activity (Bhat, Truax et al. ; Truax, Koues et al. ; Bhat, Turner et al. 
2008; Koues, Dudley et al. 2008; Koues, Dudley et al. 2009). We initially observed that protea-
some inhibition has a diminishing effect on both CIITA transactivity and on expression of MHC 
II genes. Studies by Bhat et al, demonstrated roles for the 19S ATPase Sug1 in regulating tran-
scriptional initiation of MHC II genes and showed that in the absence of Sug1, levels of CIITA 
recruited to MHC II proximal promoter are significantly reduced (Bhat, Turner et al. 2008). Stu-
dies by Koues et al implicated novel roles for the 19S ATPase Sug1 in epigenetic regulation of 
transcription of MHC II genes (Koues, Dudley et al. 2008; Koues, Dudley et al. 2009). However, 
the full role of the 19S ATPases in regulating transcription of CIITA and MHC II genes remains 
to be investigated.  
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Figure 6.1   Transcription regulation of CIITA genes.  
IFN-γ stimulation activates JAK STAT signaling pathway and results in the recruitment of gene 
specific transcription factors and histone modifying enzymes, which, enabled by the actions of 
19S ATPases, are crucial in mediating transcriptional initiation of CIITA genes. Cytokine stimu-
lation is aided by subunits of the proteasome in promoting the switch from an inactive to active 
form of P-TEF-b. Activated P-TEF-b is recruited to the CIITA promoter and phosphorylates se-
rine 5 on the CTD of RNA polymerase II to initiate mRNA synthesis. Shortly after the transcrip-
tion start site, the polymerase pauses; the release of the polymerase is mediated by a series of 
phosphorylation events involving serine 2 on the RNA pol II CTD and NTEF which initiates 
productive elongation, chromatin modifications, and termination.  
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S6a is an important, and largely unstudied, 19S ATPase known for binding to polyubiqui-
tin chains on proteins targeted for degradation (Lam, Lawson et al. 2002). Following IFN-γ sti-
mulation, our studies show S6a rapidly binds to the proximal promoters of both MHC II HLA-
DRA and CIITApIV. Decreased expression of S6a results in significant decreases in the message 
levels of both MHC II and CIITA. Previous studies have documented that expression of CIITA-
pIV following IFN-γ stimulation depends on the recruitment of the transcription factors STAT-1 
and IRF-1 to CIITA proximal promoter. Indeed, we observed S6a interactions with STAT-1, and 
significant reductions in STAT-1 and IRF-1 CIITApIV binding in the absence of S6a. S6a 
knockdown decreases acetylation of histone 3, lysine 18 and of histone 4, lysine 8 at CIITApIV, 
further indicating this 19S ATPase plays critical roles in chromatin remodeling, in recruitment of 
transcription factors, and in assembly of the preinitiation complex required for efficient tran-
scription of CIITA genes (Figure 6.1). As the 19S ATPase S6a recognizes ubiquitinated pro-
teins, we were unsurprised by our observations that decreased expression of S6a negatively im-
pacts degradation by the 26S proteasome as evidenced by increases in p53 half life. However, 
blocking proteasome activity with the proteasome inhibitor MG132 does not affect levels of ace-
tylation at CIITApIV, suggesting S6a mediated effects on acetylation and recruitment of tran-
scription factors to CIITApIV are proteasome independent. The 19S ATPase S6b also binds in-
ducibly to CIITApIV and has similar effects on chromatin structure as does S6a. Thus far, our 
studies demonstrate the 19S ATPase S6a plays important roles in transcriptional initiation of 
CIITA and MHC II genes.  
 
In regards to transcriptional elongation, we have mapped robust binding of S6a to the 
CIITA coding region, providing novel evidence that 19S ATPases may play roles in elongation. 
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In data not shown, we observe that all six of the 19S ATPases bind the CIITApIV proximal and 
coding regions following IFN-γ stimulation.  Occupancy of the 19S ATPase S6a has also been 
observed at the coding region of HIV-1 (Lassot, Latreille et al. 2007), where all the 19S ATPases 
have shown enriched binding to the coding region, but where levels of S6a binding were signifi-
cantly higher. Following successful assembly of preinitiation complexes, RNA pol II initiates 
synthesis of messenger RNA in a process mediated by phosphorylation at serine 5 on CTD re-
peats of the polymerase (Dahmus 1996; McCracken, Fong et al. 1997; Hirose, Tacke et al. 1999; 
Hirose and Manley 2000). In higher eukaryotes, polymerase frequently pauses after synthesis of 
approximately 50 bases of RNA due to actions of negative elongation factor (NELF) and 5,6-
dichloro 1-B- ribofuranosylbenzimidazole (DRB) sensitivity inducing factor (DSIF) (Saunders, 
Core et al. 2006). RNA pol II pausing is overcome by recruitment of CDK9 which phosphory-
lates NELF and DSIF as well as serine 2 at on RNA pol II CTD repeats. These phosphorylations 
initiate a cascade of events including productive elongation, mRNA synthesis, transcriptional 
termination, and chromatin modifications (Figure 6.1) (Mancebo, Lee et al. 1997; Zhu, Pe'ery et 
al. 1997; Darzacq, Shav-Tal et al. 2007). To determine if S6a plays roles in maintaining tran-
scription, we knocked down S6a expression using S6a specific siRNA and observe that in the 
absence of S6a, levels of RNA pol II and the cyclin T1component of P-TEF-b  are reduced at 
both the CIITA proximal promoter and coding region. In addition, co-immunoprecipitations stu-
dies indicate S6a associates with the Hexim-1 and CDK9 components of the P-TEF-b complex 
(Figure 6.1). Proteasome inhibition via MG132 treatment does not significantly impact levels of 
RNA pol II at either the CIITA proximal promoter or coding region, indicating effects of S6a 
siRNA are degradation independent. These observations agree with yeast studies using genome 
wide ChIP analyses which demonstrated that there are hundreds of genes that differentially asso-
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ciate with either the 19S proteasome or 20S proteasome, indicating 19S and 20S subunits of the 
26S proteasome have independent functions in regulating different genes (Sikder, Johnston et al. 
2006). As the status of chromatin plays critical roles in regulating transcription elongation, future 
investigations will address roles of the 19S ATPases in maintaining acetylation levels on histone 
H3 and histone H4 as well as methylation on histone H3 at lysine 36 on actively transcribing 
genes (Krogan, Kim et al. 2003; Liu, Kaplan et al. 2005; Pokholok, Harbison et al. 2005; Rao, 
Shibata et al. 2005).  
 
Our studies have shown that one way 19S ATPases mediate transcription regulation of 
CIITA genes is via affects on both chromatin structure and on recruitment of various transcrip-
tion factors and coactivators. To more fully address the dynamics of epigenetic events at CIITA 
genes, we have analyzed the chromatin structure of CIITApIV following cytokine stimulation. 
As CIITA is a master regulator for critical inflammatory MHC II genes, rapid alterations in 
chromatin structure of CIITApIV are necessary for rapid induction of adaptive immune res-
ponses. We have previously observed that acetylation levels on histone H3 lysine 18 rise 18 
hours post IFN-γ stimulation (Truax, Koues et al. ; Koues, Dudley et al. 2008), however the in-
crease was nonlinear, indicating rapid loosening of CIITApIV chromatin. In contrast to activat-
ing modifications are the silencing modifications of trimethylation on histone H3 lysine 9 and 
lysine 27, which are significantly reduced within the initial two hours of cytokine stimulation. 
The rapid loss of these silencing modifications from CIITApIV is opposite from the trend of ac-
tivating methylation at CIITApIV histone H3 lysine 4. Together, these observations suggest the 
changes in histone modifications observed at CIITApIV occur very rapidly following cytokine 
stimulation allowing for STAT-1 to bind to CIITApIV 20 minutes following IFN-γ treatment. 
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STAT-1 binding to CIITApIV also correlates with robust and rapid increases in CIITA tran-
scripts. Epigenetic modifications to CIITApIV following IFN- stimulation demonstrate a bal-
ance between rapidly decreasing silencing modifications and a slower gain of activating modifi-
cations. Of note are our observations that activating modifications do not reach maximum levels 
until 120 minutes post cytokine stimulation while silencing modifications are significantly re-
duced in a much more rapid fashion.  These data indicate removal of methyl groups from lysine 
27 of histone H3 at CIITApIV is the dominant histone modification in the transcriptional control 
of CIITA genes. This observation correlates with our observation that CIITApIV binding of the 
histone methyltransferase EZH2 declines rapidly following IFN-γ stimulation, suggesting EZH2 
is a master regulator of CIITA genes. As described below, we have gone on to demonstrate that 
EZH2 plays significant roles in suppressing transactivation of CIITA and cell surface expression 
of MHC II, adding support to our observations of the critical roles played by EZH2 as an impor-
tant regulator of the accessibility of CIITA genes. 
 
Metastatic tumors have altered their expression of multiple genes in order to escape host 
immune surveillance. Recent studies indicate that MHC II cell surface expression is an important 
factor in predicting tumor metastasis (Brocker, Suter et al. 1984; Concha, Esteban et al. 1991; de 
Waard-Siebinga, Kool et al. 1995). Multiple tumor types including uveal melanoma (de Waard-
Siebinga, Kool et al. 1995), T cell leukemias (van den Elsen, Gobin et al. 2001), and colorectal, 
gastric (Satoh, Toyota et al. 2004), and trophoblastic tumors (Morris, Spangler et al. 2000) avoid 
the host immune response through repressing cell surface expression of MHC II. Decreased ex-
pression of MHC II has also been observed in breast cancer, including our own study of MDA 
MB 435 cells.  Our studies tested three variants of MDA MB 435 breast cancer cells, and dem-
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onstrate that the metastatic ability of these variants negatively correlates with the cell surface ex-
pression of MHC II and with transcription of CIITA. We show that in MDA MB 435 cells CII-
TApIV is suppressed by increased binding of the HMT EZH2 which correlates with elevated le-
vels of the suppressing modification trimethylation on histone H3 lysine 27, even in the presence 
of sustained cytokine stimulation. Our studies indicate metastatic tumors may target epigenetic 
modifications of CIITA genes in order to suppress expression of MHC II and avoid the immune 
response.  
 
Of note are our observations that the metastatic variant of MDA MB 435 cells has sub-
stantially decreased surface expression of MHC II, which correlates with low transcript levels of 
MHC II and CIITA following IFN-γ stimulation. Aberrant expression of CIITA is driven by ele-
vated levels of trimethylation on histone H3 lysine 27 at CIITApIV. Conversely, neither the le-
vels of trimethylation on histone H3 lysine 9 nor the levels of acetylation on histone H3 or his-
tone H4 are impacted. These observations highlight the importance and dominance of the silenc-
ing modification of trimethylation at H3 lysine 27 in regulating expression of CIITA genes. As a 
consequence of the inaccessibility of CIITApIV DNA, we observe significantly reduced binding 
of the transcription factors STAT-1 and IRF-1, as well as RNA pol II to the proximal promoter 
of CIITApIV. In direct opposition to the closed status of CIITApIV in the metastatic variant of 
MDA MB 435 is the epigenetic state of MHC II which shows no abnormalities of any tested his-
tone modifications. In these cells, MHC II genes are open and available following cytokine sti-
mulation; therefore, it is the lack of the master regulator CIITA that drives the absence of MHC 
II expression in these IFN-γ stimulated cells.  
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Figure 6.2  Transcriptional regulation of CIITA genes by the histone methyltransferase 
EZH2.  
Metastatic breast cancer cells suppress CIITA expression to avoid recognition by the host im-
mune system. Elevated CIITApIV binding of the histone methyltransferase EZH2 results in 
hypermethylation of the CIITApIV proximal promoter on histone H3 lysine 27 and in inaccessi-
bility of the CIITA promoter. 
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Significantly, knocking down EZH2 restores suppressed expression of CIITA and MHC 
II in these cells with and without IFN-γ stimulation, suggesting that EZH2 is the critical regulator 
of CIITA gene silencing. In sum, our data shows that CIITA, the master regulator of MHC II 
genes, is suppressed in metastatic variants of MDA MB 435 cells. Our observations indicate 
hypermethylation of histone tails by the histone methyltransferase EZH2 drives significant down 
regulation of CIITApIV (Figure 6.2).  
 
It is noteworthy that the master regulator CIITA is controlled by its own master regulator, 
EZH2. Future research will determine if elevated levels of EZH2 are observed at additional 
genes that are silenced in metastatic tumors and important regulators of tumor immune surveil-
lance. The mechanisms by which EZH2 silences CIITApIV remain to be fully investigated and 
include the possibility that EZH2 recruits DNA methyltransferases to CIITApIV, as suppression 
of CIITA may result from a combination of silencing modifications to histone tails and DNA 
methylation.  
 
To conclude, we showed expression of CIITA in response to cytokine stimulation is high-
ly regulated at the level of transcription. We have added substantial evidence to demonstrate “the 
proteasome is not just degrading anymore”, as we show subunits of the 19S proteasome play im-
portant role in transcriptional regulation of mammalian genes.  The 19S ATPase S6a is an impor-
tant player in these transcriptional processes as it regulates expression of CIITA at the levels of 
transcriptional initiation and elongation (Figure 6.1). In addition our study is the first to describe 
the early epigenetic events that occur at CIITApIV.  Our data indicate CIITA coding DNA is ra-
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pidly opened and available for transcription factor binding following cytokine stimulation. 
Moreover, we show the histone methyltransferase EZH2 is powerful contributor to silencing of 
CIITA genes. Based on our observations, EZH2 plays the role of “master regulator” of epigenet-
ic modifications to CIITA associated histones (Figure 6.2). Expression of CIITA and MHC II is 
significantly decreased in metastatic breast cancer cells MDA MB 435 due to high levels of tri-
methylation on histone H3 lysine 27 facilitated by elevated occupancy of EZH2. Knowledge that 
CIITApIV is controlled by EZH2 provides new insights into our understanding of how cancer 
cells avoid recognition by the immune system. Based on the work in this dissertation, we now 
have a better understanding of how transcription of CIITA and MHC II genes is regulated. These 
findings enhance our knowledge of the role of the 26S proteasome and epigenetic modifications 
in regulating CIITA activity and MHC II expression and provide novel targets for therapeutic 
strategies to manipulate MHC II in expression in autoimmune diseases and in tumor cells.  
218 
 
7 CHAPTER VII: REFERENCES 
 
Adams, J. (2003). "The proteasome: structure, function, and role in the cell." Cancer Treat Rev 
29 Suppl 1: 3-9. 
Adamski, J., Z. Ma, et al. (2004). "17beta-Estradiol inhibits class II major histocompatibility 
complex (MHC) expression: influence on histone modifications and cbp recruitment to 
the class II MHC promoter." Mol Endocrinol 18(8): 1963-74. 
Adamski, J., Z. Ma, et al. (2004). "17beta-Estradiol inhibits class II major histocompatibility 
complex (MHC) expression: influence on histone modifications and cbp recruitment to 
the class II MHC promoter." Mol Endocrinol 18(8): 1963-74. 
Agalioti, T., G. Chen, et al. (2002). "Deciphering the transcriptional histone acetylation code for 
a human gene." Cell 111(3): 381-92. 
Agger, K., P. A. Cloos, et al. (2007). "UTX and JMJD3 are histone H3K27 demethylases in-
volved in HOX gene regulation and development." Nature 449(7163): 731-4. 
Archer, C. T., L. Burdine, et al. (2008). "Physical and functional interactions of monoubiquity-
lated transactivators with the proteasome." J Biol Chem 283(31): 21789-98. 
Bachmann, I. M., O. J. Halvorsen, et al. (2006). "EZH2 expression is associated with high proli-
feration rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the 
endometrium, prostate, and breast." J Clin Oncol 24(2): 268-73. 
Bannister, A. J. and T. Kouzarides (1996). "The CBP co-activator is a histone acetyltransferase." 
Nature 384(6610): 641-3. 
Bannister, A. J. and T. Kouzarides (2004). "Histone methylation: recognizing the methyl mark." 
Methods Enzymol 376: 269-88. 
219 
 
Barboric, M., J. Kohoutek, et al. (2005). "Interplay between 7SK snRNA and oppositely charged 
regions in HEXIM1 direct the inhibition of P-TEFb." EMBO J 24(24): 4291-303. 
Baton, F., C. Deruyffelaere, et al. (2004). "Class II transactivator (CIITA) isoform expression 
and activity in melanoma." Melanoma Res 14(6): 453-61. 
Bauer, U. M., S. Daujat, et al. (2002). "Methylation at arginine 17 of histone H3 is linked to gene 
activation." EMBO Rep 3(1): 39-44. 
Baumeister, W., J. Walz, et al. (1998). "The proteasome: paradigm of a self-compartmentalizing 
protease." Cell 92(3): 367-80. 
Bedford, M. T. and S. Richard (2005). "Arginine methylation an emerging regulator of protein 
function." Mol Cell 18(3): 263-72. 
Benoist, C. and D. Mathis (1990). "Regulation of major histocompatibility complex class-II 
genes: X, Y and other letters of the alphabet." Annu Rev Immunol 8: 681-715. 
Beresford, G. W. and J. M. Boss (2001). "CIITA coordinates multiple histone acetylation mod-
ifications at the HLA-DRA promoter." Nat Immunol 2(7): 652-7. 
Berger, S. L. (2002). "Histone modifications in transcriptional regulation." Curr Opin Genet Dev 
12(2): 142-8. 
Berger, S. L. (2007). "The complex language of chromatin regulation during transcription." Na-
ture 447(7143): 407-12. 
Berger, S. L., T. Kouzarides, et al. (2009). "An operational definition of epigenetics." Genes Dev 
23(7): 781-3. 
Bernstein, B. E., E. L. Humphrey, et al. (2002). "Methylation of histone H3 Lys 4 in coding re-
gions of active genes." Proc Natl Acad Sci U S A 99(13): 8695-700. 
220 
 
Bhat, K. P., A. D. Truax, et al. "Association of the 19S proteasomal ATPases with the ATPase-
binding domain of CIITA is essential for CIITA stability and MHC class II expression." 
Immunol Cell Biol. 
Bhat, K. P., A. D. Truax, et al. "Phosphorylation and ubiquitination of degron proximal residues 
are essential for class II transactivator (CIITA) transactivation and major histocompatibil-
ity class II expression." J Biol Chem 285(34): 25893-903. 
Bhat, K. P., A. D. Truax, et al. (2010). "Phosphorylation and ubiquitination of degron proximal 
residues are essential for class II transactivator (CIITA) transactivation and major histo-
compatibility class II expression." J Biol Chem 285(34): 25893-903. 
Bhat, K. P., J. D. Turner, et al. (2008). "The 19S proteasome ATPase Sug1 plays a critical role in 
regulating MHC class II transcription." Mol Immunol 45(8): 2214-24. 
Blazek, D., M. Barboric, et al. (2005). "Oligomerization of HEXIM1 via 7SK snRNA and 
coiled-coil region directs the inhibition of P-TEFb." Nucleic Acids Res 33(22): 7000-10. 
Boss, J. and P. Jensen (2003). "Transcriptional regulation of the MHC class II antigen presenta-
tion pathway." Curr Opin Immunol 15(1): 105-11. 
Boss, J. M. (1997). "Regulation of transcription of MHC class II genes." Curr Opin Immunol 
9(1): 107-13. 
Boss, J. M. and P. E. Jensen (2003). "Transcriptional regulation of the MHC class II antigen 
presentation pathway." Curr Opin Immunol 15(1): 105-11. 
Boulikas, T. (1990). "Poly(ADP-ribosylated) histones in chromatin replication." J Biol Chem 
265(24): 14638-47. 
Brocker, E. B., L. Suter, et al. (1984). "HLA-DR antigen expression in primary melanomas of 
the skin." J Invest Dermatol 82(3): 244-7. 
221 
 
Brooks, P., G. Fuertes, et al. (2000). "Subcellular localization of proteasomes and their regulato-
ry complexes in mammalian cells." Biochem J 346 Pt 1: 155-61. 
Buratowski, S. (1994). "The basics of basal transcription by RNA polymerase II." Cell 77(1): 1-
3. 
Calvo, O. and J. L. Manley (2003). "Strange bedfellows: polyadenylation factors at the promo-
ter." Genes Dev 17(11): 1321-7. 
Cao, R., Y. Tsukada, et al. (2005). "Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox 
gene silencing." Mol Cell 20(6): 845-54. 
Cao, R., L. Wang, et al. (2002). "Role of histone H3 lysine 27 methylation in Polycomb-group 
silencing." Science 298(5595): 1039-43. 
Cao, R. and Y. Zhang (2004). "The functions of E(Z)/EZH2-mediated methylation of lysine 27 
in histone H3." Curr Opin Genet Dev 14(2): 155-64. 
Carrozza, M. J., B. Li, et al. (2005). "Histone H3 methylation by Set2 directs deacetylation of 
coding regions by Rpd3S to suppress spurious intragenic transcription." Cell 123(4): 581-
92. 
Cedar, H. and Y. Bergman (2009). "Linking DNA methylation and histone modification: pat-
terns and paradigms." Nat Rev Genet 10(5): 295-304. 
Chamuleau, M. E., G. J. Ossenkoppele, et al. (2006). "MHC class II molecules in tumour immu-
nology: prognostic marker and target for immune modulation." Immunobiology 211(6-8): 
619-25. 
Chan, H. M. and N. B. La Thangue (2001). "p300/CBP proteins: HATs for transcriptional 
bridges and scaffolds." J Cell Sci 114(Pt 13): 2363-73. 
222 
 
Chang, C., F. Gonzalez, et al. (2001). "The Gal4 activation domain binds Sug2 protein, a protea-
some component, in vivo and in vitro." J Biol Chem 276(33): 30956-63. 
Chang, C. H., J. D. Fontes, et al. (1994). "Class II transactivator (CIITA) is sufficient for the in-
ducible expression of major histocompatibility complex class II genes." J Exp Med 
180(4): 1367-74. 
Chau, V., J. W. Tobias, et al. (1989). "A multiubiquitin chain is confined to specific lysine in a 
targeted short-lived protein." Science 243(4898): 1576-83. 
Chen, S., L. R. Bohrer, et al. (2010). "Cyclin-dependent kinases regulate epigenetic gene silenc-
ing through phosphorylation of EZH2." Nat Cell Biol 12(11): 1108-14. 
Cheung, P., K. G. Tanner, et al. (2000). "Synergistic coupling of histone H3 phosphorylation and 
acetylation in response to epidermal growth factor stimulation." Mol Cell 5(6): 905-15. 
Chiba, K., J. Yamamoto, et al. (2010). "Promoter-proximal pausing and its release: molecular 
mechanisms and physiological functions." Exp Cell Res 316(17): 2723-30. 
Chou, S. D. and T. B. Tomasi (2008). "Spatial distribution of histone methylation during MHC 
class II expression." Mol Immunol 45(4): 971-80. 
Ciechanover, A. (1994). "The ubiquitin-proteasome proteolytic pathway." Cell 79(1): 13-21. 
Ciechanover, A. (1998). "The ubiquitin-proteasome pathway: on protein death and cell life." 
EMBO J 17(24): 7151-60. 
Clapier, C. R. and B. R. Cairns (2009). "The biology of chromatin remodeling complexes." Annu 
Rev Biochem 78: 273-304. 
Collett, K., G. E. Eide, et al. (2006). "Expression of enhancer of zeste homologue 2 is signifi-
cantly associated with increased tumor cell proliferation and is a marker of aggressive 
breast cancer." Clin Cancer Res 12(4): 1168-74. 
223 
 
Collins, T., A. Korman, et al. (1984). "Immune interferon activates multiple class II major histo-
compatibility complex genes and the associated invariant chain gene in human endotheli-
al cells and dermal fibroblasts." Proc Natl Acad Sci U S A 81(15): 4917-21. 
Conaway, R. C., C. S. Brower, et al. (2002). "Emerging roles of ubiquitin in transcription regula-
tion." Science 296(5571): 1254-8. 
Conaway, R. C. and J. W. Conaway (1993). "General initiation factors for RNA polymerase II." 
Annu Rev Biochem 62: 161-90. 
Concha, A., F. Esteban, et al. (1991). "Tumor aggressiveness and MHC class I and II antigens in 
laryngeal and breast cancer." Semin Cancer Biol 2(1): 47-54. 
Cooper, C. S. and C. S. Foster (2009). "Concepts of epigenetics in prostate cancer development." 
Br J Cancer 100(2): 240-5. 
Corden, J. L., D. L. Cadena, et al. (1985). "A unique structure at the carboxyl terminus of the 
largest subunit of eukaryotic RNA polymerase II." Proc Natl Acad Sci U S A 82(23): 
7934-8. 
Cosgrove, M. S. (2007). "Histone proteomics and the epigenetic regulation of nucleosome mo-
bility." Expert Rev Proteomics 4(4): 465-78. 
Coux, O., K. Tanaka, et al. (1996). "Structure and functions of the 20S and 26S proteasomes." 
Annu Rev Biochem 65: 801-47. 
Cressman, D. E., K.-C. Chin, et al. (1999). "A Defect in the Nuclear Translocation of CIITA 
Causes a Form of Type II Bare Lymphocyte Syndrome." Immunity 10(2): 163. 
Cressman, D. E., W. J. O'Connor, et al. (2001). "Mechanisms of Nuclear Import and Export That 
Control the Subcellular Localization of Class II Transactivator." J Immunol 167(7): 
3626-3634. 
224 
 
Cresswell, P. and J. C. Howard (1997). "Antigen recognition." Curr Opin Immunol 9(1): 71-4. 
Croce, M., A. De Ambrosis, et al. (2003). "Different levels of control prevent interferon-gamma-
inducible HLA-class II expression in human neuroblastoma cells." Oncogene 22(49): 
7848-57. 
Czermin, B., R. Melfi, et al. (2002). "Drosophila enhancer of Zeste/ESC complexes have a his-
tone H3 methyltransferase activity that marks chromosomal Polycomb sites." Cell 
111(2): 185-96. 
Dadmarz, R., M. K. Sgagias, et al. (1995). "CD4+ T lymphocytes infiltrating human breast can-
cer recognise autologous tumor in an MHC-class-II restricted fashion." Cancer Immunol 
Immunother 40(1): 1-9. 
Dahmus, M. E. (1996). "Reversible phosphorylation of the C-terminal domain of RNA polyme-
rase II." J Biol Chem 271(32): 19009-12. 
Darzacq, X., Y. Shav-Tal, et al. (2007). "In vivo dynamics of RNA polymerase II transcription." 
Nat Struct Mol Biol 14(9): 796-806. 
Daujat, S., U. M. Bauer, et al. (2002). "Crosstalk between CARM1 methylation and CBP acety-
lation on histone H3." Curr Biol 12(24): 2090-7. 
Davies, N. and G. G. Lindsey (1994). "Histone H2B (and H2A) ubiquitination allows normal 
histone octamer and core particle reconstitution." Biochim Biophys Acta 1218(2): 187-
93. 
de Preval, C., M. R. Hadam, et al. (1988). "Regulation of genes for HLA class II antigens in cell 
lines from patients with severe combined immunodeficiency." N Engl J Med 318(20): 
1295-300. 
225 
 
de Ruijter, A. J., A. H. van Gennip, et al. (2003). "Histone deacetylases (HDACs): characteriza-
tion of the classical HDAC family." Biochem J 370(Pt 3): 737-49. 
de Waard-Siebinga, I., J. Kool, et al. (1995). "HLA antigen expression on uveal melanoma cells 
in vivo and in vitro." Hum Immunol 44(2): 111-7. 
Deng, W. and S. G. Roberts (2007). "TFIIB and the regulation of transcription by RNA polyme-
rase II." Chromosoma 116(5): 417-29. 
Drozina, G., J. Kohoutek, et al. (2005). "Expression of MHC II genes." Curr Top Microbiol Im-
munol 290: 147-70. 
Dulac, C., A. A. Michels, et al. (2005). "Transcription-dependent association of multiple positive 
transcription elongation factor units to a HEXIM multimer." J Biol Chem 280(34): 
30619-29. 
Eberharter, A. and P. B. Becker (2002). "Histone acetylation: a switch between repressive and 
permissive chromatin. Second in review series on chromatin dynamics." EMBO Rep 
3(3): 224-9. 
Eden, A., F. Gaudet, et al. (2003). "Chromosomal instability and tumors promoted by DNA hy-
pomethylation." Science 300(5618): 455. 
Ezhkova, E. and W. P. Tansey (2004). "Proteasomal ATPases link ubiquitylation of histone H2B 
to methylation of histone H3." Mol Cell 13(3): 435-42. 
Farber, D. L., O. Acuto, et al. (1997). "Differential T cell receptor-mediated signaling in naive 
and memory CD4 T cells." Eur J Immunol 27(8): 2094-101. 
Felsenfeld, G. and M. Groudine (2003). "Controlling the double helix." Nature 421(6921): 448-
53. 
226 
 
Ferdous, A., F. Gonzalez, et al. (2001). "The 19S regulatory particle of the proteasome is re-
quired for efficient transcription elongation by RNA polymerase II." Mol Cell 7(5): 981-
91. 
Ferdous, A., T. Kodadek, et al. (2002). "A nonproteolytic function of the 19S regulatory subunit 
of the 26S proteasome is required for efficient activated transcription by human RNA po-
lymerase II." Biochemistry 41(42): 12798-805. 
Ferry, C., M. Gianni, et al. (2009). "SUG-1 plays proteolytic and non-proteolytic roles in the 
control of retinoic acid target genes via its interaction with SRC-3." J Biol Chem 284(12): 
8127-35. 
Finley, D., A. Ciechanover, et al. (2004). "Ubiquitin as a central cellular regulator." Cell 116(2 
Suppl): S29-32, 2 p following S32. 
Finley, D., S. Sadis, et al. (1994). "Inhibition of proteolysis and cell cycle progression in a multi-
ubiquitination-deficient yeast mutant." Mol Cell Biol 14(8): 5501-9. 
Fodor, B. D., S. Kubicek, et al. (2006). "Jmjd2b antagonizes H3K9 trimethylation at pericentric 
heterochromatin in mammalian cells." Genes Dev 20(12): 1557-62. 
Fontes, J. D., B. Jiang, et al. (1997). "The class II trans-activator CIITA interacts with the TBP-
associated factor TAFII32." Nucleic Acids Res 25(12): 2522-8. 
Fontes, J. D., S. Kanazawa, et al. (1999). "Interactions between the class II transactivator and 
CREB binding protein increase transcription of major histocompatibility complex class II 
genes." Mol Cell Biol 19(1): 941-7. 
Fujiwara, H., M. Fukuzawa, et al. (1984). "The role of tumor-specific Lyt-1+2- T cells in eradi-
cating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of 
227 
 
host's cytotoxic T cell precursors for implementation of in vivo immunity." J Immunol 
133(3): 1671-6. 
Garrido, F. and F. Ruiz-Cabello (1991). "MHC expression on human tumors--its relevance for 
local tumor growth and metastasis." Semin Cancer Biol 2(1): 3-10. 
Gary, J. D. and S. Clarke (1998). "RNA and protein interactions modulated by protein arginine 
methylation." Prog Nucleic Acid Res Mol Biol 61: 65-131. 
Gelin, C., I. Sloma, et al. (2009). "Regulation of MHC II and CD1 antigen presentation: from 
ubiquity to security." J Leukoc Biol 85(2): 215-24. 
Gerloni, M. and M. Zanetti (2005). "CD4 T cells in tumor immunity." Springer Semin Immuno-
pathol 27(1): 37-48. 
Gillette, T. G., F. Gonzalez, et al. (2004). "Physical and functional association of RNA polyme-
rase II and the proteasome." Proc Natl Acad Sci U S A 101(16): 5904-9. 
Glickman, M. H., D. M. Rubin, et al. (1999). "Functional analysis of the proteasome regulatory 
particle." Mol Biol Rep 26(1-2): 21-8. 
Glimcher, L. H. and C. J. Kara (1992). "Sequences and factors: a guide to MHC class-II tran-
scription." Annu Rev Immunol 10: 13-49. 
Gobin, S. J., A. Peijnenburg, et al. (1997). "Site alpha is crucial for two routes of IFN gamma-
induced MHC class I transactivation: the ISRE-mediated route and a novel pathway in-
volving CIITA." Immunity 6(5): 601-11. 
Gomez, J. A., P. Majumder, et al. (2005). "X box-like sequences in the MHC class II region 
maintain regulatory function." J Immunol 175(2): 1030-40. 
Gonzalez, F., A. Delahodde, et al. (2002). "Recruitment of a 19S proteasome subcomplex to an 
activated promoter." Science 296(5567): 548-50. 
228 
 
Gorbea, C., D. Taillandier, et al. (1999). "Assembly of the regulatory complex of the 26S protea-
some." Mol Biol Rep 26(1-2): 15-9. 
Gorelik, E., M. Kim, et al. (1993). "Control of metastatic properties of BL6 melanoma cells by 
H-2Kb gene: immunological and nonimmunological mechanisms." Clin Exp Metastasis 
11(6): 439-52. 
Gorisch, S. M., M. Wachsmuth, et al. (2005). "Histone acetylation increases chromatin accessi-
bility." J Cell Sci 118(Pt 24): 5825-34. 
Greenberg, P. D., M. A. Cheever, et al. (1981). "Eradication of disseminated murine leukemia by 
chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syn-
geneic Lyt-1+2- lymphocytes." J Exp Med 154(3): 952-63. 
Greer, S. F., E. Zika, et al. (2003). "Enhancement of CIITA transcriptional function by ubiqui-
tin." Nat Immunol 4(11): 1074-82. 
Gupta-Rossi, N., E. Six, et al. (2004). "Monoubiquitination and endocytosis direct gamma-
secretase cleavage of activated Notch receptor." J Cell Biol 166(1): 73-83. 
Guy, K., A. Krajewski, et al. (1986). "Expression of MHC class II antigens in human B-cell leu-
kaemia and non-Hodgkin's lymphoma." Br J Cancer 53(2): 161-73. 
Guy, K., A. S. Krajewski, et al. (1986). "Expression of MHC class II antigens in human B-cell 
leukaemia and non-Hodgkin's lymphoma." Br J Cancer 53(2): 161-73. 
Hager, G. L., J. G. McNally, et al. (2009). "Transcription dynamics." Mol Cell 35(6): 741-53. 
Haglund, K. and I. Dikic (2005). "Ubiquitylation and cell signaling." EMBO J 24(19): 3353-9. 
Handunnetthi, L., S. V. Ramagopalan, et al. (2010). "Regulation of major histocompatibility 
complex class II gene expression, genetic variation and disease." Genes Immun 11(2): 
99-112. 
229 
 
Harbertson, J., E. Biederman, et al. (2002). "Withdrawal of stimulation may initiate the transition 
of effector to memory CD4 cells." J Immunol 168(3): 1095-102. 
He, H., X. M. Qi, et al. (1998). "c-Fos degradation by the proteasome. An early, Bcl-2-regulated 
step in apoptosis." J Biol Chem 273(39): 25015-9. 
Hilt, W. and D. H. Wolf (1996). "Proteasomes: destruction as a programme." Trends Biochem 
Sci 21(3): 96-102. 
Hirose, Y. and J. L. Manley (2000). "RNA polymerase II and the integration of nuclear events." 
Genes Dev 14(12): 1415-29. 
Hirose, Y., R. Tacke, et al. (1999). "Phosphorylated RNA polymerase II stimulates pre-mRNA 
splicing." Genes Dev 13(10): 1234-9. 
Hobart, M., V. Ramassar, et al. (1997). "IFN regulatory factor-1 plays a central role in the regu-
lation of the expression of class I and II MHC genes in vivo." J Immunol 158(9): 4260-9. 
Hochstrasser, M. (1996). "Ubiquitin-dependent protein degradation." Annu Rev Genet 30: 405-
39. 
Hock, H., M. Dorsch, et al. (1991). "Interleukin 7 induces CD4+ T cell-dependent tumor rejec-
tion." J Exp Med 174(6): 1291-8. 
Holen, I. and R. E. Coleman (2010). "Anti-tumour activity of bisphosphonates in preclinical 
models of breast cancer." Breast Cancer Res 12(6): 214. 
Holling, T. M., M. W. Bergevoet, et al. (2007). "A role for EZH2 in silencing of IFN-gamma 
inducible MHC2TA transcription in uveal melanoma." J Immunol 179(8): 5317-25. 
Holling, T. M., M. W. T. Bergevoet, et al. (2007). "A role for EZH2 in silencing of IFN-gamma 
inducible MHC2TA transcription in uveal melanoma." Journal of Immunology 179(8): 
5317-5325. 
230 
 
Holling, T. M., E. Schooten, et al. (2004). "Regulation of MHC class II expression in human T-
cell malignancies." Blood 103(4): 1438-44. 
Holling, T. M., M. C. van Eggermond, et al. (2006). "Epigenetic silencing of MHC2TA tran-
scription in cancer." Biochem Pharmacol 72(11): 1570-6. 
Holtz, R., J. C. Choi, et al. (2003). "Class II transactivator (CIITA) promoter methylation does 
not correlate with silencing of CIITA transcription in trophoblasts." Biol Reprod 69(3): 
915-24. 
Humphreys, J. S., D. Lyle, et al. (2000). "Roles and activities of the Commonwealth Government 
University Departments of Rural Health." Aust J Rural Health 8(2): 120-33. 
Illingworth, R. S. and A. P. Bird (2009). "CpG islands--'a rough guide'." FEBS Lett 583(11): 
1713-20. 
Ishizuka, S., M. Yamaya, et al. (2001). "Acid exposure stimulates the adherence of Streptococ-
cus pneumoniae to cultured human airway epithelial cells: effects on platelet-activating 
factor receptor expression." Am J Respir Cell Mol Biol 24(4): 459-68. 
Ivaldi, M. S., C. S. Karam, et al. (2007). "Phosphorylation of histone H3 at Ser10 facilitates 
RNA polymerase II release from promoter-proximal pausing in Drosophila." Genes Dev 
21(21): 2818-31. 
Jacobs, S. A. and S. Khorasanizadeh (2002). "Structure of HP1 chromodomain bound to a lysine 
9-methylated histone H3 tail." Science 295(5562): 2080-3. 
Janeway, C. A., Jr. (2001). "How the immune system protects the host from infection." Microbes 
Infect 3(13): 1167-71. 
Janeway, C. A., Jr. and R. Medzhitov (2002). "Innate immune recognition." Annu Rev Immunol 
20: 197-216. 
231 
 
Jelley-Gibbs, D. M., N. M. Lepak, et al. (2000). "Two distinct stages in the transition from naive 
CD4 T cells to effectors, early antigen-dependent and late cytokine-driven expansion and 
differentiation." J Immunol 165(9): 5017-26. 
Jenuwein, T. and C. Allis (2001). "Translating the histone code." Science 293(5532): 1074-80. 
Jenuwein, T. and C. D. Allis (2001). "Translating the histone code." Science 293(5532): 1074-
80. 
Jones, P. A. and S. B. Baylin (2002). "The fundamental role of epigenetic events in cancer." Nat 
Rev Genet 3(6): 415-28. 
Jones, P. A. and P. W. Laird (1999). "Cancer epigenetics comes of age." Nat Genet 21(2): 163-7. 
Jung, T., B. Catalgol, et al. (2009). "The proteasomal system." Mol Aspects Med 30(4): 191-296. 
Kanaseki, T., H. Ikeda, et al. (2003). "Histone deacetylation, but not hypermethylation, modifies 
class II transactivator and MHC class II gene expression in squamous cell carcinomas." J 
Immunol 170(10): 4980-5. 
Kanazawa, S., T. Okamoto, et al. (2000). "Tat competes with CIITA for the binding to P-TEFb 
and blocks the expression of MHC class II genes in HIV infection." Immunity 12(1): 61-
70. 
Kaufman, J., J. Salomonsen, et al. (1994). "Evolutionary conservation of MHC class I and class 
II molecules--different yet the same." Semin Immunol 6(6): 411-24. 
Kaufman, J. F., C. Auffray, et al. (1984). "The class II molecules of the human and murine major 
histocompatibility complex." Cell 36(1): 1-13. 
Kim, H. T., K. P. Kim, et al. (2007). "Certain pairs of ubiquitin-conjugating enzymes (E2s) and 
ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains contain-
ing all possible isopeptide linkages." J Biol Chem 282(24): 17375-86. 
232 
 
Kim, Y. J., S. Bjorklund, et al. (1994). "A multiprotein mediator of transcriptional activation and 
its interaction with the C-terminal repeat domain of RNA polymerase II." Cell 77(4): 
599-608. 
Kindt Thomas J, G. R. A., Osborne Barbara A. (2007). Immunology, W.H> Freeman and Com-
pany, New York. 
Kinyamu, H. K., J. Chen, et al. (2005). "Linking the ubiquitin-proteasome pathway to chromatin 
remodeling/modification by nuclear receptors." J Mol Endocrinol 34(2): 281-97. 
Kleer, C. G., Q. Cao, et al. (2003). "EZH2 is a marker of aggressive breast cancer and promotes 
neoplastic transformation of breast epithelial cells." Proc Natl Acad Sci U S A 100(20): 
11606-11. 
Klose, R. J., K. Yamane, et al. (2006). "The transcriptional repressor JHDM3A demethylates 
trimethyl histone H3 lysine 9 and lysine 36." Nature 442(7100): 312-6. 
Kohler, A., P. Cascio, et al. (2001). "The axial channel of the proteasome core particle is gated 
by the Rpt2 ATPase and controls both substrate entry and product release." Mol Cell 
7(6): 1143-52. 
Kohoutek, J., D. Blazek, et al. (2006). "Hexim1 sequesters positive transcription elongation fac-
tor b from the class II transactivator on MHC class II promoters." Proc Natl Acad Sci U S 
A 103(46): 17349-54. 
Kornberg, R. D. and J. O. Thomas (1974). "Chromatin structure; oligomers of the histones." 
Science 184(139): 865-8. 
Koues, O. I., R. K. Dudley, et al. (2009). "The 19S proteasome positively regulates histone me-
thylation at cytokine inducible genes." Biochim Biophys Acta 1789(11-12): 691-701. 
233 
 
Koues, O. I., R. K. Dudley, et al. (2009). "The 19S proteasome positively regulates histone me-
thylation at cytokine inducible genes." Biochim Biophys Acta. 
Koues, O. I., R. K. Dudley, et al. (2008). "Regulation of acetylation at the major histocompatibil-
ity complex class II proximal promoter by the 19S proteasomal ATPase Sug1." Mol Cell 
Biol 28(19): 5837-50. 
Koues, O. I., R. K. Dudley, et al. (2008). "Regulation of Acetylation at the MHC-II Proximal 
Promoter by the 19S Proteasomal ATPase Sug1." Mol Cell Biol 28(19): 5837-50. 
Koues, O. I., N. T. Mehta, et al. "Roles for common MLL/COMPASS subunits and the 19S pro-
teasome in regulating CIITApIV and MHC class II gene expression and promoter methy-
lation." Epigenetics Chromatin 3(1): 5. 
Koues, O. I., N. T. Mehta, et al. (2010). "Roles for common MLL/COMPASS subunits and the 
19S proteasome in regulating CIITApIV and MHC class II gene expression and promoter 
methylation." Epigenetics Chromatin 3(1): 5. 
Kouzarides, T. (2007). "Chromatin modifications and their function." Cell 128(4): 693-705. 
Kretsovali, A., T. Agalioti, et al. (1998). "Involvement of CREB binding protein in expression of 
major histocompatibility complex class II genes via interaction with the class II transacti-
vator." Mol Cell Biol 18(11): 6777-83. 
Krogan, N. J., M. Kim, et al. (2003). "Methylation of histone H3 by Set2 in Saccharomyces ce-
revisiae is linked to transcriptional elongation by RNA polymerase II." Mol Cell Biol 
23(12): 4207-18. 
Kuo, E., T. Maruyama, et al. (2005). "Molecular mechanisms of chronic rejection following 
transplantation." Immunol Res 32(1-3): 179-85. 
234 
 
Kuzmichev, A., K. Nishioka, et al. (2002). "Histone methyltransferase activity associated with a 
human multiprotein complex containing the Enhancer of Zeste protein." Genes Dev 
16(22): 2893-905. 
Lachner, M. and T. Jenuwein (2002). "The many faces of histone lysine methylation." Curr Opin 
Cell Biol 14(3): 286-98. 
Lachner, M., D. O'Carroll, et al. (2001). "Methylation of histone H3 lysine 9 creates a binding 
site for HP1 proteins." Nature 410(6824): 116-20. 
Laible, G., A. Wolf, et al. (1997). "Mammalian homologues of the Polycomb-group gene En-
hancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae 
telomeres." EMBO J 16(11): 3219-32. 
Lam, Y. A., T. G. Lawson, et al. (2002). "A proteasomal ATPase subunit recognizes the polyu-
biquitin degradation signal." Nature 416(6882): 763-7. 
Landmann, S., A. Muhlethaler-Mottet, et al. (2001). "Maturation of dendritic cells is accompa-
nied by rapid transcriptional silencing of class II transactivator (CIITA) expression." J 
Exp Med 194(4): 379-91. 
Langlade-Demoyen, P., F. Garcia-Pons, et al. (2003). "Role of T cell help and endoplasmic reti-
culum targeting in protective CTL response against influenza virus." Eur J Immunol 
33(3): 720-8. 
Lassot, I., D. Latreille, et al. (2007). "The proteasome regulates HIV-1 transcription by both pro-
teolytic and nonproteolytic mechanisms." Mol Cell 25(3): 369-83. 
Lauritzsen, G. F., S. Weiss, et al. (1994). "Naive idiotype-specific CD4+ T cells and immuno-
surveillance of B-cell tumors." Proc Natl Acad Sci U S A 91(12): 5700-4. 
235 
 
Lee, D., E. Ezhkova, et al. (2005). "The Proteasome regulatory particle alters the SAGA coacti-
vator to enhance its interactions with transcriptional activators." Cell 123(3): 423-36. 
Lee, J. S. and A. Shilatifard (2007). "A site to remember: H3K36 methylation a mark for histone 
deacetylation." Mutat Res 618(1-2): 130-4. 
Lee, M. G., J. Norman, et al. (2007). "Physical and functional association of a trimethyl H3K4 
demethylase and Ring6a/MBLR, a polycomb-like protein." Cell 128(5): 877-87. 
Lee, M. G., R. Villa, et al. (2007). "Demethylation of H3K27 regulates polycomb recruitment 
and H2A ubiquitination." Science 318(5849): 447-50. 
Lee, T. I. and R. A. Young (2000). "Transcription of eukaryotic protein-coding genes." Annu 
Rev Genet 34: 77-137. 
Legube, G. and D. Trouche (2003). "Regulating histone acetyltransferases and deacetylases." 
EMBO Rep 4(10): 944-7. 
Lehnertz, B., Y. Ueda, et al. (2003). "Suv39h-mediated histone H3 lysine 9 methylation directs 
DNA methylation to major satellite repeats at pericentric heterochromatin." Curr Biol 
13(14): 1192-200. 
Lennon, A. M., C. Ottone, et al. (1997). "Isolation of a B-cell-specific promoter for the human 
class II transactivator." Immunogenetics 45(4): 266-73. 
Li, J., Q. Lin, et al. (2002). "Involvement of histone methylation and phosphorylation in regula-
tion of transcription by thyroid hormone receptor." Mol Cell Biol 22(16): 5688-97. 
Li, Q., J. P. Price, et al. (2005). "Analysis of the large inactive P-TEFb complex indicates that it 
contains one 7SK molecule, a dimer of HEXIM1 or HEXIM2, and two P-TEFb mole-
cules containing Cdk9 phosphorylated at threonine 186." J Biol Chem 280(31): 28819-
26. 
236 
 
Lipford, J. R., G. T. Smith, et al. (2005). "A putative stimulatory role for activator turnover in 
gene expression." Nature 438(7064): 113-6. 
Lis, J. T., P. Mason, et al. (2000). "P-TEFb kinase recruitment and function at heat shock loci." 
Genes Dev 14(7): 792-803. 
Liu, C. L., T. Kaplan, et al. (2005). "Single-nucleosome mapping of histone modifications in S. 
cerevisiae." PLoS Biol 3(10): e328. 
Lo, W. S., R. C. Trievel, et al. (2000). "Phosphorylation of serine 10 in histone H3 is functional-
ly linked in vitro and in vivo to Gcn5-mediated acetylation at lysine 14." Mol Cell 5(6): 
917-26. 
Lotocki, G., O. F. Alonso, et al. (2003). "Monoubiquitination and cellular distribution of XIAP 
in neurons after traumatic brain injury." J Cereb Blood Flow Metab 23(10): 1129-36. 
Lucero, P., E. Penalver, et al. (2000). "Monoubiquitination is sufficient to signal internalization 
of the maltose transporter in Saccharomyces cerevisiae." J Bacteriol 182(1): 241-3. 
Luger, K., A. W. Mader, et al. (1997). "Crystal structure of the nucleosome core particle at 2.8 A 
resolution." Nature 389(6648): 251-60. 
Mach, B., V. Steimle, et al. (1996). "Regulation of MHC class II genes: lessons from a disease." 
Annu Rev Immunol 14: 301-31. 
Magner, W. J., A. L. Kazim, et al. (2000). "Activation of MHC class I, II, and CD40 gene ex-
pression by histone deacetylase inhibitors." J Immunol 165(12): 7017-24. 
Mahanta, S. K., T. Scholl, et al. (1997). "Transactivation by CIITA, the type II bare lymphocyte 
syndrome-associated factor, requires participation of multiple regions of the TATA box 
binding protein." Proc Natl Acad Sci U S A 94(12): 6324-9. 
237 
 
Maiorana, A., A. M. Cesinaro, et al. (1995). "Expression of MHC class I and class II antigens in 
primary breast carcinomas and synchronous nodal metastases." Clin Exp Metastasis 
13(1): 43-8. 
Mancebo, H. S., G. Lee, et al. (1997). "P-TEFb kinase is required for HIV Tat transcriptional 
activation in vivo and in vitro." Genes Dev 11(20): 2633-44. 
Mandel, R. and G. D. Fasman (1976). "Chromatin and nucleosome structure." Nucleic Acids Res 
3(8): 1839-55. 
Mantovani, R. (1999). "The molecular biology of the CCAAT-binding factor NF-Y." Gene 
239(1): 15-27. 
Martinez-Garcia, E. and J. D. Licht (2010). "Deregulation of H3K27 methylation in cancer." Nat 
Genet 42(2): 100-1. 
Masternak, K., E. Barras, et al. (1998). "A gene encoding a novel RFX-associated transactivator 
is mutated in the majority of MHC class II deficiency patients." Nat Genet 20(3): 273-7. 
Masternak, K., A. Muhlethaler-Mottet, et al. (2000). "CIITA is a transcriptional coactivator that 
is recruited to MHC class II promoters by multiple synergistic interactions with an en-
hanceosome complex." Genes Dev 14(9): 1156-66. 
Masternak, K., N. Peyraud, et al. (2003). "Chromatin remodeling and extragenic transcription at 
the MHC class II locus control region." Nat Immunol 4(2): 132-7. 
McCracken, S., N. Fong, et al. (1997). "The C-terminal domain of RNA polymerase II couples 
mRNA processing to transcription." Nature 385(6614): 357-61. 
Medhurst, A. D., D. C. Harrison, et al. (2000). "The use of TaqMan RT-PCR assays for semi-
quantitative analysis of gene expression in CNS tissues and disease models." J Neurosci 
Methods 98(1): 9-20. 
238 
 
Mehta, N. T., A. D. Truax, et al. (2011). "Early epigenetic events regulate the adaptive immune 
response gene CIITA." Epigenetics 6(4). 
Meissner, M., T. L. Whiteside, et al. (2008). "Loss of interferon-gamma inducibility of the MHC 
class II antigen processing pathway in head and neck cancer: evidence for post-
transcriptional as well as epigenetic regulation." Br J Dermatol 158(5): 930-40. 
Michels, A. A., A. Fraldi, et al. (2004). "Binding of the 7SK snRNA turns the HEXIM1 protein 
into a P-TEFb (CDK9/cyclin T) inhibitor." EMBO J 23(13): 2608-19. 
Mohn, F., M. Weber, et al. (2008). "Lineage-specific polycomb targets and de novo DNA methy-
lation define restriction and potential of neuronal progenitors." Mol Cell 30(6): 755-66. 
Moreno, C. S., G. W. Beresford, et al. (1999). "CREB regulates MHC class II expression in a 
CIITA-dependent manner." Immunity 10(2): 143-51. 
Morimoto, Y., M. Toyota, et al. (2004). "Inactivation of class II transactivator by DNA methyla-
tion and histone deacetylation associated with absence of HLA-DR induction by interfe-
ron-gamma in haematopoietic tumour cells." Br J Cancer 90(4): 844-52. 
Morris, A., G. Beresford, et al. (2002). "Kinetics of a gamma interferon response: expression and 
assembly of CIITA promoter IV and inhibition by methylation." Mol Cell Biol 22(13): 
4781-91. 
Morris, A., W. Spangler, et al. (2000). "Methylation of class II trans-activator promoter IV: a 
novel mechanism of MHC class II gene control." J Immunol 164(8): 4143-9. 
Morris, A. C., G. W. Beresford, et al. (2002). "Kinetics of a gamma interferon response: expres-
sion and assembly of CIITA promoter IV and inhibition by methylation." Mol Cell Biol 
22(13): 4781-91. 
239 
 
Morris, A. C., W. E. Spangler, et al. (2000). "Methylation of class II trans-activator promoter IV: 
a novel mechanism of MHC class II gene control." J Immunol 164(8): 4143-9. 
Morris, M. C., P. Kaiser, et al. (2003). "Cks1-dependent proteasome recruitment and activation 
of CDC20 transcription in budding yeast." Nature 423(6943): 1009-13. 
Morris, S. A., B. Rao, et al. (2007). "Identification of histone H3 lysine 36 acetylation as a highly 
conserved histone modification." J Biol Chem 282(10): 7632-40. 
Muhlethaler-Mottet, A., W. Di Berardino, et al. (1998). "Activation of the MHC class II transac-
tivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and 
USF-1." Immunity 8(2): 157-66. 
Muhlethaler-Mottet, A., L. Otten, et al. (1997). "Expression of MHC class II molecules in differ-
ent cellular and functional compartments is controlled by differential usage of multiple 
promoters of the transactivator CIITA." Embo J 16(10): 2851-60. 
Muhlethaler-Mottet, A., L. A. Otten, et al. (1997). "Expression of MHC class II molecules in dif-
ferent cellular and functional compartments is controlled by differential usage of multiple 
promoters of the transactivator CIITA." Embo J 16(10): 2851-60. 
Muller, J., C. M. Hart, et al. (2002). "Histone methyltransferase activity of a Drosophila Poly-
comb group repressor complex." Cell 111(2): 197-208. 
Muller, J. and P. Verrijzer (2009). "Biochemical mechanisms of gene regulation by polycomb 
group protein complexes." Curr Opin Genet Dev 19(2): 150-8. 
Muratani, M. and W. P. Tansey (2003). "How the ubiquitin-proteasome system controls tran-
scription." Nat Rev Mol Cell Biol 4(3): 192-201. 
Murphy, S. P., J. C. Choi, et al. (2004). "Regulation of major histocompatibility complex class II 
gene expression in trophoblast cells." Reprod Biol Endocrinol 2: 52. 
240 
 
Naeem, H., D. Cheng, et al. (2007). "The activity and stability of the transcriptional coactivator 
p/CIP/SRC-3 are regulated by CARM1-dependent methylation." Mol Cell Biol 27(1): 
120-34. 
Nagarajan, U. M., P. Louis-Plence, et al. (1999). "RFX-B is the gene responsible for the most 
common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency." 
Immunity 10(2): 153-62. 
Nakayama, J., J. C. Rice, et al. (2001). "Role of histone H3 lysine 9 methylation in epigenetic 
control of heterochromatin assembly." Science 292(5514): 110-3. 
Nathan, D., D. E. Sterner, et al. (2003). "Histone modifications: Now summoning sumoylation." 
Proc Natl Acad Sci U S A 100(23): 13118-20. 
Nelbock, P., P. J. Dillon, et al. (1990). "A cDNA for a protein that interacts with the human im-
munodeficiency virus Tat transactivator." Science 248(4963): 1650-3. 
Ng, H. H., F. Robert, et al. (2003). "Targeted recruitment of Set1 histone methylase by elongat-
ing Pol II provides a localized mark and memory of recent transcriptional activity." Mol 
Cell 11(3): 709-19. 
Ng, H. H., R. M. Xu, et al. (2002). "Ubiquitination of histone H2B by Rad6 is required for effi-
cient Dot1-mediated methylation of histone H3 lysine 79." J Biol Chem 277(38): 34655-
7. 
Nguyen, V. T., T. Kiss, et al. (2001). "7SK small nuclear RNA binds to and inhibits the activity 
of CDK9/cyclin T complexes." Nature 414(6861): 322-5. 
Ni, Z., E. Karaskov, et al. (2005). "Apical role for BRG1 in cytokine-induced promoter assem-
bly." Proc Natl Acad Sci U S A 102(41): 14611-6. 
241 
 
Ni, Z., E. Karaskov, et al. (2005). "Apical role for BRG1 in cytokine-induced promoter assem-
bly." Proc Natl Acad Sci U S A 102(41): 14611-6. 
Nowak, S. J. and V. G. Corces (2000). "Phosphorylation of histone H3 correlates with transcrip-
tionally active loci." Genes Dev 14(23): 3003-13. 
Ogbourne, S. and T. M. Antalis (1998). "Transcriptional control and the role of silencers in tran-
scriptional regulation in eukaryotes." Biochem J 331 ( Pt 1): 1-14. 
Ogryzko, V. V., R. L. Schiltz, et al. (1996). "The transcriptional coactivators p300 and CBP are 
histone acetyltransferases." Cell 87(5): 953-9. 
Ooi, S. K., C. Qiu, et al. (2007). "DNMT3L connects unmethylated lysine 4 of histone H3 to de 
novo methylation of DNA." Nature 448(7154): 714-7. 
Ouchida, R., M. Kusuhara, et al. (2003). "Suppression of NF-kappaB-dependent gene expression 
by a hexamethylene bisacetamide-inducible protein HEXIM1 in human vascular smooth 
muscle cells." Genes Cells 8(2): 95-107. 
Pai, R. K., D. Askew, et al. (2002). "Regulation of class II MHC expression in APCs: roles of 
types I, III, and IV class II transactivator." J Immunol 169(3): 1326-33. 
Parham, P. (2009). The Immune system, Garland Science, Taylor and Francis Group. 
Pattenden, S., R. Klose, et al. (2002). "Interferon-gamma-induced chromatin remodeling at the 
CIITA locus is BRG1 dependent." Embo J 21(8): 1978-86. 
Pattenden, S. G., R. Klose, et al. (2002). "Interferon-gamma-induced chromatin remodeling at 
the CIITA locus is BRG1 dependent." EMBO J 21(8): 1978-86. 
Peng, J., N. F. Marshall, et al. (1998). "Identification of a cyclin subunit required for the function 
of Drosophila P-TEFb." J Biol Chem 273(22): 13855-60. 
242 
 
Peterlin, B. M. and D. H. Price (2006). "Controlling the elongation phase of transcription with P-
TEFb." Mol Cell 23(3): 297-305. 
Peters, J. M., W. W. Franke, et al. (1994). "Distinct 19 S and 20 S subcomplexes of the 26 S pro-
teasome and their distribution in the nucleus and the cytoplasm." J Biol Chem 269(10): 
7709-18. 
Pickart, C. M. (2004). "Back to the future with ubiquitin." Cell 116(2): 181-90. 
Ping, Y. H. and T. M. Rana (1999). "Tat-associated kinase (P-TEFb): a component of transcrip-
tion preinitiation and elongation complexes." J Biol Chem 274(11): 7399-404. 
Piskurich, J. F., M. H. Blanchard, et al. (1995). "Molecular cloning of the mouse polymeric Ig 
receptor. Functional regions of the molecule are conserved among five mammalian spe-
cies." J Immunol 154(4): 1735-47. 
Piskurich, J. F., J. A. France, et al. (1993). "Interferon-gamma induces polymeric immunoglobu-
lin receptor mRNA in human intestinal epithelial cells by a protein synthesis dependent 
mechanism." Mol Immunol 30(4): 413-21. 
Piskurich, J. F., C. A. Gilbert, et al. (2006). "Expression of the MHC class II transactivator (CII-
TA) type IV promoter in B lymphocytes and regulation by IFN-gamma." Mol Immunol 
43(6): 519-28. 
Piskurich, J. F., M. W. Linhoff, et al. (1999). "Two distinct gamma interferon-inducible promo-
ters of the major histocompatibility complex class II transactivator gene are differentially 
regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta." 
Mol Cell Biol 19(1): 431-40. 
243 
 
Piskurich, J. F., Y. Wang, et al. (1998). "Identification of distinct regions of 5' flanking DNA that 
mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the 
class II transactivator gene." J Immunol 160(1): 233-40. 
Piskurich, J. F., K. R. Youngman, et al. (1997). "Transcriptional regulation of the human poly-
meric immunoglobulin receptor gene by interferon-gamma." Mol Immunol 34(1): 75-91. 
Platanias, L. C. (2005). "Mechanisms of type-I- and type-II-interferon-mediated signalling." Nat 
Rev Immunol 5(5): 375-86. 
Plath, K., J. Fang, et al. (2003). "Role of histone H3 lysine 27 methylation in X inactivation." 
Science 300(5616): 131-5. 
Pokholok, D. K., C. T. Harbison, et al. (2005). "Genome-wide map of nucleosome acetylation 
and methylation in yeast." Cell 122(4): 517-27. 
Price, D. H. (2000). "P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polyme-
rase II." Mol Cell Biol 20(8): 2629-34. 
Price, J. E. (1990). "The biology of metastatic breast cancer." Cancer 66(6 Suppl): 1313-20. 
Rabl, J., D. M. Smith, et al. (2008). "Mechanism of gate opening in the 20S proteasome by the 
proteasomal ATPases." Mol Cell 30(3): 360-8. 
Raman, J. D., N. P. Mongan, et al. (2005). "Increased expression of the polycomb group gene, 
EZH2, in transitional cell carcinoma of the bladder." Clin Cancer Res 11(24 Pt 1): 8570-
6. 
Rao, B., Y. Shibata, et al. (2005). "Dimethylation of histone H3 at lysine 36 demarcates regulato-
ry and nonregulatory chromatin genome-wide." Mol Cell Biol 25(21): 9447-59. 
Rasti, M., R. J. Grand, et al. (2006). "Roles for APIS and the 20S proteasome in adenovirus 
E1A-dependent transcription." Embo J 25(12): 2710-22. 
244 
 
Reijm, E. A., M. P. Jansen, et al. "Decreased expression of EZH2 is associated with upregulation 
of ER and favorable outcome to tamoxifen in advanced breast cancer." Breast Cancer Res 
Treat. 
Reith, W., S. LeibundGut-Landmann, et al. (2005). "Regulation of MHC class II gene expression 
by the class II transactivator." Nat Rev Immunol 5(10): 793-806. 
Reith, W. and B. Mach (2001). "The bare lymphocyte syndrome and the regulation of MHC ex-
pression." Annu Rev Immunol 19: 331-73. 
Richmond, C., C. Gorbea, et al. (1997). "Specific interactions between ATPase subunits of the 
26 S protease." J Biol Chem 272(20): 13403-11. 
Richmond, C., C. Gorbea, et al. (1997). "Specific Interactions between ATPase Subunits of the 
26 S Protease." J. Biol. Chem. 272(20): 13403-13411. 
Richmond, T. J. and C. A. Davey (2003). "The structure of DNA in the nucleosome core." Na-
ture 423(6936): 145-50. 
Roeder, R. G. (1996). "The role of general initiation factors in transcription by RNA polymerase 
II." Trends Biochem Sci 21(9): 327-35. 
Rojo, J. M., K. Saizawa, et al. (1989). "Physical association of CD4 and the T-cell receptor can 
be induced by anti-T-cell receptor antibodies." Proc Natl Acad Sci U S A 86(9): 3311-5. 
Roth, S., J. Denu, et al. (2001). "Histone acetyltransferases." Annu Rev Biochem 70: 81-120. 
Rubin, D. M., O. Coux, et al. (1996). "Identification of the gal4 suppressor Sug1 as a subunit of 
the yeast 26S proteasome." Nature 379(6566): 655-7. 
Rubin, D. M., M. H. Glickman, et al. (1998). "Active site mutants in the six regulatory particle 
ATPases reveal multiple roles for ATP in the proteasome." EMBO J 17(17): 4909-19. 
245 
 
Ruiz-Cabello, F., E. Klein, et al. (1991). "MHC antigens on human tumors." Immunol Lett 29(3): 
181-9. 
Rybtsova, N., E. Leimgruber, et al. (2007). "Transcription-coupled deposition of histone modifi-
cations during MHC class II gene activation." Nucleic Acids Res 35(10): 3431-41. 
Sandelin, A., P. Carninci, et al. (2007). "Mammalian RNA polymerase II core promoters: in-
sights from genome-wide studies." Nat Rev Genet 8(6): 424-36. 
Santin, A. D., P. L. Hermonat, et al. (1998). "Effects of retinoic acid combined with irradiation 
on the expression of major histocompatibility complex molecules and adhe-
sion/costimulation molecules ICAM-1 in human cervical cancer." Gynecol Oncol 70(2): 
195-201. 
Santos-Rosa, H., R. Schneider, et al. (2002). "Active genes are tri-methylated at K4 of histone 
H3." Nature 419(6905): 407-11. 
Satijn, D. P. and A. P. Otte (1999). "Polycomb group protein complexes: do different complexes 
regulate distinct target genes?" Biochim Biophys Acta 1447(1): 1-16. 
Satoh, A., M. Toyota, et al. (2004). "Epigenetic inactivation of class II transactivator (CIITA) is 
associated with the absence of interferon-gamma-induced HLA-DR expression in colo-
rectal and gastric cancer cells." Oncogene 23(55): 8876-86. 
Satoh, T., T. Ishizuka, et al. (2009). "Tat-binding Protein-1, an ATPase of 19S Regulatory Par-
ticles of the 26S Proteasome, Enhances Androgen Receptor Function in Cooperation with 
Tat-binding Protein-1-interacting Protein/Hop2." Endocrinology. 
Saunders, A., L. J. Core, et al. (2006). "Breaking barriers to transcription elongation." Nat Rev 
Mol Cell Biol 7(8): 557-67. 
246 
 
Schnappauf, F., S. B. Hake, et al. (2003). "N-terminal destruction signals lead to rapid degrada-
tion of the major histocompatibility complex class II transactivator CIITA." Eur J Immu-
nol 33(8): 2337-47. 
Schubeler, D., D. M. MacAlpine, et al. (2004). "The histone modification pattern of active genes 
revealed through genome-wide chromatin analysis of a higher eukaryote." Genes Dev 
18(11): 1263-71. 
Schulte, A., N. Czudnochowski, et al. (2005). "Identification of a cyclin T-binding domain in 
Hexim1 and biochemical analysis of its binding competition with HIV-1 Tat." J Biol 
Chem 280(26): 24968-77. 
Schulz, W. A. and J. Hatina (2006). "Epigenetics of prostate cancer: beyond DNA methylation." 
J Cell Mol Med 10(1): 100-25. 
Seder, R. A. and R. Ahmed (2003). "Similarities and differences in CD4+ and CD8+ effector and 
memory T cell generation." Nat Immunol 4(9): 835-42. 
Shi, B., A. Vinyals, et al. (2006). "Differential expression of MHC class II molecules in highly 
metastatic breast cancer cells is mediated by the regulation of the CIITA transcription 
Implication of CIITA in tumor and metastasis development." Int J Biochem Cell Biol 
38(4): 544-62. 
Shiio, Y. and R. N. Eisenman (2003). "Histone sumoylation is associated with transcriptional 
repression." Proc Natl Acad Sci U S A 100(23): 13225-30. 
Shilatifard, A. (2006). "Chromatin modifications by methylation and ubiquitination: implications 
in the regulation of gene expression." Annu Rev Biochem 75: 243-69. 
247 
 
Shimizu, N., R. Ouchida, et al. (2005). "HEXIM1 forms a transcriptionally abortive complex 
with glucocorticoid receptor without involving 7SK RNA and positive transcription elon-
gation factor b." Proc Natl Acad Sci U S A 102(24): 8555-60. 
Shmueli, A. and M. Oren (2005). "Life, death, and ubiquitin: taming the mule." Cell 121(7): 963-
5. 
Shukla, A. and S. R. Bhaumik (2007). "H2B-K123 ubiquitination stimulates RNAPII elongation 
independent of H3-K4 methylation." Biochem Biophys Res Commun 359(2): 214-20. 
Shukla, A., N. Stanojevic, et al. (2006). "Functional analysis of H2B-Lys-123 ubiquitination in 
regulation of H3-Lys-4 methylation and recruitment of RNA polymerase II at the coding 
sequences of several active genes in vivo." J Biol Chem 281(28): 19045-54. 
Sigismund, S., S. Polo, et al. (2004). "Signaling through monoubiquitination." Curr Top Micro-
biol Immunol 286: 149-85. 
Sikder, D., S. A. Johnston, et al. (2006). "Widespread, but non-identical, association of protea-
somal 19 and 20 S proteins with yeast chromatin." J Biol Chem 281(37): 27346-55. 
Simon, J. A. and C. A. Lange (2008). "Roles of the EZH2 histone methyltransferase in cancer 
epigenetics." Mutat Res 647(1-2): 21-9. 
Sims, R. J., 3rd, R. Belotserkovskaya, et al. (2004). "Elongation by RNA polymerase II: the short 
and long of it." Genes Dev 18(20): 2437-68. 
Sisk, T. J., T. Gourley, et al. (2000). "MHC class II transactivator inhibits IL-4 gene transcription 
by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300." J 
Immunol 165(5): 2511-7. 
248 
 
Smith, D. M., S. C. Chang, et al. (2007). "Docking of the proteasomal ATPases' carboxyl termini 
in the 20S proteasome's alpha ring opens the gate for substrate entry." Mol Cell 27(5): 
731-44. 
Sotiriadou, R., S. A. Perez, et al. (2001). "Peptide HER2(776-788) represents a naturally 
processed broad MHC class II-restricted T cell epitope." Br J Cancer 85(10): 1527-34. 
Sparmann, A. and M. van Lohuizen (2006). "Polycomb silencers control cell fate, development 
and cancer." Nat Rev Cancer 6(11): 846-56. 
Spilianakis, C., A. Kretsovali, et al. (2003). "CIITA regulates transcription onset viaSer5-
phosphorylation of RNA Pol II." Embo J 22(19): 5125-36. 
Spilianakis, C., J. Papamatheakis, et al. (2000). "Acetylation by PCAF enhances CIITA nuclear 
accumulation and transactivation of major histocompatibility complex class II genes." 
Mol Cell Biol 20(22): 8489-98. 
Stallcup, M. R. (2001). "Role of protein methylation in chromatin remodeling and transcriptional 
regulation." Oncogene 20(24): 3014-20. 
Sterner, D. E. and S. L. Berger (2000). "Acetylation of histones and transcription-related fac-
tors." Microbiol Mol Biol Rev 64(2): 435-59. 
Strickland, E., K. Hakala, et al. (2000). "Recognition of misfolding proteins by PA700, the regu-
latory subcomplex of the 26 S proteasome." J Biol Chem 275(8): 5565-72. 
Struhl, K. (1998). "Histone acetylation and transcriptional regulatory mechanisms." Genes Dev 
12(5): 599-606. 
Sulahian, R., S. A. Johnston, et al. (2006). "The proteasomal ATPase complex is required for 
stress-induced transcription in yeast." Nucl. Acids Res. 34(5): 1351-1357. 
249 
 
Sun, L., S. A. Johnston, et al. (2002). "Physical association of the APIS complex and general 
transcription factors." Biochemical and Biophysical Research Communications 296(4): 
991. 
Sun, Z. W. and C. D. Allis (2002). "Ubiquitination of histone H2B regulates H3 methylation and 
gene silencing in yeast." Nature 418(6893): 104-8. 
Swaffield, J. C., J. F. Bromberg, et al. (1992). "Alterations in a yeast protein resembling HIV 
Tat-binding protein relieve requirement for an acidic activation domain in GAL4." Na-
ture 357(6380): 698-700. 
Swaffield, J. C., K. Melcher, et al. (1995). "A highly conserved ATPase protein as a mediator 
between acidic activation domains and the TATA-binding protein." Nature 374(6517): 
88. 
Swanberg, M., O. Lidman, et al. (2005). "MHC2TA is associated with differential MHC mole-
cule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocar-
dial infarction." Nat Genet 37(5): 486-94. 
Tan, J. M., E. S. Wong, et al. (2007). "Lysine 63-linked polyubiquitin potentially partners with 
p62 to promote the clearance of protein inclusions by autophagy." Autophagy 4(2). 
Terrell, J., S. Shih, et al. (1998). "A function for monoubiquitination in the internalization of a G 
protein-coupled receptor." Mol Cell 1(2): 193-202. 
Thrower, J. S., L. Hoffman, et al. (2000). "Recognition of the polyubiquitin proteolytic signal." 
Embo J 19(1): 94-102. 
Ting, J. and J. Trowsdale (2002). "Genetic control of MHC class II expression." Cell 109 Suppl: 
S21-33. 
250 
 
Ting, J. P. and J. Trowsdale (2002). "Genetic control of MHC class II expression." Cell 109 
Suppl: S21-33. 
Truax, A. D., O. I. Koues, et al. "The 19S ATPase S6a (S6'/TBP1) regulates the transcription in-
itiation of class II transactivator." J Mol Biol 395(2): 254-69. 
Truax, A. D., O. I. Koues, et al. (2010). "The 19S ATPase S6a (S6'/TBP1) regulates the tran-
scription initiation of class II transactivator." J Mol Biol 395(2): 254-69. 
Tsukada, Y., J. Fang, et al. (2006). "Histone demethylation by a family of JmjC domain-
containing proteins." Nature 439(7078): 811-6. 
Utley, R. T., K. Ikeda, et al. (1998). "Transcriptional activators direct histone acetyltransferase 
complexes to nucleosomes." Nature 394(6692): 498-502. 
van den Elsen, P. J., S. J. Gobin, et al. (2001). "Transcriptional control of MHC genes in fetal 
trophoblast cells." J Reprod Immunol 52(1-2): 129-45. 
van den Elsen, P. J., T. M. Holling, et al. (2004). "Transcriptional regulation of antigen presenta-
tion." Curr Opin Immunol 16(1): 67-75. 
van den Elsen, P. J., N. van der Stoep, et al. (2000). "Lack of CIITA expression is central to the 
absence of antigen presentation functions of trophoblast cells and is caused by methyla-
tion of the IFN-gamma inducible promoter (PIV) of CIITA." Hum Immunol 61(9): 850-
62. 
Varambally, S., S. M. Dhanasekaran, et al. (2002). "The polycomb group protein EZH2 is in-
volved in progression of prostate cancer." Nature 419(6907): 624-9. 
Varier, R. A. and H. T. Timmers (2011). "Histone lysine methylation and demethylation path-
ways in cancer." Biochim Biophys Acta 1815(1): 75-89. 
251 
 
Vire, E., C. Brenner, et al. (2006). "The Polycomb group protein EZH2 directly controls DNA 
methylation." Nature 439(7078): 871-4. 
Walter, W., K. Lingnau, et al. (2000). "MHC class II antigen presentation pathway in murine 
tumours: tumour evasion from immunosurveillance?" Br J Cancer 83(9): 1192-201. 
Wang, H., Z. Q. Huang, et al. (2001). "Methylation of histone H4 at arginine 3 facilitating tran-
scriptional activation by nuclear hormone receptor." Science 293(5531): 853-7. 
Wang, R. F. (2003). "Identification of MHC class II-restricted tumor antigens recognized by 
CD4+ T cells." Methods 29(3): 227-35. 
Warabi, M., M. Kitagawa, et al. (2000). "Loss of MHC class II expression is associated with a 
decrease of tumor-infiltrating T cells and an increase of metastatic potential of colorectal 
cancer: immunohistological and histopathological analyses as compared with normal co-
lonic mucosa and adenomas." Pathol Res Pract 196(12): 807-15. 
Ward, R., A. Bowman, et al. (2009). "Long distance PELDOR measurements on the histone core 
particle." J Am Chem Soc 131(4): 1348-9. 
Wei, J., L. Zhai, et al. (2006). "Role of Bmi1 in H2A ubiquitylation and Hox gene silencing." J 
Biol Chem 281(32): 22537-44. 
Whetstine, J. R., A. Nottke, et al. (2006). "Reversal of histone lysine trimethylation by the 
JMJD2 family of histone demethylases." Cell 125(3): 467-81. 
Widom, J. (1998). "Chromatin structure: linking structure to function with histone H1." Curr Bi-
ol 8(22): R788-91. 
Wittmann, B. M., K. Fujinaga, et al. (2005). "The breast cell growth inhibitor, estrogen down 
regulated gene 1, modulates a novel functional interaction between estrogen receptor al-
pha and transcriptional elongation factor cyclin T1." Oncogene 24(36): 5576-88. 
252 
 
Wray, G. A., M. W. Hahn, et al. (2003). "The evolution of transcriptional regulation in euka-
ryotes." Mol Biol Evol 20(9): 1377-419. 
Wright, K. and J. Ting (2006). "Epigenetic regulation of MHC-II and CIITA genes." Trends 
Immunol 27(9): 405-12. 
Wright, K. L. and J. P. Ting (2006). "Epigenetic regulation of MHC-II and CIITA genes." 
Trends Immunol 27(9): 405-12. 
Wu, M., P. Wang, et al. (2008). "Molecular regulation of H3K4 trimethylation by Wdr82, a 
component of human Set1/COMPASS." Mol Cell Biol 28(24): 7337-44. 
Wysocka, J., T. A. Milne, et al. (2005). "Taking LSD 1 to a new high." Cell 122(5): 654-8. 
Xiao, Y. (2011). "Enhancer of zeste homolog 2: A potential target for tumor therapy." Int J Bio-
chem Cell Biol. 
Xu, Q., R. A. Singer, et al. (1995). "Sug1 modulates yeast transcription activation by Cdc68." 
Mol Cell Biol 15(11): 6025-35. 
Yamane, K., C. Toumazou, et al. (2006). "JHDM2A, a JmjC-containing H3K9 demethylase, fa-
cilitates transcription activation by androgen receptor." Cell 125(3): 483-95. 
Yan, X., H. Shen, et al. (2006). "External Qi of Yan Xin Qigong differentially regulates the Akt 
and extracellular signal-regulated kinase pathways and is cytotoxic to cancer cells but not 
to normal cells." Int J Biochem Cell Biol 38(12): 2102-13. 
Yang, X. J. (2004). "The diverse superfamily of lysine acetyltransferases and their roles in leu-
kemia and other diseases." Nucleic Acids Res 32(3): 959-76. 
Yang, Z., Q. Zhu, et al. (2001). "The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 ki-
nase to control transcription." Nature 414(6861): 317-22. 
253 
 
Yik, J. H., R. Chen, et al. (2003). "Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA po-
lymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA." Mol 
Cell 12(4): 971-82. 
Zhang, H., L. Sun, et al. (2006). "The catalytic subunit of the proteasome is engaged in the entire 
process of estrogen receptor-regulated transcription." EMBO J 25(18): 4223-33. 
Zhang, R. D., I. J. Fidler, et al. (1991). "Relative malignant potential of human breast carcinoma 
cell lines established from pleural effusions and a brain metastasis." Invasion Metastasis 
11(4): 204-15. 
Zhang, Y. and D. Reinberg (2001). "Transcription regulation by histone methylation: interplay 
between different covalent modifications of the core histone tails." Genes Dev 15(18): 
2343-60. 
Zhou, Q., D. Chen, et al. (1998). "Transcription elongation factor P-TEFb mediates Tat activa-
tion of HIV-1 transcription at multiple stages." EMBO J 17(13): 3681-91. 
Zhu, Q., G. Wani, et al. (2007). "The ubiquitin-proteasome system regulates p53-mediated tran-
scription at p21waf1 promoter." Oncogene 26(29): 4199-208. 
Zhu, X.-S., M. W. Linhoff, et al. (2000). "Transcriptional Scaffold: CIITA Interacts with NF-Y, 
RFX, and CREB To Cause Stereospecific Regulation of the Class II Major Histocompa-
tibility Complex Promoter." Mol. Cell. Biol. 20(16): 6051-6061. 
Zhu, X. S. and J. P. Ting (2001). "A 36-amino-acid region of CIITA is an effective inhibitor of 
CBP: novel mechanism of gamma interferon-mediated suppression of collagen al-
pha(2)(I) and other promoters." Mol Cell Biol 21(20): 7078-88. 
Zhu, Y., T. Pe'ery, et al. (1997). "Transcription elongation factor P-TEFb is required for HIV-1 
tat transactivation in vitro." Genes Dev 11(20): 2622-32. 
254 
 
Zika, E., L. Fauquier, et al. (2005). "Interplay among coactivator-associated arginine methyl-
transferase 1, CBP, and CIITA in IFN-gamma-inducible MHC-II gene expression." Proc 
Natl Acad Sci U S A 102(45): 16321-6. 
Zika, E., S. F. Greer, et al. (2003). "Histone deacetylase 1/mSin3A disrupts gamma interferon-
induced CIITA function and major histocompatibility complex class II enhanceosome 
formation." Mol Cell Biol 23(9): 3091-102. 
 
 
